<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> Stellar Biotechnologies, Inc. (Form: 10-K, Received: 12/14/2016 17:23:36) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_NAME_AND_TITLE_2 **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_OPTIONS_AGGREGATE **FIS_OPTIONS **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_BENEFICIAL_OWNERS_2 **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_EXHIBIT_INDEX **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_CASH_FLOW **FIS_STOCKHOLDERS_EQUITY **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="109">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V453489_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	UNITED STATES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	SECURITIES
	AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	FORM
	10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 3IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 3IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 3IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
<B>
	&thorn;
</B>
</FONT>
</TD>
<TD>
<B>
	ANNUAL REPORT PURSUANT
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	TO SECTION 13 OR 15(
</FONT>
	d
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	)
	OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the fiscal year ended September 30, 2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	OR
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 27.35PT">
<FONT STYLE="FONT-FAMILY: WINGDINGS; TEXT-TRANSFORM: UPPERCASE">
<B>
	&uml;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(
</B>
</FONT>
<B>
	d
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	)
	OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the transition period
	from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: -0.35PT">
<B>
	Commission file number:
	000-54598
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Exact name of registrant as specified in
	its charter)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	British Columbia, Canada
</B>
</TD>
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	N/A
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(State or other jurisdiction of
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	incorporation or organization)
</P>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(I.R.S. Employer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Identification No.)
</P>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	332 E. Scott Street
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Port Hueneme, California
</B>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	93041
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	(Address of principal executive offices)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	(Zip Code)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Registrant&rsquo;s telephone number, including
	area code: (805) 488-2800
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant to Section
	12(b) of the Act:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name of each exchange on which
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
	of each class
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	registered
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Common Shares, without par value
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The Nasdaq Stock Market LLC&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant to Section&nbsp;12(g)
	of the Act:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	None
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if the registrant is
	a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark if the registrant is
	not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
	preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
	to such filing requirements for the past 90 days. &nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark
	whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
	required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding
	12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark
	if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K (&sect;229.405 of this chapter) is not contained
	herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements
	incorporated by reference in Part III of this Form 10-K or any amendment to this Form&nbsp;10-K.
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark
	whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.
	See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
	in Rule 12b-2 of the Exchange Act.
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; COLOR: MAROON">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; COLOR: MAROON">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Large Accelerated Filer&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; COLOR: MAROON; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Accelerated Filer&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; COLOR: MAROON">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="COLOR: MAROON">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="COLOR: MAROON">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Non-Accelerated Filer&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</TD>
<TD STYLE="COLOR: MAROON; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Smaller Reporting
	Company&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</FONT>
</TD>
<TD STYLE="COLOR: MAROON">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	Indicate by check mark whether the registrant
	is a shell company (as defined in Rule 12b-2 of the Act). Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	As of March 31, 2016, the
	last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate market value of the registrant&rsquo;s
	outstanding common shares held by non-affiliates was approximately $39,507,208, which was calculated based on 8,448,758 common
	shares outstanding as of that date, of which 8,145,816 common shares were held by non-affiliates, and a price per share of $4.85,
	which was the closing price of the registrant&rsquo;s common shares on The Nasdaq Capital Market on such date.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE; TEXT-INDENT: 0.25IN; TEXT-ALIGN: JUSTIFY">
	As of December 9, 2016,
	the registrant had 10,136,258 common shares issued and outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Documents
	incorporated by reference:
</B>
</FONT>
<B>
	NONE&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Annual
	Report ON FORM 10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Fiscal Year Ended September 30, 2016
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Table of Contents
</P>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Item
</B>
</P>
</TD>
<TD STYLE="WIDTH: 84%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Page
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER">
<A HREF="#V453489_10K_HTM_SBI_001">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART I
</B>
</FONT>
</A>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_002">
<FONT STYLE="FONT-SIZE: 10PT">
	Business
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1A.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_003">
<FONT STYLE="FONT-SIZE: 10PT">
	Risk Factors
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	17
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	1B.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_004">
<FONT STYLE="FONT-SIZE: 10PT">
	Unresolved Staff Comments
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_005">
<FONT STYLE="FONT-SIZE: 10PT">
	Properties
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_006">
<FONT STYLE="FONT-SIZE: 10PT">
	Legal Proceedings
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_007">
<FONT STYLE="FONT-SIZE: 10PT">
	Mine Safety Disclosures
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	30
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER">
<A HREF="#V453489_10K_HTM_SBI_008">
<B>
	PART II
</B>
</A>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<A HREF="#V453489_10K_HTM_SBI_009">
<FONT STYLE="FONT-SIZE: 10PT">
	Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	31
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	6.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_010">
<FONT STYLE="FONT-SIZE: 10PT">
	Selected Financial Data
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	34
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_011">
<FONT STYLE="FONT-SIZE: 10PT">
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	35
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	7A.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_012">
<FONT STYLE="FONT-SIZE: 10PT">
	Quantitative and Qualitative Disclosures About Market Risk
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	49
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	8.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_013">
<FONT STYLE="FONT-SIZE: 10PT">
	Financial Statements and Supplementary Data
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	50
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	9.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_014">
<FONT STYLE="FONT-SIZE: 10PT">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	50
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	9A.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_015">
<FONT STYLE="FONT-SIZE: 10PT">
	Controls and Procedures
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	51
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	9B.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_016">
<FONT STYLE="FONT-SIZE: 10PT">
	Other Information
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	52
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER">
<A HREF="#V453489_10K_HTM_SBI_017">
<B>
	PART III
</B>
</A>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	10.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_018">
<FONT STYLE="FONT-SIZE: 10PT">
	Directors, Executive Officers and Corporate Governance
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	53
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	11.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_019">
<FONT STYLE="FONT-SIZE: 10PT">
	Executive Compensation
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	57
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	12.
</FONT>
</TD>
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<A HREF="#V453489_10K_HTM_SBI_020">
<FONT STYLE="FONT-SIZE: 10PT">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	64
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	13.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_021">
<FONT STYLE="FONT-SIZE: 10PT">
	Certain Relationships and Related Transactions, and Director Independence
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	66
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	14.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_022">
<FONT STYLE="FONT-SIZE: 10PT">
	Principal Accounting Fees and Services
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	67
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER">
<A HREF="#V453489_10K_HTM_SBI_023">
<B>
	PART IV
</B>
</A>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 0; PADDING-RIGHT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	15.
</FONT>
</TD>
<TD>
<A HREF="#V453489_10K_HTM_SBI_024">
<FONT STYLE="FONT-SIZE: 10PT">
	Exhibits, Financial Statement Schedules
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	69
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<A HREF="#V453489_10K_HTM_SBI_025">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SIGNATURES
</B>
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: BOTTOM">
	73
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="COLOR: MAROON; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: WINDOWTEXT">
	This
	Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act
	of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended (the
	&ldquo;Exchange Act&rdquo;) and, as such, may involve known and unknown risks, uncertainties and assumptions. Forward-looking statements
	are based upon our current expectations, speak only as of the date hereof, and are subject to change. Forward-looking statements
	are those that predict or describe future events or trends and that do not relate solely to historical matters. You can generally
	identify forward-looking statements as those statements containing the words
</FONT>
<FONT STYLE="COLOR: #222222">
	&ldquo;anticipate,&rdquo;
	&ldquo;believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
	&ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;might,&rdquo; &ldquo;potential,&rdquo;
	&ldquo;continue&rdquo;
</FONT>
<FONT STYLE="COLOR: WINDOWTEXT">
	or other similar expressions. You should not rely on our forward-looking
	statements as they are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove
	to be accurate because the matters they describe are subject to assumptions, known and unknown risks, uncertainties and other unpredictable
	factors, many of which are beyond our control. Our actual results could differ materially and adversely from those expressed in
	any forward-looking statements as a result of various factors, some of which are listed under the &ldquo;Risk Factors&rdquo; section
	of this Annual Report. Risks and uncertainties include, among others, the availability of funds and resources to pursue our research
	and development projects, the successful and timely completion of preclinical or clinical studies by third parties in which our
	products are utilized, our ability to meet the goals of our joint ventures and strategic partnerships, the degree of market acceptance
	for our products or for other companies&rsquo; products in which our products are components, our ability to take advantage of
	business opportunities in the pharmaceutical industry, changes in our strategy or development plans, our ability to protect our
	intellectual property, uncertainties related to governmental regulations and regulatory processes, the volatility of our common
	share price, the effect of competition, the effect of technological changes, reliance on key personnel, and general changes in
	economic or business conditions. Except as required by law, we undertake no obligation to update forward-looking statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As used in this Annual Report on Form 10-K,
	&ldquo;Stellar,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Stellar
	Biotechnologies, Inc. and our consolidated subsidiaries, except where the context otherwise requires.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our logo,
	Stellar KLH&trade; and other trademarks or service marks of Stellar Biotechnologies, Inc. appearing in this Annual Report on Form
	10-K are the property of Stellar Biotechnologies, Inc. This Annual Report on Form 10-K contains additional trade names, trademarks
	and service marks of other companies. We do not intend our use or display of other companies&rsquo; trade names, trademarks or
	service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_001">
</A>
<B>
	PART I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -55.1PT">
<A NAME="V453489_10K_HTM_SBI_002">
</A>
<B>
	Item&nbsp;1.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Business Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Stellar Biotechnologies, Inc.
	is a biotechnology company engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet
	Hemocyanin (KLH). KLH is an immune-stimulating protein with an extensive history of safe and effective use in immunological applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	KLH can be used as an active
	pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a variety
	of diseases. The protein is currently being utilized in active immunotherapies in clinical development for Alzheimer&rsquo;s disease,
	metastatic breast cancer, Crohn&rsquo;s disease, systemic lupus erythematous, ovarian cancer and various other cancers and diseases.
	The KLH protein can also be used as a finished, injectable product in the immunodiagnostic market for measuring immune response
	in patients and research settings. Immunotherapies (also known as therapeutic vaccines) involve using the body&rsquo;s own immune
	system to target and treat disease. Immunodiagnostics involve assessing the body&rsquo;s immune status in relation to the effects
	of a new drug, a disease, or the environment. Our KLH products can be used to stimulate the immune system in both applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We extract and manufacture
	KLH from the hemolymph (a fluid equivalent to blood) of a relatively scarce ocean mollusk, the Giant Keyhole Limpet. Based upon
	our specialized knowledge of aquaculture science and KLH, we have built unique land-based aquaculture, laboratory and production
	facilities in Port Hueneme, California, and developed sustainable and scalable manufacturing processes to produce KLH using Current
	Good Manufacturing Practices (cGMP or GMP).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We market and sell GMP grade and research grade
	KLH products to third parties under the brand Stellar KLH&trade;. Our customers and partners include multinational biotechnology
	and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. We believe we are positioning
	our business to meet the anticipated long-term demand within the pharmaceutical industry for GMP grade KLH by providing a sustainable
	source for its scalable, controlled, and traceable production. The versatility of the KLH molecule and the growing need for commercial-scale
	GMP grade KLH provide multiple commercial opportunities for us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Competitive Strengths
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="COLOR: BLACK">
	We
	believe that we possess a number of competitive strengths that position us to become
</FONT>
	the world leader in the sustainable
	manufacture of GMP grade KLH and KLH-conjugated vaccines
<FONT STYLE="COLOR: BLACK">
	, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Mature, land-based aquaculture facility produces a barrier to market entry.
</I>
	Using our proprietary methods and achievements
	in aquaculture science, we can support the source animal for KLH from embryo to protein-producing adult, and we now support multiple
	generations of limpets grown entirely within our land-based aquaculture facility. Other KLH suppliers do not have this capability
	and thus are reliant on scarce, wild populations. Due to the time needed to raise the source animal to maturity, and the time needed
	to build and validate facilities and manufacturing processes, we believe that we have a five to seven year lead over any new market
	entrants attempting to produce KLH in a similar manner. Due to its exceptional size and complexity, KLH has not been reproduced
	synthetically.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
<I>
	&nbsp;
</I>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Fully traceable, GMP grade product offerings benefit commercialization programs.
</I>
	Using our proprietary production and
	manufacturing methods, we are able to produce a high quality, GMP grade KLH product that is fully traceable and controlled from
	native source to finished product, which we believe are important considerations for our pharmaceutical partners as they pursue
	later-stage trials and commercial introductions subject to more rigorous regulatory standards than early-stage research. Due to
	the known origin of material and continuity of data, we believe we are able to create a more consistent, high quality, immunogenic
	product than other KLH proteins in the market. In contrast, commercial supplies of KLH from other sources have historically differed
	widely in their source, traceability, purity, form and preparation, as well as their immunogenicity (their ability to stimulate
	an immune response). We believe that we are the only company that offers GMP grade KLH supported by fully traceable manufacturing
	methods.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Multiple supply and collaboration agreements reduce single-customer dependence.
</I>
	We believe
	that our supply and collaboration agreements with drug developers, which include binding orders, allow us to better manage our
	working capital as well as build long-term relationships. Our manufacturing and quality experts work closely with our collaboration
	partners and customers to deliver KLH products according to their specifications. We believe that our record for reliably providing
	high quality KLH has created customer trust and loyalty.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
<I>
	&nbsp;
</I>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Business model leverages growth potential.
</I>
	We believe we have an attractive business model
	due to the unique nature of our product offerings, embedded growth opportunities within our existing customer base and operating
	leverage. As we increase production volumes and sales, we expect our operating expenses to decrease as a percentage of revenue,
	providing for greater operating leverage. In addition, we have established a model via our joint venture, Neostell, S.A.S., to
	participate in the manufacturing of KLH-conjugated vaccines, which provides additional revenue and growth opportunities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Intellectual property portfolio includes protection for specialized systems and technologies.
</I>
	We
	have intellectual property related to KLH development and manufacturing and to the environmental protection of the
	Giant Keyhole Limpet, including patents, trade secrets and know-how related to specialized aquaculture systems and technologies;
	spawning, selection and maintenance of the species; non-lethal KLH protein extraction methods; and the processing, purification
	and production of KLH formulations.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Sustainability practices protect marine source and promote scalability.
</I>
	Our KLH protein is
	produced using environmentally sound, sustainable practices intended to protect and renew the live marine source. We believe this
	is a critical component of ensuring long-term, scalable supplies, since rapid growth in demand has had severe consequences to other
	related species. In California, for example, failure to manage wild populations of abalone resulted in dramatic declines and eventually
	led to closure of commercial abalone harvests.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; COLOR: BLACK">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Leadership team provides extensive aquaculture production and related industry expertise.
</I>
<FONT STYLE="COLOR: BLACK">
	Our
	leadership team includes industry experts who have extensive experience in the field of aquaculture and Giant Keyhole Limpet production,
	and possess a deep understanding of a variety of biotechnology businesses. Our President and CEO has more than 40 years of experience
	leading commercial aquaculture businesses and projects focused on mollusk domestication and production.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We plan to use our proprietary methods and intellectual
	property to serve the growing demand for KLH in immunotherapy and immunodiagnostics applications. Key elements of our business
	strategy include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Expand infrastructure and capacity while maintaining a strong balance sheet.
</I>
	We plan to incrementally increase our infrastructure, manufacturing capabilities and KLH production capacity based on our customers&rsquo; forecasts and the anticipated future requirements of commercial-scale vaccine manufacturing, which we estimate could require multiple kilograms of GMP grade KLH per year. In order to produce such volumes and to provide our customers with greater certainty of future supply, we intend to have the capacity to support commercial drug launches in a variety of indications, with planned redundancy at multiple locations. We believe we can scale up capacity to meet anticipated customer demand for the next one to two years with current resources.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<I>
	Pursue additional supply and collaboration agreements.
</I>
	We plan to continue pursuing opportunities for commercial growth
	that build on our strengths and core competencies in KLH development and manufacturing, including additional supply and collaboration
	agreements. We regularly engage in discussions with various entities involved in immunotherapies, in connection with opportunities
	for licensing, supply and collaborative research.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;&nbsp;&nbsp;
</I>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Support continuing development of our Neostell Growth Initiative.
</I>
	In July 2016, we formed Neostell S.A.S., a joint venture with Neovacs S.A, to produce Neovacs&rsquo; Kinoid immunotherapy product candidates which utilize Stellar KLH&trade; as a carrier molecule. In addition to expanding our market opportunities related to manufacturing of Neovacs&rsquo; KLH-conjugated vaccines, this joint venture provides the opportunity to manufacture and sell KLH-based immunotherapies for third party customers.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Continue innovation and new product development.
</I>
	We plan to expand our KLH technology portfolio through ongoing research and development. Our research and development (R&amp;D) activities are focused primarily on the aquaculture of the Giant Keyhole Limpet; improvements in KLH protein analysis and manufacturing; the development of functional assays; and new uses for KLH in immunotherapy and immunodiagnostic applications. We believe that these activities provide long-term strategic, revenue and clinical opportunities by extending the commercial use of Stellar KLH&trade; and furthering our understanding of the KLH molecule.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Keyhole Limpet Hemocyanin (KLH)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	KLH is a safe, potent, immune-stimulating protein.
	Specifically, it is a very large, high molecular weight, oxygen-carrying glycoprotein made of millions of atoms. In addition to
	the native molecule, KLH can be chemically dissociated into a subunit formulation commonly used in the production of immunotherapies.
	Both the native, high molecular weight molecule and subunit forms of KLH are excellent immune stimulants. The KLH molecular structure
	offers numerous sites for conjugation, and can generate multiple product configurations. Because of its large size, immune-stimulating
	properties, numerous sites for conjugation, and safety profile, KLH is used by researchers and product developers as a vaccine
	carrier protein. However, due to its exceptional size and complexity, KLH has not been reproduced synthetically.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	KLH can be used as an active pharmaceutical
	ingredient, or API, or it can be used as a finished, injectable product in the immunodiagnostic market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As an active pharmaceutical ingredient, KLH
	is an effective and safe carrier molecule for conjugation to vaccine antigens that are used to promote the generation of antibody
	and cell-mediated immune responses against targeted diseases. By themselves, the small haptens (partial antigens) and vaccine antigens
	used to target these diseases are not usually immunogenic enough to awaken the immune system and therefore, require a carrier molecule
	or adjuvant, like KLH, in order to be effective. The combination of an antigen against specific pathogenic targets, such as tumors,
	and over-expressed proteins, conjugated to the immunogenic KLH molecule, is the basis for a promising new class of drugs in development
	known as active immunotherapies or therapeutic vaccines. Unlike preventative vaccines, active immunotherapies are designed to stimulate
	the body&rsquo;s own immune system to generate an immune response to target and attack an existing disease or condition. We believe
	immunotherapies are, and will continue to be, one of the fastest-growing sectors of pharmaceutical research and development. KLH
	is an important component for drugs used in clinical development, including major indications such as Alzheimer&rsquo;s disease,
	metastatic breast cancer, Crohn&rsquo;s disease, systemic lupus erythematous, ovarian cancer and various other cancers and diseases.
	New indications entering clinical trials, such as dermatomyositis, point to expanding clinical potential for KLH.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As a finished injectable product, KLH has been
	used extensively by pharmaceutical companies and researchers as a safe, immune-stimulating antigen in drug-screening, drug immunotoxicology,
	and assessment of immune status. KLH is a standard immunogen in T-Cell Dependent Antibody Response (TDAR), a functional assay which
	is widely recognized as a standard test for monitoring the effects of drugs on the immune system.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	KLH protein is derived only from the hemolymph
	of the Giant Keyhole Limpet (
<I>
	Megathura crenulata
</I>
	), a mollusk native only to a limited stretch of the Pacific Ocean coastline
	along Southern California and Baja California, Mexico. Historically, suppliers other than us have obtained KLH protein directly
	from wild and sensitive populations of Giant Keyhole Limpet, or have utilized lethal production processes. Based on publicly available
	information and reports, commercial supplies of KLH differ widely in their source, traceability, purity, form, and preparation,
	as well as in immunogenicity (their ability to stimulate an immune response). We believe that highly-specialized aquaculture manufacturing
	methods, like the methods we practice, protect the KLH molecule&rsquo;s source species and provide sustainable, scalable supplies
	of quality KLH protein. The concept of sustainability involves sound, responsible management of environmental resources and, especially
	where biological systems are concerned, includes protecting native species so that the species thrive and remain diverse and productive
	over time. Further, we believe that environmentally sound methods associated with professional and specialized aquaculture can
	minimize variability in KLH products and assure full traceability to their biological source.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Technology
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We have committed over 15 years to the advancement
	of aquaculture science and sustainable KLH production methods, specifically focused on protection of the Giant Keyhole Limpet and
	the non-lethal extraction of KLH protein. We believe our proprietary methods will provide a sustainable supply of GMP grade KLH
	and meet pharmaceutical industry standards for immune response, consistency, purity, and traceability while protecting the natural
	source species.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Our Aquaculture Technology &amp; Manufacturing
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our proprietary aquaculture technology involves
	methods we developed and optimized to control the reproduction and growth of the Giant Keyhole Limpet including, but not limited
	to, culture systems, nutritional requirements, and the recirculation of seawater. We achieved a significant milestone in aquaculture
	science by developing the capability to sustain the complete life cycle of the Giant Keyhole Limpet. Using our proprietary methods,
	we can support the marine mollusk from embryo to protein-producing adult, and we now support multiple generations of limpets grown
	entirely within our land-based aquaculture facility. Other KLH suppliers do not have this capability and thus are reliant on scarce,
	wild populations of limpets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The aquaculture cycle to raise Giant Keyhole
	Limpets from fertilized eggs to maturity for KLH production is approximately five years, with multiple complex larval and juvenile
	stages. KLH can be extracted from mature limpets a limited number of times per year and, if properly maintained, the average extracted
	quantity of KLH per year per limpet is predictable and useful in estimating targets for production planning and optimizing the
	use of the hemolymph. The hemolymph is extracted in a non-lethal manner utilizing our patented methods. Once extracted, the hemolymph
	is processed through our proprietary methods, which are protected as trade secrets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We currently maintain a production inventory
	of limpets sufficient for an annual capacity of 1,500 grams/year of KLH pharmaceutical intermediate, which can be further processed
	and purified to produce various final product grades and formulations. Given current resources, we believe we can scale up capacity
	to meet anticipated customer demand for the next one to two years. Given sufficient funding to continue scale-up, our projected
	production capacity is up to 20,000 grams (20 kg) of KLH pharmaceutical intermediate in five to seven years. We plan to incrementally
	increase hatchery production of limpets and expand aquaculture infrastructure, which will thereby increase our KLH production capacity,
	in order to meet the anticipated future multi-kilogram KLH requirements of immunotherapy commercialization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We contract with contract manufacturing organizations
	and contract testing organizations for certain steps of cGMP processing and quality control testing. The services currently performed
	by these contract vendors include sterile fill/finish and release testing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As a result of these operational capabilities,
	we believe we will be able to supply GMP grade KLH in commercial quantities to meet the anticipated long-term demand within the
	pharmaceutical industry, while protecting the natural source species. We base these beliefs on our intellectual property, achievements
	in aquaculture science, KLH production capacity, KLH sustainable manufacturing know-how, and survey data used to estimate population
	of Giant Keyhole Limpets in the wild.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Our Facilities
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We maintain research and manufacturing facilities
	directly along the Pacific Ocean with dedicated, land-based aquaculture operations in Port Hueneme, California. We have approximately
	37,000 square feet of leased aquaculture, manufacturing, and laboratory space. We believe our waterfront location is a proprietary
	asset that allows our marine scientists to work in close proximity to naturally resident Giant Keyhole Limpet
<I>
</I>
	colonies,
	and to be at the forefront in developing protective measures and environmentally sound practices for KLH production.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our aquaculture operations were specially developed
	in the late 1990s for production and research on gastropod mollusks, have been in near continuous operation since that time, and
	have since been expanded significantly by us for the specialized purpose of conducting the intensive steps required to support
	the complete life cycle of the Giant Keyhole Limpet and for the commercial production of KLH protein. Our aquaculture facility
	includes, among other specialized infrastructure, systems for spawning, larval development, and maturation of limpets, a fully
	permitted seawater supply system, recirculating seawater supply systems, environmental controls and regulated seawater return to
	the ocean. Our facility currently includes multiple production tanks and numerous individual limpet production modules in two independent
	aquaculture production systems. Each closed recirculating system is equipped with temperature controlled seawater distribution,
	filtration and treatment equipment. The facility also contains a fabrication shop for production of equipment and culture apparatus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In July 2015, we entered into an exclusive collaboration
	agreement with Ostiones Guerrero, SA de CV to secure a unique strategic site in Baja California, Mexico, for the potential development
	of an additional aquaculture locale and future expansion of our KLH production. The collaboration with Ostiones is intended to
	include design, expansion and development of marine aquaculture resources for hatchery and maturation of Giant Keyhole Limpets.
	In connection with the collaboration agreement, we also entered into a lease agreement with Ostiones for undeveloped land on which
	suitability studies are to be conducted by Stellar over the next two years. We believe this expansion will support our goal to
	meet the anticipated long-term industry demand for KLH protein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are committed to applying our proprietary
	Stellar KLH&trade; technology to improve immunotherapy and immunodiagnostics, and to protecting the natural resource for KLH. To
	that end, we are actively engaged in research and development focused primarily on the aquaculture of the Giant Keyhole Limpet;
	improvements in KLH protein analysis and manufacturing; the development of functional assays; and new uses for KLH in immunotherapy
	and immunodiagnostic applications. These activities involve both internal programs and external collaborations with other biopharmaceutical
	companies or research organizations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our internal research has included, among other
	activities, improvement of methods for the culture and growth of Giant Keyhole Limpet, innovations in aquaculture systems and infrastructure,
	biophysical and biochemical characterization of the KLH molecule, analytical processes to enhance performance of our products,
	KLH manufacturing process improvements, new KLH formulations and KLH-related technologies, and early development of potential new
	KLH-based immunotherapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our external collaborations involve both development
	and evaluation projects, with multiple biopharmaceutical companies and research institutions, for the use of Stellar KLH&trade;
	in their programs. We believe that these collaborations provide for strategic, revenue and clinical opportunities for our future
	business by extending the commercial use of Stellar KLH&trade; and furthering our understanding of the KLH molecule.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	For the years ended September 30, 2016 and 2015 and August 31, 2014, research and development expense were
	$1,715,992, $1,029,489 and $2,458,934, respectively. These amounts related mainly to research and development in aquaculture, improvements
	in analytical, manufacturing, and purification processes, stability studies, formulation development, and primarily in fiscal 2014,
	preclinical research for a potential KLH-based immunotherapy approach against C. diff infection. None of these expenses were borne
	by our customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Stellar KLH&trade; Products
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We market Stellar KLH&trade; protein in various grades, formulations
	and configurations for both preclinical and clinical applications, and certain KLH-based in vitro diagnostic kits for preclinical
	use. Our Stellar KLH&trade; product offerings include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Stellar KLH&trade; protein for conjugation and
	as carrier molecule in immunotherapy development. We offer a variety of Stellar KLH&trade; products (HMW and subunit
	formulations, GMP and research grades, and bulk and vial configurations) for use in these clinical and research
	applications.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Stellar KLH&trade; protein and ELISA test kits for immune function testing: KLH can be used in research and clinical studies
	as an antigen for assessing immune function and in immunotoxicology studies for monitoring the immunosuppressive effects of drug
	candidates. We also offer a line of Stellar KLH&trade; ELISA assay test kits for the detection of anti-KLH antibodies in preclinical
	research settings.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We currently have limited
	revenue from sales of our Stellar KLH&trade; products. The list price for Stellar KLH&trade; protein ranges from approximately
	$15,000 to $50,000 per gram, depending on the purity, grade, preparation, packaging configuration and volume ordered. Product
	sales are highly dependent upon the rate of development and clinical trials of the active immunotherapies and other technologies
	being developed by third party customers, which utilize our products. The advancement and commercial success of third-party products
	utilizing Stellar KLH is dependent upon many factors, including available capital, trial recruitment and progress, and regulatory
	review. Revenue from these customers is highly variable, but historically is not subject to seasonal fluctuations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Revenues from
	the sale of Stellar KLH&trade; products and contract services revenues related to Stellar KLH&trade; products in fiscal years
	2016, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: JUSTIFY">
	Product sales
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,239,689
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	563,689
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	143,553
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Contract services revenue
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	195,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	192,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The geographic breakdown of revenues in fiscal
	years 2016, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%">
	Europe
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Asia
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	U.S.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other countries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Customers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We primarily market and distribute our products
	directly to biotechnology and pharmaceutical companies, academic institutions, clinical research organizations and research centers.
	Products are shipped to our customers from our facilities in Port Hueneme, California using a common carrier chosen by the customer.
	The geographic markets of our customers are principally Europe, the United States and Asia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The customers that represent a significant portion
	of our total consolidated revenue in fiscal years 2016, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Customer
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	OBI Pharma, Inc.
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	41
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Eurogentec
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Neovacs SA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	30
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	AXON Neuroscience SE
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Amaran Biotechnology, Inc.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	35
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Araclon Biotech, SL
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Contracts, Supply Agreements and Collaboration Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have previously entered
	into, and intend to continue to enter into, agreements with third parties that will allow us to supply Stellar KLH&trade; in exchange
	for fees, revenues, or royalties. Supply agreements generally involve a customer&rsquo;s commitment to purchase our Stellar KLH&trade;
	for use as an active pharmaceutical ingredient in the customer&rsquo;s own immunotherapy products or as a finished product in their
	development programs. To date, our Stellar KLH&trade; protein has been used in research and development, preclinical, and clinical
	phases but has not yet been used in any commercialized and marketed products. Quantities required for clinical trials depend on,
	among other variables, the nature of the trial, the clinical indication, the number of patients enrolled, dosing regimens and vaccine
	manufacturing processes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Agreements with Neovacs S.A.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0.5IN">
<I>
	Joint Venture Agreement and Formation of Neostell
	S.A.S.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In May 2016, we entered into a joint venture
	agreement with Neovacs S.A., a publicly-held biotechnology company in Paris, France for the formation of a joint venture company
	to manufacture and sell conjugated therapeutic vaccines. In July 2016, Neostell S.A.S., a French simplified stock corporation (Neostell),
	was formed to carry out the business of the joint venture. Neostell is expected to produce Neovacs&rsquo; Kinoid immunotherapy
	product candidates which utilize Stellar KLH&trade; as a carrier molecule ingredient. Neostell may also manufacture and sell other
	KLH-based immunotherapy products for third-party customers worldwide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We hold a 30% equity interest in the joint venture
	in exchange for an initial capital contribution of &euro;120,000. One-half of the initial contribution, approximately $67,000,
	was paid prior to June 30, 2016 with the balance due upon the occurrence of certain defined future events. We will also provide
	additional financing to Neostell, as may be required, on a pro rata basis in line with our equity interest. If Neostell does not
	achieve certain milestones by December 2017, it will be dissolved, unless the parties mutually agree to pursue the joint venture
	arrangement, or either party decides to purchase the equity interests of the other party. Each of the parties is entitled, upon
	the occurrence of certain defined events, to acquire the interest of the other party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In connection with the formation of Neostell
	and the execution of its strategy, the parties intend over time to enter into an exclusive supply agreement within a limited field
	of use for Stellar to supply KLH to Neostell, a supply agreement designating Neostell as the exclusive manufacturer and supplier
	of the Neovacs&rsquo; vaccines, and services agreements for the provision of various knowledge and expertise by each of the parties.
	Neovacs will also license certain of its intellectual property to Neostell.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The joint venture has an initial ten-year term,
	renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration date of an
	applicable term that it does not wish to continue its participation in the joint venture, the other party will have a right to
	acquire all of such terminating party&rsquo;s equity interests in Neostell.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The joint venture agreement contains customary
	restrictions on transfer of the equity interests, tag-along and drag-along rights, non-competition, non-solicitation, confidentiality
	and termination provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	Supply Agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In April 2015, we entered into a supply agreement
	with Neovacs to extend and expand two prior supply agreements entered into in 2008 for the use of Stellar KLH&trade; in the development
	and manufacture of Neovacs&rsquo; active immunotherapies. Stellar KLH&trade; is used by Neovacs as a carrier molecule to stimulate
	an immune response in its Kinoid immunotherapy technology, which has two products currently in Phase II clinical trials for the
	treatment of lupus and Crohn&rsquo;s disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The agreement provides for Neovacs to purchase
	Stellar KLH&trade; for use in its proprietary KLH-based Kinoid immunotherapies in the European Union, Latin America, Asia, the
	U.S. and Canada. Neovacs will use Stellar KLH&trade; for its planned Phase II and Phase III clinical trials and for expected commercial
	manufacturing of its products for up to one year following market approval. Neovacs will manage and fund all product development
	and regulatory submissions for its immunotherapy products and act as the sponsor company for the future clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Under the terms of the agreement, we will supply
	GMP grade KLH to Neovacs according to agreed specifications, quantities and pricing, as well as maintain a master file with the
	U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) for the KLH product. We will also provide professional, technical and
	regulatory support to Neovacs. The agreement has an initial five-year term, which may be renewed by Neovacs in one-year increments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Collaboration Agreement and Lease Agreement with Ostiones Guerrero
	S.A. de C.V.(Ostiones)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In July 2015, we entered into a collaboration
	agreement with Ostiones, a privately held commercial fishing corporation in Baja California, Mexico. The purpose of the agreement
	is to secure a strategic site in Baja California, Mexico for the potential development of an additional aquaculture locale and
	future expansion of our KLH production, subject to a site suitability study to be conducted over the next three years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The agreement provides for Stellar and Ostiones
	to collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities in Baja California,
	Mexico to provide, exclusively for Stellar, an additional site for hatchery and maturation of Giant Keyhole Limpets and production
	of KLH. Ostiones will provide local manpower, labor and operational support, the costs of which are subject to our prior approval
	and monthly reimbursement. As part of the collaboration, Ostiones will gain access to our proprietary aquaculture techniques and
	expertise, support services and training to facilitate the expansion of Ostiones&rsquo; seafood production business. During the
	three-year term of the agreement and for five years thereafter, the parties are subject to customary non-competition and non-contravention
	provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In June 2015, we entered into a lease agreement
	with Ostiones whereby Ostiones leased to Stellar undeveloped land in Baja California, Mexico to assess its suitability for the
	long-term development and potential expansion of our production capability. The first two years rent was prepaid in June 2015.
	The lease agreement and the collaboration agreement each expire in June 2018, unless terminated earlier. If we decide to proceed
	with development of the site, we have options to extend the lease for 30 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Under the terms of the collaboration and lease
	agreements, we will be responsible for certain improvements to the leased, undeveloped land, including construction of certain
	structures and a power-generating facility, which will be owned by us. We expect to enter into separate usage and supply agreements
	covering the use of site resources and utilities such as seawater and power, and for the production of Giant Keyhole Limpets by
	Ostiones exclusively for us. However, any such agreements are contingent upon completion of our site suitability assessment and
	we are currently under no obligation to execute such agreements at this time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Supply Agreement with Araclon Biotech, S.L.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In November 2014, we entered into an exclusive
	supply agreement with Araclon Biotech SL, a privately-held biotechnology company headquartered in Spain and majority-owned by global
	healthcare company Grifols (Araclon). Araclon is developing beta amyloid-targeting active immunotherapies for neurodegenerative
	diseases with a primary focus on Alzheimer's disease. Araclon's patented technology involves immunization against amyloid-beta
	together with KLH as a carrier protein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The purpose of the agreement is to ensure a stable
	supply of KLH to Araclon to support Phase II/III clinical trials of Araclon&rsquo;s Alzheimer's drugs, including the development
	of manufacturing processes and production capacity. Under the agreement, Araclon will manage and fund all product development and
	regulatory submissions for its products. We will supply GMP grade Stellar KLH&trade; protein and provide technical and regulatory
	support to Araclon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Under the terms of the
	agreement, Araclon will purchase KLH exclusively from us, and we will supply KLH exclusively to Araclon, for use in Araclon&rsquo;s
	beta amyloid-targeting active immunotherapies against Alzheimer&rsquo;s at agreed specifications, quantities and pricing. In addition,
	the agreement provides us with first negotiation rights for the exclusive supply of KLH in connection with the potential future
	commercialization by Araclon of its beta amyloid-targeting immunotherapy products. The agreement has an initial five-year term,
	which may be renewed by Araclon for additional one-year periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Intellectual Property and License Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We hold important proprietary intellectual property
	related to KLH development and manufacture and to the environmental protection of the Giant Keyhole Limpet including, but not limited
	to, patents and trade secrets related to specialized aquaculture systems and technologies; spawning, selection and maintenance
	of the Giant Keyhole Limpet; non-lethal KLH protein extraction methods; and the processing, purification and production of KLH
	formulations. Our proprietary methods also include methods for the control of larval development, metamorphosis and maturation
	of the Giant Keyhole Limpets, which we protect as trade secrets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our success depends in part on our ability to
	obtain and maintain proprietary protection for our product technology and know-how, to operate without infringing proprietary rights
	of others, and to prevent others from infringing our proprietary rights. We seek to protect our proprietary position by, among
	other methods, filing, when possible, U.S. and foreign patent applications relating to our technology, inventions and improvements
	that are important to our business. We also rely on trade secrets, know-how, continuing technological innovation, and in-licensing
	opportunities to develop and maintain our proprietary position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We hold patent protection for our non-lethal
	extraction methods of hemocyanin in the United States and other countries, including one issued patent in the United States, U.S.
	Patent No. 6,852,338, which currently expires in 2023, and covers a two-step method for obtaining hemolymph from a live gastropod
	mollusk. This U.S. patent was originally granted to our Chief Executive Officer, Frank Oakes, who assigned the patent to the Company
	in August 2002. Foreign patent counterparts were granted in Canada, France and Germany.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We have a worldwide exclusive license with the
	University of Guelph to one issued patent in the United States, U.S. Patent No. 8,597,663, which currently expires in 2030, for
	certain novel cell surface polysaccharides and their chemical structures and vaccine compositions for the treatment, prevention
	and diagnosis of C. difficile infection. We also have foreign patent counterparts and foreign patent applications and patents claiming
	priority therefrom in certain jurisdictions outside the United States, including Europe, Australia, Canada, China, Japan and New
	Zealand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The scope of any patent protection may not exclude
	competitors or provide competitive advantages to us, and any of our patents may not be held valid if subsequently challenged, and
	others may claim rights in or ownership of our patents and proprietary rights. Furthermore, others may develop products similar
	to our products and may duplicate any of our products or design around our patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our trademarks include, but are not limited
	to, &ldquo;Powering and Improving Immunotherapy&trade;&rdquo;, &ldquo;Stellar KLH&trade;&rdquo; and &ldquo;KLH Site&trade;&rdquo;.
	In addition to patents and trademarks, we rely on trade secrets and other intellectual property laws, nondisclosure agreements
	and other measures to protect our intellectual property rights. We believe that in order to have a competitive advantage, we must
	develop and maintain the proprietary aspects of our technologies. We require our employees, consultants and advisors to execute
	confidentiality agreements in connection with their employment, consulting or advisory relationship with us. We also require our
	employees, and to the extent practicable, our consultants and advisors with whom we expect to work on our products to agree to
	disclose and assign to us all inventions made in the course of our working relationship with them, while using our intellectual
	property or which relate to our business. Despite any measures taken to protect our intellectual property, unauthorized parties
	may attempt to copy aspects of our products or to wrongfully obtain or use information that we regard as proprietary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	License Agreement with University of Guelph
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In July 2013, we acquired the exclusive,
	worldwide license to certain patented technology for the development of human immunotherapies against
<I>
	Clostridium difficile
</I>
	infection (C. diff), a highly contagious bacteria spread by human contact, from the University of Guelph, Ontario,
	Canada (the &ldquo;Guelph License&rdquo;). Under the terms of the Guelph License, we have the exclusive rights to develop, manufacture,
	and sell active immunotherapies to treat C. diff infection that derive from the technology covered by certain of the University&rsquo;s
	international patents and patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Guelph License agreement required an initial,
	non-refundable license fee of $25,000, which was paid in fiscal 2013, payment of an aggregate of $200,000 in delayed license fees,
	which were paid in fiscal 2014, and a license fee of $20,000 to be paid annually thereafter, creditable against royalties due,
	if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a percentage of
	related non-royalty sublicensing revenue, if any. No royalties have been incurred to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As additional consideration, we also issued
	to the University of Guelph 37,120 common shares and warrants to purchase up to 27,840 of our common shares with an exercise price
	of C$12.50 per share.&nbsp;The warrants expired on January 23, 2015 without being exercised.&nbsp;We reimbursed patent filing costs
	of approximately $11,000, $52,000, and $34,000 in fiscal 2016, 2015 and 2014, respectively, and will reimburse certain future patent
	filing, prosecution, and maintenance costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are required to pay up to an aggregate of
	$6,020,000 in milestone payments to the University of Guelph upon achievement of various financing and development targets up to
	the first regulatory approval. Remaining milestone payments totaling $57,025,000 are related to achievement of sales targets. We
	are required to provide regular reports to the University of Guelph regarding product development efforts, and progress toward
	meeting certain milestones. A financing milestone was met during fiscal 2014 and, accordingly, we made a milestone payment of $100,000
	to the University of Guelph. No other milestones have been met to date, and there can be no assurance that any remaining milestones
	will be met in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Guelph License agreement expires when the
	last valid patent claim licensed under the agreement expires, which is currently 2030. Prior to that time, the agreement can be
	terminated by the University of Guelph upon certain conditions including: (i) our failure to make any payments or submit any reports
	when due; (ii) our failure to diligently pursue development or commercialization of the product based upon our reports; (iii) our
	material breach of any provision of the Guelph License; or (iv) providing a false report. We will have 30 days after written notice
	from the University of Guelph to cure the problem prior to termination of the agreement. We can terminate the Guelph License with
	three months&rsquo; prior written notice to the University of Guelph.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Collaboration Agreement and Exclusive Licensing Rights with Bayer
	Innovation GmbH
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In August 2011 we acquired an exclusive, worldwide
	sub-licensable and royalty-free license to the technology we developed under collaboration with Bayer Innovation GmbH (Bayer)
	for the improved production method and process yields for Stellar KLH&trade;. The license included a carve-out by Bayer to use
	the technology in certain non-Hodgkin Lymphoma active immunotherapies, but we may exclusively commercialize the technology in other
	fields. We paid Bayer $200,000 in 2011 for the licensing rights, which are jointly owned by Bayer and us. We assessed the licensing
	rights for impairment and wrote off the unamortized balance in July 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Grants
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We have historically financed a portion of our
	operations through the receipt of monetary grants made available through programs funded and administered by various U.S. government
	entities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the fiscal 2014,
	we recognized, through our California subsidiary, the remaining $36,579 in grant funding from the National Science Foundation
	(NSF) Small Business Innovation Research (SBIR) through the Technology Enhancement for Commercial Partnerships program under Phase
	II and Phase IIB grants, which totaled approximately $1.2 million over a 4-year period. Our project was entitled &ldquo;
<I>
	Megathura
	Crenulata
</I>
	Post Larval Culture - Bottleneck for a Valuable Medical Resource,&rdquo; and the purpose of the project was to allow
	for the full implementation of the commercial scale aquaculture systems for KLH production and development of a validated KLH-based
	immunogenicity assay. Grant revenues were recorded as we fulfilled the grant requirements. In addition to NSF grants, we also
	receive grants from time to time for the development of new technology from the National Institutes of Health, National Cancer
	Institute (NIH), the California Technology Investments Program (CalTIP), and Internal Revenue Service (IRS) qualifying therapeutic
	discovery project grants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The immunotherapy industry is rapidly evolving and new competitors
	with competing technologies and products are regularly entering clinical development and the market. We compete on the basis of:
	the advantages and disadvantages of Stellar KLH
<SUP>
	TM
</SUP>
	as compared to other KLH proteins manufactured by our competitors;
	our ability to educate the industry about the high quality, and sustainable and traceable features, of Stellar KLH
<SUP>
	TM
</SUP>
	;
	our ability to supply scalable quantities of GMP grade KLH; product efficacy; customer service; and the price and demonstrated
	cost-effectiveness of Stellar KLH
<SUP>
	TM
</SUP>
	as compared to our competitors. We believe that our products and services currently
	compete favorably with respect to such factors. However, we may not be able to maintain our competitive position against current
	and potential competitors. We compete directly with Biosyn Corporation, a pharmaceutical and biotechnology company which manufactures
	KLH starting material and offers clinical and research grade KLH products. We also compete directly with SAFC, a division of Sigma-Aldrich,
	which offers clinical and research grade KLH products manufactured from its own starting material from ocean harvested limpets
	and from aquaculture starting material purchased from us. In addition to competition from current suppliers of KLH, we also face
	indirect competition from developers of other carrier proteins, adjuvants or therapeutic vaccine platforms. We are unable to predict
	what effect evolution of the KLH and immunotherapy industries and potential new entrants may have on price, selling strategies,
	intellectual property or our competitive position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Government Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our operations, including our aquaculture and
	harvesting activities, as well as production operations, site development, and drug research, development and sales, are subject
	to complex regulation at the local, state and federal levels in the United States by a number of regulatory agencies including,
	but not limited to, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, the U.S. Fish and Wildlife
	Service, the U.S. Secretary of the Navy, the Regional Water Quality Control Board Los Angeles Region, the California Department
	of Fish and Wildlife, the California Coastal Commission, the California Air Pollution Control Board, the County of Ventura, and
	the City of Port Hueneme.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are subject to laws and regulations covering
	clean water and waste discharge, and are required to hold licenses for the aquaculture production and wild harvesting of the Giant
	Keyhole Limpet. Our aquaculture facility is subject to regulation by the California Department of Fish and Wildlife and the Regional
	Water Quality Control Board, Los Angeles Region. These agencies impose regulations that restrict any activity that could pose a
	potential risk to the California marine environment including, but not limited to, seawater waste discharge limitations specified
	in our National Pollution Discharge Elimination Systems (NPDES) permit. We have operated in compliance with all environmental regulations
	imposed by these agencies since the formation of our California subsidiary in 1999, apart from a
<I>
	de minimus
</I>
	settlement in
	April 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition to regulations in the United States,
	we may be subject to a variety of foreign regulations related to research, manufacturing, and the commercial sale and distribution
	of our products, to the extent we choose to manufacture, sell or distribute any products outside of the United States. The requirements
	governing our activities in jurisdictions outside the United States vary greatly from country to country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Product Development and Customer Regulatory Support
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Currently, none of our
	products are subject to approval as a drug by any regulatory authority. However, a number of our customers and strategic partners
	are utilizing Stellar KLH&trade; in the development of pharmaceuticals and immunotherapies that are subject to the regulatory approval
	process in various jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have submitted Type
	II Master Files for our KLH drug substance and drug product formulations to the FDA Center for Biologics Evaluation and Research
	(CBER) and the FDA Center for Drug Evaluation and Research (CDER). A Master File is a confidential, detailed dossier kept on file
	at the FDA that contains the proprietary information on the manufacture and safety of a drug component. These files can be used
	to support the regulatory approval process for customers&rsquo; immunotherapy products that use our Stellar KLH&trade;, while allowing
	us to control access to our manufacturing data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The regulatory approval process for new drugs
	under development by our customers is typically long and expensive. Clinical trials that they conduct may not be successful and
	such products may not receive regulatory approval.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Delays by our customers
	in obtaining, or the inability to obtain, regulatory approvals for their products which use Stellar KLH
<SUP>
	TM
</SUP>
	will have
	a direct effect on the demand for our products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Good Manufacturing Practices
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The FDA and other regulatory agencies regulate
	and inspect equipment, facilities and processes used in the manufacture of pharmaceutical and biologic products prior to approving
	a product. If, after receiving approval from regulatory agencies, a company makes a material change in manufacturing equipment,
	location or process, additional regulatory review and approval may be required. All facilities and manufacturing techniques used
	for the manufacture of our products must comply with applicable regulations governing the production of pharmaceutical products
	known as Current Good Manufacturing Practices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The FDA and other regulatory agencies also conduct
	regular, periodic visits to re-inspect equipment, facilities and processes following initial approval of a product. If, as a result
	of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and
	conditions of product approval, regulatory agencies may issue warning or similar letters or may seek civil, criminal, or administrative
	sanctions against us. To date, we have not been subject to inspection by the FDA or other drug regulatory agency because none of
	our customers or partners has filed an application in any country for marketing approval of a product encompassing our Stellar
	KLH&trade; protein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Backlog and Renegotiation of Profits
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Orders for our products are generally filled
	on a current basis, and order backlog is not material to our business. In addition, our business is not subject to renegotiation
	of profits or termination of contracts at the election of a government.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Employees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As of December 9, 2016, we had 23 employees.
	We consider our employee relations to be good. None of our employees are represented by a labor union or collective bargaining
	agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Corporate Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We operate through our wholly-owned
	subsidiary, Stellar Biotechnologies, Inc., a California corporation which was organized September 9, 1999. We acquired the subsidiary
	on April 12, 2010 through a reverse merger and began trading on the TSX Venture Exchange (TSX-V) under the symbol &ldquo;KLH&rdquo;
	on April 19, 2010. We were originally incorporated in Canada on June 12, 2007 under the name China Growth Capital, Inc. and subsequently
	changed our name to CAG Capital, Inc. on April 15, 2008. We began trading on the TSX Venture Exchange as a Canadian capital pool
	company on August 29, 2008, and became a British Columbia corporation on November 25, 2009. Our reverse merger in April 2010 constituted
	our &ldquo;qualifying transaction&rdquo; under Canadian law, at which time we changed our name to Stellar Biotechnologies, Inc.
	In January 2013, we began trading on the U.S. OTCQB Marketplace Exchange under the symbol &ldquo;SBOTF&rdquo; and, on November
	5, 2015, our common shares began trading on The Nasdaq Capital Market (Nasdaq) under the symbol &ldquo;SBOT.&rdquo; On March 29,
	2016, at our request, our common shares were voluntarily delisted from the TSX-V in Canada and ceased trading on the TSX-V as of
	the close of business on April 8, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our executive offices are
	located at 332 East Scott Street, Port Hueneme, California 93041. Our phone number is (805) 488-2800. Our website address is www.stellarbiotechnologies.com.
	The contents of our website are not part of this Annual Report on Form 10-K for any purpose or otherwise incorporated by reference.
	Our website address is included for information only.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Available Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	We file or furnish
	periodic reports, including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and current reports on Form 8-K,
	proxy statements and other information with the SEC
</FONT>
	, and amendments to such reports filed or furnished pursuant to Section
	13(a) or 15(d) of the Securities Exchange of 1934, as amended, as soon as reasonably practicable after we electronically file or
	furnish such materials to the SEC.
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	Such reports
</FONT>
	and filings may
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	be
	obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549, by calling the SEC at (800)
	SEC-0330 or by sending an email to the SEC at publicinfo@sec.gov. In addition, the SEC maintains a website (www.sec.gov) that contains
	reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our reports,
	proxy statements and other information are also made available, free of charge, on our investor relations website at http://ir.stellarbiotechnologies.com
	as soon as reasonably practicable after we electronically file such information with the SEC. References to our corporate website
	address (www.stellarbiotechnologies.com) in this Annual Report on Form 10-K are intended to be inactive textual references only,
	and none of the information contained on our website is part of this report or incorporated in this report by reference
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="V453489_10K_HTM_SBI_003">
</A>
<B>
	Item 1A.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-INDENT: -55.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Certain factors may
	have a material adverse effect on our business, financial conditions and results of operations. You should carefully consider
	the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form
	10-K, including our financial statements and the related notes, before deciding to invest in our common shares. The risks and
	uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that
	we currently believe to be immaterial may also adversely affect our business. If any of the following risks actually occurs, our
	business, financial condition, results of operations and future prospects could be materially and adversely affected.&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to Our Business
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have a history of net losses and limited cash flow to sustain
	our operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We currently have limited revenue from product
	sales of Stellar KLH
<SUP>
	TM
</SUP>
	, and anticipate our planned total operating expenses will be greater than our revenues for the
	foreseeable future. We incurred net losses of $5.03 million in fiscal 2016, $
<FONT STYLE="FONT-SIZE: 10PT">
	2.84
</FONT>
	million in
	fiscal 2015 and $8.44 million in fiscal 2014. As of September 30, 2016, we have an accumulated deficit of $40
<FONT STYLE="FONT-SIZE: 10PT">
	.2
	million
</FONT>
	since inception. To date, we have not paid dividends on our common shares and do not anticipate doing so in the
	foreseeable future. We have historically relied upon the sale of common shares to help fund our operations and meet our obligations.
	Any future additional equity financing would cause dilution to current shareholders. If we do not have sufficient capital for our
	operations, management would be forced to reduce or discontinue our activities, which would have a negative effect on our operations
	and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We depend heavily on the success and market acceptance of
	Stellar KLH
<SUP>
	TM
</SUP>
	and we may never recoup our investment into its research and development.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We have invested a significant portion of our
	time and financial resources into the development of Stellar KLH
<SUP>
	TM
</SUP>
	. We anticipate that in the near term our ability
	to generate revenues will depend solely on the commercial success of Stellar KLH
<SUP>
	TM
</SUP>
	, which depends upon its market acceptance
	by purchasers in the pharmaceutical market and the future market demand and medical need for products and research utilizing KLH.
	The degree of market acceptance of Stellar KLH
<SUP>
	TM
</SUP>
	depends on a number of factors including: the advantages and disadvantages
	of Stellar KLH
<SUP>
	TM
</SUP>
	as compared to other KLH proteins; our ability to educate the industry about the high quality, sustainable
	and traceable qualities of Stellar KLH
<SUP>
	TM
</SUP>
	; product efficacy; customer service; and the price and demonstrated cost-effectiveness
	of Stellar KLH
<SUP>
	TM
</SUP>
	as compared to our competitors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our customers face uncertainties related to regulatory approval,
	which could reduce the market for our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	A primary market for our Stellar KLH
<SUP>
	TM
</SUP>
	products is
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	its use as a component
</FONT>
	of active immunotherapies
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	under
	development
</FONT>
	. The pharmaceutical industry is subject to significant government regulation, which varies from country to country.
	Many of the products
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	being
</FONT>
	developed by our customers that utilize
	our Stellar KLH
<SUP>
	TM
</SUP>
	are not yet approved for commercial sale. Before regulatory approvals for the commercial sale of any
	drug is granted, it must be demonstrated through preclinical research and clinical trials to be safe and effective for its intended
	use in humans. The process to determine safety and efficacy, including clinical trials, is expensive, prolonged and uncertain.
	The time necessary to complete these processes and clinical trials, and to submit applications for regulatory approvals, is difficult
	to predict and is subject to numerous factors outside of our control. Such clinical trials may not be successful. Larger or later
	stage clinical trials may not produce the same results as earlier trials. Successful results in clinical trials may not result
	in regulatory approval, due to certain factors including unacceptable side effects or safety issues. If regulatory approval is
	granted for any drug or product that utilizes Stellar KLH
<SUP>
	TM
</SUP>
	, it will be subject to ongoing regulatory requirements,
	which include registration, manufacturing, labeling, advertising and promotion, packaging, distribution, record keeping and reporting,
	and storage. Manufacturing facilities, both those operated by us and by our contractors, would be subject to continual review and
	inspection, and failure to meet these regulatory requirements can interrupt, delay, or shut down these facilities. Previously unknown
	problems may result in regulatory restrictions on such products, including withdrawal from the marketplace. Delays in obtaining
	regulatory approvals for products developed by our customers that use Stellar KLH
<SUP>
	TM
</SUP>
	, or failure to obtain or maintain
	regulatory approvals altogether, would have a negative effect on market demand for our Stellar KLH
<SUP>
	TM
</SUP>
	products, and have
	a negative effect on our operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our business is geographically concentrated and if a catastrophic
	event, such as a hurricane, an earthquake or coastal flooding, were to impact our facilities, our business may be disrupted which
	could result in serious harm to our business, results of operations and financial condition.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our aquaculture operations, research and manufacturing
	facilities, laboratory space, and executive offices are all located in Port Hueneme, California, a coastal city located along the
	Pacific Ocean. To date, we have conducted all of our aquaculture operations, research and manufacturing at these facilities and
	we currently have no active backup facilities or second sites. In July 2015, we entered into a collaboration agreement with Ostiones
	Guerrero S.A. de C.V. to secure a strategic site in Baja California, Mexico for the development of an additional aquaculture locale
	and expansion of our KLH production. However, we do not anticipate the site to be available for manufacture and production until
	2018 at the earliest. There can be no assurance that these expansion plans will result in successful development of additional
	sites of research and manufacturing and KLH production outside of our Port Hueneme location. If a hurricane, an earthquake or other
	natural disaster, including coastal flooding, or a virus affecting our limpet colony, were to impact our facilities, we may be
	unable to manufacture our KLH products, which would have a serious disruptive impact on our business and a material adverse effect
	on our results of operations and financial condition. While we carry personal property insurance, such insurance may not be adequate
	to compensate us for losses from any damage or interruption of our business operations resulting from a hurricane, an earthquake,
	coastal flooding or other catastrophic event.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Uncertainty in the global geopolitical landscape from recent
	events may impede the implementation of our strategy outside the United States.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There may be uncertainty
	as to the position the United States will take with respect to world affairs and events following the 2016 U.S. presidential election
	and related change in political agenda, coupled with the transition of administrations. This uncertainty may include such issues
	as U.S. support for existing treaty and trade relationships with other countries. This uncertainty, together with other key global
	events during 2016 (such as the continuing uncertainty arising from the Brexit referendum in the United Kingdom as well as ongoing
	terrorist activity), may adversely impact (i) the ability or willingness of non-U.S. companies to transact business in the United
	States, including with Stellar (ii) regulation and trade agreements affecting U.S. companies, (iii) global stock markets ( including
	The Nasdaq Capital Market on which our common shares are traded), and (iv) general global economic conditions. All of these factors
	are outside of our control, but may nonetheless cause us to adjust our strategy in order to compete effectively in global markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our joint venture with Neovacs involves numerous risks that
	could adversely impact our financial results.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In May 2016, we entered into a strategic relationship
	with Neovacs S.A. to manufacture and sell conjugated therapeutic vaccines through a newly-formed joint venture entity in France
	called Neostell S.A.S. This relationship is subject to various risks that could adversely affect the value of our investments and
	our results of operations. These risks include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our interests could diverge from those of Neovacs or we may not be able to agree on ongoing manufacturing and operational activities,
	or on the amount, timing, or nature of further investments in Neostell;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience difficulties in transferring technology to Neostell;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience difficulties and delays in manufacturing and production at Neostell;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	as a minority partner, our control over the operations of Neostell is limited;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Neovacs may be unable to meet its commitments to us or to Neostell, which may pose credit risks for our transactions with them;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	due to differing business models or long-term business goals, we and Neovacs may not participate to the same extent on funding
	capital investments in Neostell;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our working capital or cash flows may be inadequate to fund increased capital requirements in Neostell;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may experience difficulties or delays in collecting amounts due to us from Neostell and/or Neovacs due to multinational
	financial regulations or geopolitical forces beyond our control; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	shifts in the geopolitical landscape resulting from the 2016 U.S. presidential election may result in tax, legal, or regulatory
	changes in the United States, France and/or the European Union, thereby necessitating amendments to the agreements with Neovacs
	and/or the structure of the joint venture.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	If our joint venture with Neovacs is unsuccessful,
	our business, results of operations, or financial condition may be materially adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our expansion plans include the design and development of
	aquaculture infrastructure and KLH production in Mexico which presents substantial risks to our business and personnel. We may
	never recoup our investment into this location.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We plan to develop an additional aquaculture
	locale and expand KLH production on leased, undeveloped land in Baja California, Mexico. We are currently engaged in a three-year
	study to assess the suitability of the site, and to initiate the design, expansion, and development of aquaculture resources and
	KLH production facilities there. There are certain administrative, legal, governmental and societal risks to operating in Mexico
	that could adversely impact our ability to expand our operations there. Any one or more of the risks that could adversely affect
	our ability to successfully implement our expansion and therefore ultimately have a material adverse effect on our business, financial
	condition and results of operations include, without limitation:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	geopolitical factors resulting from the 2016 U.S. presidential election and related change in administration, that could adversely
	impact the ongoing relationship between the United States and Mexico and/or the continuity of the North American Free Trade Agreement,
	or NAFTA, in its present form;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regional political and economic instability;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	rate of crime in Mexico;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	ability to hire and maintain a significant work force;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	burdensome and evolving government regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	cooperation of various departments of the Mexican government in issuing permits, and inspecting our operations on a timely
	basis;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	providing adequate security for our employees; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	change in the value of the Mexican peso.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our sales in international markets subject us to foreign currency
	exchange and other
</I>
</B>
<B>
<I>
	risks and costs, which could harm our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 39.05PT; TEXT-ALIGN: JUSTIFY">
	Substantial portions of our revenues are derived
	from outside the United States; primarily from Europe and Asia. We anticipate that revenues from international customers will continue
	to represent a substantial portion of our revenues for the foreseeable future. All our revenues are generated in U.S. dollars.
	However, if the effective price of our products were to increase as a result of fluctuations in foreign currency exchange rates,
	demand for our products could decline and adversely affect our results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<BR>
<B>
<I>
	We compete with other companies in KLH production and manufacturing that may have greater resources than we do.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The immunotherapy industry is rapidly evolving
	and new competitors with competing technologies and products are regularly entering the market. Our Stellar KLH
<SUP>
	TM
</SUP>
	products
	are similar to KLH-based products produced by other companies. While we believe we are the only company that offers GMP grade KLH
	supported by fully traceable manufacturing methods, we may not be able to maintain our competitive position against current and
	potential competitors. We compete directly with Biosyn Corporation, a pharmaceutical and biotechnology company which manufactures
	KLH starting material and offers clinical and research grade KLH products. We also compete directly with SAFC, a division of Sigma-Aldrich,
	which offers clinical and research grade KLH products manufactured from its own starting material from ocean harvested limpets
	and from aquaculture starting material purchased from us. Some of our competitors, both public and private, have greater financial
	and personnel resources than us, and have greater sales and marketing experience in the industry than us. If they are able to produce
	and sell comparable KLH products for less than us, it will have a negative effect on our operations and financial position. In
	addition to competition from current suppliers of KLH, we also face indirect competition from developers of other carrier proteins,
	adjuvants or therapeutic vaccine platforms. We are unable to predict what effect evolution of the KLH and immunotherapy industries
	and potential new entrants may have on price, selling strategies, intellectual property or our competitive position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may not be able to meet demand for KLH from either internally
	raised or ocean harvest sources.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are dependent upon a supply of Giant Keyhole
	Limpets (
<I>
	Megathura crenulata
</I>
	) for KLH production. The range of the Giant Keyhole Limpet in the wild is limited, and due
	to the lack of a regulated harvest, the wild stocks of Giant Keyhole Limpets are believed to be declining. If the wild stocks are
	depleted, and our hatchery and aquaculture operations are unable to produce sufficient supplies of captive Giant Keyhole Limpets
	to meet demand, it would have a negative effect on our operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may not be able to manufacture our products in commercial
	quantities and currently depend on third parties for certain steps in our manufacturing operations, which could prevent us from
	marketing our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We contract with third party vendors, including
	contract manufacturing organizations and contract testing organizations, for certain steps in the manufacture and testing of our
	products, and may be unable to establish and maintain relationships with qualified manufacturers in order to produce sufficient
	supplies of our finished products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are currently dependent upon a small number
	of contractors and locations for certain steps in our manufacturing operations, namely fill/finish of vialed products and release
	testing. We do not currently have backup manufacturing capacity for some of our key products. If we are unable to retain our current
	contractors, or are unable to obtain new contractors to provide manufacturing services in a timely manner and on similar terms,
	it will have a negative effect on our operations. Further, these contract manufacturers and testing organizations provide services
	to many biotechnology and research companies, and such third party contractors may not provide acceptable quality, quantity or
	costs required by us. In addition, they may not be able to provide the services required on a schedule acceptable to us. These
	issues may result in us being unable to manufacture our products in the required quantities or at an acceptable cost, which would
	have a negative effect on our operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have been, and expect to continue to be in the future,
	significantly dependent on collaboration and supply agreements for the development and sales of Stellar KLH
<SUP>
	TM
</SUP>
	.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In conducting our research and development and
	commercialization activities, we currently rely, and expect to continue to rely, on collaboration and supply agreements with third
	parties, such as contract research organizations, commercial partners, universities, gover
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	nmental
	agencies and not-for-profit organizations, for strategic, technological, and financial resources. The inability to secure agreements
	on acceptable terms, the termination of these relationships, changes in our strategy or development plans or those of third parties,
	or failure to perform by us or third parties who are subject to regulatory, competitive and other risks, under their respective
	agreements or arrangements with us, would substantially disrupt or delay our research and development and commercialization activities,
	including anticipated commercial sales. Any such loss would likely increase our expenses and materially harm our business, financial
	condition and results of operation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We have limited marketing, sales and distribution experience
	and capabilities. We will need to establish sales and marketing capabilities or enter into agreements with third parties to market
	and sell our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We currently have limited experience in the
	marketing, sales and distribution of KLH-based therapeutic or diagnostic products. Depending on market acceptance of our Stellar
	KLH
<SUP>
	TM
</SUP>
	products, we may need to expand our capabilities. We may not be able to establish such additional capabilities
	in-house, and then will need to enter into agreements with third parties to successfully perform these tasks. If we contract or
	make arrangements with third parties for the sales and marketing of our products, our revenues will be dependent on the efforts
	of these third parties, whose efforts may not be successful. If we market any of our products directly, we must either internally
	develop or acquire a marketing and sales force, which would require substantial resources and management attention.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We rely on the significant experience and specialized expertise
	of our Chief Executive Officer and other members of our senior management team, and we will need to hire and retain other highly
	skilled personnel to maintain and grow our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our ability to be successful in the highly competitive
	biotechnology and pharmaceutical industries depends in large part upon our ability to attract and retain highly qualified managerial,
	scientific, medical, sales and other personnel. Our performance is substantially dependent on the research and development and
	business development expertise of Frank Oakes, our President and Chief Executive Officer, and other executive officers. We do not
	have employment agreements currently in effect with Mr. Oakes and other executive officers, and they are free to leave their employment
	with us at any time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	There is little possibility that this dependence
	will decrease in the near term. The loss of the services of Mr. Oakes, or the increased demands placed on our key executives and
	personnel by our continued growth, could adversely affect our financial performance and our ability to execute our strategies.
	Our continued success also depends on our ability to attract and retain qualified team members to meet our future growth needs.
	We may not be able to attract and retain necessary team members to operate our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition, our future success depends on our
	ability to identify, attract, hire, train, retain and motivate highly skilled technical, managerial and research personnel in all
	areas within our organization. We plan to continue to grow our business and will need to hire additional personnel to support this
	growth. We believe that there are only a limited number of individuals with the requisite skills to serve in many of our key positions,
	and we compete for key personnel with other biotechnology companies, as well as universities and research institutions. It is often
	difficult to hire and retain these persons, and we may be unable to timely replace key persons if they leave or be unable to fill
	new positions, as they become available, requiring key persons with appropriate experience. If we fail to attract, integrate and
	retain the necessary personnel, our ability to maintain and grow our business could suffer significantly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We are subject to the risk of product liability claims, for
	which we may not have, or be able to obtain, adequate insurance coverage.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The pharmaceutical industry is subject to product
	liability claims in the event of adverse effects, even in respect to products that have received regulatory approval for commercial
	sale. Such claims might be made directly by consumers, healthcare providers or by pharmaceutical companies, or others selling or
	utilizing our Stellar KLH
<SUP>
	TM
</SUP>
	products. Although we currently maintain liability insurance for our products, we may not
	be able to obtain or maintain sufficient and affordable insurance coverage for all claims that may occur. The cost of any product
	liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain
	or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims
	could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business,
	financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Our activities are subject
	to regulation in the United States and in the foreign jurisdictions in which we operate. Failure to comply with applicable laws
	and regulations could adversely impact our operations
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our operations, including our aquaculture and
	harvesting activities, and our production activities, are subject to regulation at the local, state and federal levels in the United
	States by a number of regulatory agencies including, but not limited to, the U.S. Food and Drug Administration, the U.S. Environmental
	Protection Agency, the U.S. Fish and Wildlife Service, the U.S. Secretary of the Navy, The Regional Water Quality Control Board,
	the California Department of Fish and Wildlife, and similar foreign agencies. In addition to regulations in the United States,
	we may be subject to a variety of foreign regulations related to research, manufacturing, and the commercial sales and distribution
	of our products, to the extent we choose to manufacture, sell or distribute any products outside of the United States. If we are
	unable to comply with laws and regulations in the United States and elsewhere, our operations could be restricted, or sanctions
	could be imposed on us, if we are found to not be in compliance with any such regulation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	We may face environmental
	risks related to handling regulated substances and hazardous materials.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our research
	and clinical development activities, as well as the manufacture of materials and products, are subject to federal, state and local
	laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling
	and disposal of certain materials, biological specimens and wastes. We may be required to incur significant costs to comply with
	environmental and health and safety regulations in the future. Our research and clinical development, both now and in the future,
	may involve the controlled use of hazardous materials, including but not limited to certain hazardous chemicals. We cannot completely
	eliminate the risk of accidental contamination or injury from these materials. In the event of such an occurrence, we could be
	held liable for any damages that result and any such liability could exceed our resources.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	We deal with hazardous
	materials and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we
	do business and/or give rise to significant liabilities.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	As we
	operate a manufacturing facility, we are subject to various environmental, health and safety laws and regulations, including those
	governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous materials
	and wastes, and the cleanup of contaminated sites. The cost of compliance with these laws and regulations could be significant.
	In the event of a violation of these requirements, including from accidental contamination or injury, we could be held liable for
	damages exceeding our available financial resources. We could be subject to monetary fines, penalties or third party damage claims
	as a result of violations of such laws and regulations or noncompliance with environmental permits required at our facility. As
	an operator of real property and a generator of hazardous materials and wastes, we also could be subject to environmental cleanup
	liability, in some cases without regard to fault or whether we were aware of the conditions giving rise to such liability. In addition,
	we may be subject to liability and may be required to comply with new or existing environmental laws regulating pharmaceuticals
	in the environment. Environmental laws or regulations (or their interpretation) may become more stringent in the future. If any
	such future revisions require significant changes in our operations, or if we engage in the development and manufacturing of new
	products or otherwise expand our operations requiring new or different environmental controls, we will have to dedicate additional
	management resources and incur additional expenses to comply with such laws and regulations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	the event of an accident, applicable authorities may curtail our use of hazardous materials and interrupt our business operations.
	In addition, with respect to our manufacturing facility, we may incur substantial costs to comply with environmental regulations
	and may become subject to the risk of accidental contamination or injury from the use of hazardous materials in our manufacturing
	process.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	The inability to protect our intellectual property rights
	could result in competitive harm to our Company.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our success and ability to maintain our competitive
	position depends on our ability to protect our intellectual property, including by obtaining patent protection in the United States
	and other countries, or through protection of our trade secrets, including unpatented know-how, technology and other proprietary
	information. When appropriate, we seek to protect our proprietary position by filing patent applications in the United States and
	other countries. If we are unable to protect our intellectual property, whether by obtaining patents or through trade secret protection,
	our competitors could develop and commercialize products similar or identical to ours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We may not have adequate remedies for any infringement
	or funds to take action against those infringing any of our intellectual property rights, or if our trade secrets otherwise become
	known or independently developed by competitors. There can be no assurance that any current or future patents held, licensed by
	or applied for by us will be upheld, if challenged, or that the protections afforded will not be circumvented by others.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The
	patent positions of biotechnology and pharmaceutical companies, which often involve licensing agreements, are frequently uncertain
	and involve complex legal and factual questions. In addition, the coverage claimed in a patent application can be significantly
	reduced before the patent is issued. Consequently, our patents, patent applications and licensed rights may not provide protection
	against competitive technologies or may be held invalid if challenged or could be circumvented.
</FONT>
	If we enter litigation in
	regards to our business or to protect or enforce our patents, it may involve substantial expenditures and require significant management
	attention, even if we ultimately prevail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The patent position of biotechnology companies
	is generally highly uncertain. The degree of patent protection we require may be unavailable or severely limited in some cases
	and may not adequately protect our rights, provide sufficient exclusivity, or preserve our competitive advantage. For example:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we might not have been the first to invent or the first to file patent applications on the inventions covered by each of our
	pending patent applications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 2.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others may independently develop similar or alternative technologies or duplicate any of our technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 2.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the patents of others may have an adverse effect on our business;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 2.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any patents we obtain or license from others in the future may not encompass commercially viable products, may not provide
	us with any competitive advantages or may be challenged by third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 2.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any patents we have obtained, will obtain or license from others in the future may not be valid or enforceable; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 2.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may not develop additional proprietary technologies that are patentable.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 39.05PT; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Patents have a limited lifespan. In the United
	States, the natural expiration of a utility patent typically is generally 20 years after it is filed. Various extensions may be
	available; however, the life of a patent, and the protection it affords, is limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition, some of our technologies are not
	covered by any patent application and we rely instead on confidentiality agreements and trade secret law to protect such intellectual
	property rights. We require all of our employees and consultants to sign confidentiality agreements. The agreements also oblige
	our employees, and to the extent practicable, our consultants, and advisors, to assign to us ideas, developments, discoveries and
	inventions made by such persons in connection with their work with us. We cannot be sure that these agreements will maintain confidentiality,
	will prevent disclosure, or will protect our proprietary information or intellectual property, or that others will not independently
	develop substantially equivalent proprietary information or intellectual property.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The failure of our patents, patent applications,
	applicable intellectual property law or our confidentiality agreements to protect our intellectual property and other proprietary
	information, including our trade secrets, could have a material adverse effect on our competitive advantages and on our operations
	and financial position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Changes in patent law could diminish the value of patents
	in general, thereby impairing our ability to protect our products and our technologies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	There are numerous recent changes to the U.S.
	patent laws and proposed changes to the rules of the United States Patent and Trademark Office (USPTO) that may have
	a significant impact on our ability to obtain and enforce intellectual property rights. In particular, the Leahy-Smith America
	Invents Act (the &ldquo;Leahy-Smith Act&rdquo;) was adopted in September 2011. The Leahy-Smith Act includes a number of significant
	changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect
	patent litigation. Under the Leahy-Smith Act, the United States transitioned from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-inventor-to-file&rdquo;
	system for patent applications filed on or after March 16, 2013. With respect to patent applications filed on or after March 16,
	2013, if we are the first to invent but not the first to file a patent application, we may not be able to fully protect our intellectual
	property rights and may be found to have violated the intellectual property rights of others if we continue to operate in the absence
	of a patent issued to us. Many of the substantive changes to patent law associated with the Leahy-Smith Act have recently become
	effective. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However,
	the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
	applications and the enforcement or defense of any patents that issue, all of which could have a material adverse effect on our
	business and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition, patent reform legislation may pass
	in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense
	of patent applications and any patents we may obtain. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the
	Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted.
	Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions
	are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be
	enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents and patent applications
	or any patents we may obtain and our ability to obtain and enforce or defend additional patent protection in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may not be able to adequately protect our intellectual
	property rights throughout the world.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Filing, prosecuting and defending patents on
	our products and technologies in all countries throughout the world would be prohibitively expensive. The requirements for patentability
	may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent.
	In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as laws in
	the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside
	the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop
	their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement
	on infringing activities is inadequate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We seek to protect our proprietary position
	by, among other methods, filing, when possible, U.S. and foreign patent applications relating to our technology, inventions and
	improvements that are important to our business. We have obtained patent protection for our non-lethal extraction methods of hemocyanin
	in the United States and other countries. We also rely on trade secrets, know-how, continuing technological innovation, and in-licensing
	opportunities to develop and maintain our proprietary position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We plan to file other international patent applications
	directed to patentable features of our products and technologies from time to time. If patent rights are obtained in foreign jurisdictions,
	proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of
	our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our pending patent applications
	at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we
	initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop
	a competitor from marketing and selling in foreign countries products that are the same as or similar to our product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may become involved in lawsuits to protect or enforce our
	patents and patent applications, any patents that may be issued to us or other intellectual property, which could be expensive,
	time consuming and unsuccessful.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Competitors may infringe our patents or patent
	applications, or other of our intellectual property. To counter infringement or unauthorized use, we may be required to file infringement
	or misappropriation claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could
	provoke these parties to assert counterclaims against us alleging that we infringe their patents or claiming that our patents are
	invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
	including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion
	could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO,
	or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the
	USPTO in post-grant proceedings such as
<I>
	ex parte
</I>
	reexaminations,
<I>
	inter partes
</I>
	review, or post-grant review, or oppositions
	or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome
	following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating
	prior art, of which we and the patent examiner were unaware during prosecution. For any patents and patent applications we may
	license, we may have limited or no right to participate in the defense of any such patents against challenge by a third party.
	If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps
	all, of any future patent protection on our products. Such a loss of patent protection could harm our business. In addition, in
	a patent infringement proceeding, a court may decide that our patent applications or patents, if issued, are invalid or unenforceable,
	in whole or in part, construe the patent&rsquo;s claims narrowly, or refuse to stop the other party from using the technology at
	issue on the grounds that our patent applications do not cover the technology. An adverse result in any litigation proceeding could
	put one or more of our patents at risk of being invalidated or interpreted narrowly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Our trade secrets are difficult to protect and misappropriation
	could reduce the market for our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We may not be able to obtain adequate remedies
	for the unauthorized use or disclosure of our proprietary information, including our trade secrets. Enforcing a claim that a party
	illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable.
	If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to
	prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our
	trade secrets were to be disclosed to or independently developed by a competitor, our competitive position could be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Third parties may initiate legal proceedings alleging that
	we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse
	effect on the success of our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our success depends, in part, on our ability
	to operate without infringing the patents and other proprietary intellectual property rights of third parties. This is generally
	referred to as having the &ldquo;freedom to operate.&rdquo; The biotechnology and pharmaceutical industries are characterized by
	extensive litigation regarding patents and other intellectual property rights. The defense and prosecution of intellectual property
	claims, interference proceedings and related legal and administrative proceedings, both in the United States and internationally,
	involve complex legal and factual questions. As a result, such proceedings are lengthy, costly and time-consuming, and their outcome
	is highly uncertain. We may become involved in protracted and expensive litigation in order to determine the enforceability, scope
	and validity of the proprietary rights of others, or to determine whether we have the freedom to operate with respect to the intellectual
	property rights of others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Patent applications in the United States are,
	in most cases, maintained in secrecy until approximately 18 months after the patent application is filed. The publication of discoveries
	in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries
	were made. Therefore, patent applications relating to a product or method similar to ours may have already been filed by others
	without our knowledge. In the event that a third party has also filed a patent application covering our products, methods or other
	claims, we may have to participate in an adversarial proceeding, such as an interference or derivation proceeding in the USPTO
	or similar proceedings in other countries, to determine the priority of invention. In the event an infringement claim is brought
	against us, we may be required to pay substantial legal fees and other expenses to defend such a claim and, if we are unsuccessful
	in defending the claim, we may be subject to injunctions or damage awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In the future, the USPTO or a foreign patent
	office may grant patent rights to our claims to third parties. Subject to the issuance of these future patents, the claims of which
	will be unknown until issued, we may need to obtain a license or sublicense to these rights in order to have the appropriate freedom
	to further use, develop or commercialize such products or methods. Any required licenses may not be available to us on acceptable
	terms, if at all. If it is determined that we have infringed an issued patent and do not have the freedom to operate, we could
	be subject to injunctions, and compelled to pay significant damages, including punitive damages. In any cases where we in-license
	intellectual property, our failure to comply with the terms and conditions of such licensing agreements could harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	If we become involved in any patent litigation
	or other legal proceedings, we could incur substantial expense, and the efforts of our technical and management personnel could
	be significantly diverted. A negative outcome of such litigation or proceedings may expose us to the loss of our proprietary position
	or to significant liabilities, or require us to seek licenses that may not be available from third parties on commercially acceptable
	terms, if at all. We may be restricted or prevented from using or developing methods, or manufacturing and selling our products
	in the event of an adverse determination in a judicial or an administrative proceeding, or if we fail to obtain necessary licenses.
	Further, even if we are successful in defending against claims of infringement, such litigation could be burdensome and costly,
	and divert management&rsquo;s attention away from executing our business plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may be subject to claims that our employees, consultants
	or independent contractors have wrongfully used or disclosed confidential information of third parties.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Certain of our employees were previously employed
	at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent
	contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our
	employees&rsquo; former employers. We may also be subject to claims that former employees, consultants, independent contractors
	or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to
	defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail
	in defending any such claims, we may lose our rights to such information, in addition to paying monetary damages. Such an outcome
	could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could
	result in substantial cost and be a distraction to our management and employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks Related to Ownership of Our Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	The price of our common shares may be subject to substantial
	volatility.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Although our common shares are listed on The
	Nasdaq Capital Market in the United States, there can be no assurance that an active public market will be sustained for our common
	shares. If there is a thin trading market or &ldquo;float&rdquo; for our common shares, the market price for our common shares
	may fluctuate significantly more than the stock market as a whole. Without a large float, our common shares would be less liquid
	than the stock of companies with broader public ownership and, as a result, the trading price of our common shares may be more
	volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Furthermore, the stock market is subject to
	significant price and volume fluctuations, and the price of our common shares has been in the past, and may continue in the future
	to be subject to wide fluctuations in response to several factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our quarterly or annual operating results;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our cash and cash equivalents position;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in our earnings estimates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	investment recommendations by securities analysts following our business or our industry;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	additions or departures of key personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in the business, earnings estimates or market perceptions of our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our failure to achieve operating results consistent with securities analysts&rsquo; projections;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements or the expectation of raising additional financing;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	sales of our common shares by us, our insiders or other shareholders;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the status of our listing on the Nasdaq;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in industry, general market or economic conditions; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements of legislative or regulatory changes in the United States and in other countries where we transact business.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The stock markets in general, and the small-cap
	biotech market, in particular, have experienced extreme price and volume fluctuations in recent years that have significantly affected
	the quoted prices of the securities of many companies, including companies in our industry. The changes often appear to occur without
	regard to specific operating performance. The price of our common shares could fluctuate based upon factors that have little or
	nothing to do with our company and these fluctuations could materially reduce our share price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	If we cannot meet Nasdaq&rsquo;s continuing
	listing requirements and Nasdaq rules, Nasdaq may delist our securities, which could negatively affect our company and the price
	of our securities.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	On November 3, 2015, our common shares were
	approved for listing on The Nasdaq Capital Market and began trading on November 5, 2015. In order to meet certain initial listing
	requirements of Nasdaq, on September 2, 2015, we effected a consolidation of our issued and outstanding common shares on the basis
	of one (1) post-consolidation common share for every ten (10) pre-consolidation shares. We also amended our Articles to comply
	with certain corporate governance requirements set forth in the Nasdaq Listing Guide, which amendment was approved at a special
	meeting of our shareholders. These actions were time consuming and required substantial expense on the part of our Company. Although
	our shares are currently listed on Nasdaq, in the future, we may not be able to meet the continued listing requirements of Nasdaq,
	which require, among other things, a minimum bid price of $1.00 per share for common shares listed on the exchange. If we are unable
	to satisfy the Nasdaq criteria for maintaining our listing, our securities could be subject to delisting. Trading of our securities
	may still be eligible for an over-the-counter market or electronic bulletin board. As a consequence of any such delisting, our
	shareholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the prices of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We may require additional financing or financings, which would
	result in substantial dilution to existing shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Management currently estimates
	that our operations, including research and development, capital expenditures and general and administrative expenses, will require
	approximately $6.5 million for the fiscal year ending September 30, 2017. We believe our cash and cash equivalents and short-term
	investments at September 30, 2016 are sufficient to meet estimated working capital requirements and fund planned operations for
	at least the next 12 months. Notwithstanding the above, we may decide to expand operations, undertake strategic acquisitions or
	determine some other business need. In such case, we would then seek financing for such events through the sale of additional common
	shares, debt securities or bank loans. Our ongoing research and development activities may be dependent upon our ability to obtain
	funds, which may include the sale of common shares, as well as possible debt financings, joint ventures, or other means. Such sources
	of financing may not be available on acceptable terms, if at all. Failure to obtain such financing may result in delay or indefinite
	postponement of research and development of our Stellar KLH
<SUP>
	TM
</SUP>
	. Any transaction involving the issuance of previously
	authorized but unissued common shares, or securities convertible into common shares, could result in dilution, possibly substantial,
	to present and prospective holders of common shares and may be on terms less favorable to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We could be deemed a &ldquo;passive foreign investment company&rdquo;
	in the future, which could have negative consequences for U.S. investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We would be designated as a &ldquo;passive foreign
	investment company&rdquo;, or a PFIC, under the meaning of Section 1297 of the United States Internal Revenue Code of 1986, as
	amended, or the Code, if (a) 75% or more of our gross income is &ldquo;passive income&rdquo; (generally, dividends, interest, rents,
	royalties and gains from the disposition of assets producing passive income) in any taxable year, or (b) at least 50% of the average
	value of our assets produce, or are held for the production of, passive income. If we are designated a PFIC for any taxable year
	during which a U.S. shareholder holds our common shares, it would likely result in materially adverse U.S. federal income tax consequences
	for such U.S. shareholder, including, but not limited to, any gain from the sale of our common shares would be taxed as ordinary
	income, as opposed to capital gain, and such gain and certain distributions on our common shares would be subject to an interest
	charge, except in certain circumstances. In addition, U.S. shareholders should be aware that there can be no assurances that we
	would be able to satisfy the record keeping requirements that apply to a PFIC, or that we would supply U.S. shareholders with the
	information that such U.S. shareholders require to make certain elections available under the Code that are intended to mitigate
	the adverse tax consequences of the PFIC rules. The PFIC rules are extremely complex. A U.S. shareholder of our common shares is
	encouraged to consult a tax advisor regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership
	and disposition of our common shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We are governed by the corporate laws in British Columbia,
	Canada which in some cases have a different effect on shareholders than the corporate laws in Delaware.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The material
	differences between the British Columbia
<B>
<I>
</I>
</B>
	Business Corporations Act (the &ldquo;BCBCA&rdquo;) as compared to the
	Delaware General Corporation Law (the &ldquo;DGCL&rdquo;) which may be of most interest to shareholders include the
	following: (i) for material corporate transactions (such as amalgamations, other extraordinary corporate transactions,
	amendments to the notice of articles and amendments to the Articles), the BCBCA generally requires a two-thirds majority vote
	by shareholders (and, in addition, especially where the holders of a class of shares are being affected differently from
	others, approval will be required by holders of two-thirds of the shares of such class voting in a meeting called for that
	purpose), whereas the DGCL generally only requires a majority vote of shareholders for similar material corporate
	transactions; (ii) quorum for shareholders meetings is not prescribed under the BCBCA and is 33-1/3% under our Articles (to
	assure compliance with Nasdaq corporate governance requirements); whereas, under the DGCL, quorum requires the holders of a
	majority of the shares entitled to vote to be present; and (iii) our Articles require a two-thirds majority vote of
	shareholders to pass a resolution for one or more directors to be removed, whereas the DGCL requires only the affirmative
	vote of a majority of the shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Risks Related to an Emerging Growth Company
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	We are an &ldquo;emerging growth company&rdquo; under the
	JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make
	our common shares less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of
	2012 (JOBS Act), and as a result, we may take advantage of certain exemptions from various reporting requirements that are applicable
	to other public companies that are not &ldquo;emerging growth companies.&rdquo; We may take advantage of these reporting exemptions
	until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an &ldquo;emerging growth company&rdquo; until
	the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the date of our initial registration
	statement on Form 20-F, which was February 3, 2012, (b) in which we have more than $1.0 billion in annual revenues, or (c) in which
	we are deemed to be a large accelerated filer, which means the market value of our common shares that is held by non-affiliates
	exceeded $700 million as of the prior March 31
<SUP>
	st
</SUP>
	, and (ii) the date on which we have issued more than $1.0 billion in
	non-convertible debt securities during the prior three-year period. We may choose to take advantage of some but not all of these
	reduced reporting burdens.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	For so long as we remain an emerging growth
	company, we will not be required to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	have an auditor report on our internal control over financial reporting pursuant to Section 404(b) of Sarbanes-Oxley;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	comply with any requirement that may be adopted by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), regarding
	mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and
	the financial statements (auditor discussion and analysis);
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	submit certain executive compensation matters to shareholders advisory votes pursuant to the &ldquo;say on frequency&rdquo;
	and &ldquo;say on pay&rdquo; provisions (requiring a non-binding shareholder vote to approve compensation of certain executive
	officers) and the &ldquo;say on golden parachute&rdquo; provisions (requiring a non-binding shareholder vote to approve golden
	parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the
	Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	include detailed compensation discussion and analysis in our filings under the Exchange Act, and, instead, may provide a reduced
	level of disclosure concerning executive compensation.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	In addition, Section 107 of the JOBS Act also
	provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section
	7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &ldquo;emerging growth
	company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
	We have elected not to take advantage of the extended transition period for complying with new or revised accounting standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	If we take advantage of any of these reduced
	reporting burdens in future filings, the information that we provide our security holders may be different than information such
	security holders might receive from other public companies in which they hold equity interests. We cannot predict if investors
	will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less
	attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT>
<I>
	&nbsp;&nbsp;
</I>
</FONT>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_004">
</A>
<B>
	Item&nbsp;1B.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNRESOLVED STAFF COMMENTS.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_005">
</A>
<B>
	Item&nbsp;2.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROPERTIES.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We currently lease 4,300 square feet of executive
	office and laboratory space in Port Hueneme, California under a lease which was renewed in July 2016 for a two-year term, with
	options to renew for three successive two-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our aquaculture operations are land-based, and
	encompass three buildings and a 37,000 square foot oceanfront leasehold facility in the Port Hueneme Aquaculture Business Park,
	located along the Pacific Coast. These facilities include our aquaculture, manufacturing, and laboratory operations, and are leased
	from the Oxnard Harbor District under three sublease agreements that expire in September and October 2020 with options to extend
	the leases for two additional five-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	We also currently lease undeveloped land in Baja
	California, Mexico under a lease agreement which we entered into in June 2015, with a three-year term, which lease agreement is
	terminable at will at any time with 30 days prior notice by either party. We expect to utilize the undeveloped land to conduct
	suitability studies over the next three years for the potential development of an additional aquaculture locale and future expansion
	of production.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_006">
</A>
<B>
	Item&nbsp;3.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	From time to time, we may be involved in legal
	proceedings, claims and litigation arising in the ordinary course of business, including contract disputes, employment matters
	and intellectual property disputes. We are not currently a party to any material legal proceedings or claims outside the ordinary
	course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs,
	diversion of management resources and other factors.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_007">
</A>
<B>
	Item 4.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_008">
</A>
<B>
	PART II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<B>
<A NAME="V453489_10K_HTM_SBI_009">
</A>
	Item 5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED
	STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Market Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our common shares trade on The Nasdaq Capital
	Market in the United States under the symbol &ldquo;SBOT&rdquo; since November 5, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	From January 15, 2013 through November 4, 2015,
	our common shares were traded in the United States on the U.S. OTCQB Marketplace Exchange under the symbol &ldquo;SBOTF.&rdquo;
	From April 19, 2010 to April 8, 2016 our common shares traded on the TSX Venture Exchange in Canada under the symbol &ldquo;KLH.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The table below lists the
	high and low closing prices for our common shares for each fiscal quarter during 2016 and 2015 as reported by Nasdaq, Inc. or OTC
	Markets Group, Inc, as applicable. The OTC quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission,
	and may not necessarily represent actual transactions. The prices have been adjusted to reflect the one share for ten shares reverse
	share split completed on September 2, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Common Shares Trading Activity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Nasdaq Capital Market and OTCQB Marketplace
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	U.S. Dollars
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
	Fiscal Year 2016
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Fourth Quarter Ended 9/30/16
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3.82
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.13
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third Quarter Ended 6/30/16
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4.70
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.44
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Second Quarter Ended 3/31/16
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6.85
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4.81
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	First Quarter Ended 12/31/15 (after 11/4/15)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9.41
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6.49
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	First Quarter Ended 12/31/15 (through 11/4/15)*
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8.56
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6.75
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
	Fiscal Year 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Fourth Quarter Ended 9/30/15*
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9.04
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5.30
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Third Quarter Ended 6/30/15*
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9.15
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6.11
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Second Quarter Ended 3/31/15*
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	11.72
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8.50
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First Quarter Ended 12/31/14*
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	15.40
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	10.20
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	* OTC quotations
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
</B>
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The table below lists the
	high and low sales prices for our common shares on the TSX Venture Exchange for the first two fiscal quarters during 2016 and the
	partial third quarter through April 8, 2016, and for each fiscal quarter during 2015. The quotations on the TSX Venture Exchange
	were obtained from QuoteMedia.com. These quotations reflect adjusted close prices, and may not necessarily represent actual transactions.
	The prices have been adjusted to reflect the one share for ten shares reverse share split completed on September 2, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Common Shares Trading Activity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	TSX Venture Exchange
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Canadian Dollars
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: JUSTIFY">
	Fiscal Year 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: JUSTIFY">
	Third Quarter Ended 6/30/16 (through 4/8/16)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6.07
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4.90
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Second Quarter Ended 3/31/16
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	First Quarter Ended 12/31/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Fiscal Year 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE">
	Fourth Quarter Ended 9/30/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	Third Quarter Ended 6/30/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE">
	Second Quarter Ended 3/31/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	First Quarter Ended 12/31/14
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Holders
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	As of December 9, 2016, we had 10,136,258 common
	shares outstanding, with 18 shareholders of record. The number of record shareholders was determined from the records of our stock
	transfer agent and does not reflect persons or entities that hold their shares in nominee or &ldquo;street&rdquo; name through
	various brokerage firms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Securities Authorized for Issuance Under
	Equity Compensation Plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	See Item 12 &ldquo;
<I>
	Security
	Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</I>
	&rdquo; of this report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Dividends
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have not declared any
	dividends on our common shares since our incorporation and do not anticipate that we will do so in the foreseeable future. Our
	present policy is to retain future earnings, if any, for use in our operations and the expansion of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Performance Graph
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	The following performance graph and related information shall
	not be deemed to be &ldquo;soliciting material&rdquo; or to be &ldquo;filed&rdquo; with the SEC, nor shall such information be
	incorporated by reference into any future filing under the Securities Act, except to the extent that we specifically incorporate
	it by reference into such filing.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The graph set forth below compares the cumulative
	total return of our common shares to the Nasdaq Composite Index and the Nasdaq Biotechnology Index based on the period from August
	31, 2011 through the Company&rsquo;s fiscal year end on September 30, 2016. The graph assumes $100 was invested on August 31, 2011
	in our common shares and in each of the comparative indices and assumes reinvestment of dividends, if any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The comparisons shown in the graph below are
	based on historical data. We caution that the stock price performance showing in the graph below is not necessarily indicative
	of, nor is it intended to forecast, the potential future performance of our common shares. Information used in the graph was obtained
	from S&amp;P Capital IQ, a source believed to be reliable, but we are not responsible for any errors or omissions in such information.
	Please also note that, due to the fact that the graph begins in August and includes a transition period resulting from a change
	in fiscal year-end, the horizontal segments of the graph do not represent equal time intervals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001144204-16-139528_PG35IMG1_10K.JPG" ALT="">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	8/31/11
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8/31/12
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8/31/13
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8/31/14
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/15
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/16
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Stellar Biotechnologies, Inc.
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	60.71
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	253.73
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	288.17
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	115.99
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	43.50
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Nasdaq Composite Index
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	120.26
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	142.81
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	184.44
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	188.33
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	219.26
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Nasdaq Biotechnology Index
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	141.71
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	202.24
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	289.21
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	316.85
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	302.65
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Recent Sales of Unregistered Securities; Use of Proceeds from
	Registered Securities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Purchase of Equity Securities by the Issuer and Affiliated Purchasers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_010">
</A>
<B>
	Item&nbsp;6.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our selected financial
	data in the table below is derived from our audited financial statements, which have been prepared in accordance with accounting
	principles generally accepted in the United States (US GAAP). Our auditors for the fiscal years ended September 30, 2016 and 2015
	and August 31, 2014, Moss Adams LLP, conducted the audits in accordance with United States generally accepted auditing standards,
	and the standards of the Public Company Accounting Oversight Board. Our auditors for the fiscal years ended August 31, 2013 and
	2012, D&amp;H Group LLP, conducted the audits in accordance with Canadian generally accepted auditing standards, and the standards
	of the Public Company Accounting Oversight Board. You should read these selected financial data together with &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in Item 7 and our audited financial statements
	and notes thereto that are included in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Selected Financial Data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	Expressed in U.S. dollars
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Year Ended
<BR>
	September 30,
<BR>
	2016
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Year Ended
<BR>
	September 30,
<BR>
	2015
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Year Ended
<BR>
	August 31,
<BR>
	2014
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Year Ended
<BR>
	August 31,
<BR>
	2013
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Year Ended
<BR>
	August 31,
<BR>
	2012
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Net revenues
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,271,689
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	758,689
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	372,132
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	545,469
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	286,054
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,026,080
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,843,029
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(8,439,523
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(14,495,779
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,529,278
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.57
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(0.36
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(1.11
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2.81
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(1.26
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Total assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	12,937,804
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	10,385,927
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	14,473,962
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	8,513,358
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,543,878
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	Long-term obligations
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,352,663
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,835,199
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	124,141
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Supplementary Financial Information
</B>
</P>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Selected Quarterly Financial Data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<I>
	U.S. dollars are shown in thousands, except
	per share data
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q4
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q3
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q2
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q1
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q4
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q3
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q2
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q1
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; WIDTH: 20%">
	Revenues
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	277
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	181
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	326
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	488
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	158
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	188
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	213
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net income (loss) for period
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(1,349
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(1,194
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(861
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(1,622
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(1,538
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	464
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(426
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(1,343
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	Income (loss) per share - Basic
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.14
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.19
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.19
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0.06
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	Income (loss) per share - Diluted
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.14
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.19
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.19
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	0.05
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.35PT">
	Fluctuations in net income
	(loss) between quarters can be mainly attributed to changes in fair value of warrant liability shown in thousands as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.35PT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q4
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q3
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q2
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q1
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q4
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q3
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q2
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Q1
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Change in fair value of warrant liability - gain (loss)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(212
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(325
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,254
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,062
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 56.1PT; TEXT-INDENT: -56.1PT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_011">
</A>
<B>
	Item 7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
	CONDITION AND RESULTS OF OPERATIONS
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	This discussion
	contains forward-looking statements that involve risks and uncertainties that could cause actual results or events to differ materially
	from those expressed or implied by such forward-looking statements as a result of many important factors, including those set forth
	in Part I of this Annual Report on Form 10-K under the caption &ldquo;Risk Factors.&rdquo; Please see &ldquo;Special Note Regarding
	Forward-Looking Statements&rdquo; in Part I above. We do not undertake any obligation to update forward-looking statements to reflect
	events or circumstances occurring after the date of this Annual Report.
</I>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Operating and Financial Review and Prospects
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Overview
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our financial statements
	have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
	and include the accounts of the Company and our wholly-owned subsidiary, Stellar Biotechnologies, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Since inception, we have
	primarily financed our activities through the issuance of common shares, exercise of warrants, grant revenues, contract services
	revenue, and product sales. In July 2016, the Company closed a $6.75 million registered direct offering. Management believes our
	financial resources are adequate to support our current initiatives at the current level for at least the next 12 months. Management
	is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and we may seek additional
	financing alternatives, including additional equity financing, debt financing, bank loans, or nondilutive financing alternatives
	including applying for grants and entering into collaboration and/or licensing arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The greatest impact on
	the comparison of our consolidated statements of operations is from fluctuations in the change in fair value of our warrant liability.
	As a result of having exercise prices denominated in a currency other than our functional currency, our warrants with Canadian
	dollar exercise prices met the definition of derivatives and were therefore classified as derivative liabilities measured at fair
	value with noncash adjustments to fair value recognized through the consolidated statements of operations. Fair values were based
	on the Black-Scholes option valuation model. The losses and gains in each year were a reflection of our share price fluctuations
	whereby increases in share prices caused greater warrant liability and a resulting loss on fair value of warrant liability, while
	decreases in share prices caused a resulting gain on fair value of warrant liability. Changes in fair value of warrant liability
	had no impact on cash flow. If the warrants were exercised, the warrant liability was reclassified to common shares. If the warrants
	expired, the decrease in warrant liability offset the changes in fair value. All warrants with exercise prices denominated in Canadian
	dollars were exercised or expired by December 31, 2015. Therefore, there was no change in fair value after that time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Fiscal Year Ended September 30, 2016
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our total revenues
	increased by $513,000 to $1,271,689 for fiscal 2016 compared to $758,689 for fiscal 2015. Product sales increased by $676,000 to
	$1,239,689 for fiscal 2016 compared to $563,689 for fiscal 2015 primarily due to an increase in the number of customers and greater
	product sales volume, including sales under supply agreements and custom manufactured products. Contract services revenue decreased
	by $163,000 to $32,000 for fiscal 2016 compared to $195,000 for fiscal 2015 as a result of the successful conclusion of a collaboration
	agreement in December 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our total expenses
	increased by $1,082,764 to $6,180,045 for fiscal 2016 compared to $5,097,281 for fiscal 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our costs of sales
	and contract services increased by $237,742 to $818,556 for fiscal 2016 compared to $580,824 for fiscal 2015, due to increased
	product sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our research and development
	expenses increased by $699,956 to $1,729,445 fiscal 2016 compared to $1,029,489 for fiscal 2015. The increase was a result of additional
	research and development in aquaculture, both in the U.S. and for our aquaculture feasibility assessment in Baja California, Mexico;
	improvements in analytical, manufacturing, and purification processes; stability studies; and formulation development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our general and administrative
	expenses increased by $95,227 to $3,322,772 for fiscal 2016 compared to $3,227,545 for fiscal 2015. The increase resulted from
	increased corporate expenses, including our Nasdaq listing fees; compensation increases; and expanded business development and
	investor relations activities; offset by decreases in legal fees due to the Form S-3 shelf registration statement and our transition
	to reporting as a U.S. domestic issuer during fiscal 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Other income decreased
	by $1,642,887 to an overall loss of $110,524 for fiscal 2016 compared to an overall gain of $1,532,363 for fiscal 2015 primarily
	due to a noncash change in fair value of warrant liability, which fluctuated to a loss of $211,956 for fiscal 2016 compared to
	a gain of $2,131,062 in fiscal 2015. All warrants with Canadian dollar exercise prices were exercised or expired by December 2015
	and, consequently, there was no warrant liability and no gain/loss in fair value of warrant liability after that time. These fair
	value gains and losses occur in inverse relation to changes in our share price that affect the Black Scholes valuation model. The
	loss in fiscal 2016 is a result of the increase in our share price from September 30, 2015 to the exercise dates of the warrants
	compared to the gain in fiscal 2015 as a reflection of both the decrease in our share price from September 30, 2014 to the exercise
	dates of warrants during the year and the decrease in our share price from $11.90 at September 30, 2014 to $6.40 for warrants outstanding
	at September 30, 2015. Our foreign exchange gain in fiscal 2016 was $76,800 compared to a foreign exchange loss of $653,333 in
	fiscal 2015. The change over the prior year was due to improved exchange rates for our Canadian cash and cash equivalents. The
	portion of foreign exchange realized in cash was gain of $2,137 in fiscal 2016 and loss of $14,995 in fiscal 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our net loss for fiscal
	2016 was $5,026,080, or $0.57 per basic share, compared to a net loss of $2,843,029, or $0.36 per basic share, for fiscal 2015.
	The increase in net loss of approximately $2.2 million for fiscal 2016 was primarily due to significant fluctuations in non-cash
	gain/loss in fair value of warrant liability and non-cash foreign exchange gain/loss, as well as increased research and development
	expenses, which were offset by increased product sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Fiscal Year Ended September 30, 2015
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our total revenues
	increased by $386,557 to $758,689 for fiscal 2015 compared to $372,132 for fiscal 2014. Product sales increased by $420,136 to
	$563,689 for fiscal 2015 compared to $143,553 for fiscal 2014 due to an increase in the number of customers and greater product
	sales volume including sales under supply agreements and custom manufactured products. Contract services revenue increased by
	$3,000 to 195,000 for fiscal 2015 compared to $192,000 for fiscal 2014 due to the net impact of services performed under a collaboration
	agreement entered into December 2013 and completion of services in December 2014 related to a supply agreement. There were no
	grant revenues for fiscal 2015 compared to $36,579 in fiscal 2014 due to the completion of work associated with our Phase II/IIB
	grants from the National Science Foundation (NSF) Small Business Innovation Research (SBIR) through the Technology Enhancement
	for Commercial Partnerships program.
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our total expenses
	decreased by $993,367 to $5,097,281 for fiscal 2015 compared to $6,090,648 for fiscal 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our costs of sales
	and contract services increased by $111,675 to $580,824 for fiscal 2015 compared to $469,149 for fiscal 2014, due to increased
	sales and contract services revenue. Also, due to the early stage of our development in fiscal 2014, all manufacturing costs of
	production were expensed during that period. There were no grant expenses for fiscal 2015 compared to $36,579 in fiscal 2014 due
	to the closeout of NSF Phase II/IIB grants in November 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our research and development
	expenses decreased by $1,429,445 to $1,029,489 for fiscal 2015, as compared to $2,458,934 for fiscal 2014 due to the decreased
	use of contract research organizations as we realigned our focus from internal research and process development to manufacturing
	our Stellar KLH&trade; products in response to increased customer demand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our general and administrative
	expenses increased by $356,090 to $3,227,545 for fiscal 2015, compared to $2,871,455 for fiscal 2014. The increase was due to the
	net impact of increased corporate expenses, including legal and audit fees related to our transition to reporting as a U.S. domestic
	issuer rather than a foreign private issuer, our Nasdaq application and listing, and increased business development and investor
	relations activity, partially offset by decreases in share-based compensation. Share-based compensation is allocated to all expense
	types but the greatest portion is recorded as general and administrative expenses. Share-based compensation was $267,222 for fiscal
	2015, which was a decrease from $956,634 recorded in fiscal 2014. The decrease for fiscal 2015 was related to fewer share options
	granted, fluctuations in our share price that affect the valuation model and vesting of options granted in prior years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Other income increased
	by $4,226,170 to an overall gain of $1,532,363 for fiscal 2015 compared to an overall loss of $2,693,807 for fiscal 2014 primarily
	due to a noncash change in fair value of warrant liability, which fluctuated to a gain of $2,131,062 for fiscal 2015 from a loss
	of $2,533,305 in fiscal 2014. These fair value gains and losses occur in inverse relation to changes in our share price that affect
	the valuation model. The gain in fiscal 2015 is a reflection of the decrease in our share price from $11.90 to $6.40 compared to
	the loss in fiscal 2014 as a result of the increase in our share price from $14.00 to $15.90. Also, there were fewer Canadian denominated
	warrants outstanding than each prior year. The increase in overall gain in fiscal 2015 was offset by an increase in foreign exchange
	loss to $653,333 over the same period. Our foreign exchange loss in fiscal 2014 was $222,437. The change over the prior year was
	due to unfavorable exchange rates for our Canadian cash and cash equivalents. The portion of foreign exchange loss realized in
	cash was $14,995 in fiscal 2015, and $26,778 in the fiscal 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our net loss for fiscal
	2015 was $2,843,029, or $0.36 per basic share, compared to a net loss of $8,439,523, or $1.11 per basic share, for fiscal 2014.
	The decrease in net loss of approximately $5.6 million for fiscal 2015 was primarily due to a significant noncash gain in the fair
	value of warrant liability, increased sales and decreased research and development expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Capital Expenditures
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our capital expenditures,
	which primarily consist of scientific, manufacturing, and aquaculture equipment, and facility leasehold improvements for the previous
	three fiscal years are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 40%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fiscal Year
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Capital Expenditures
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: CENTER">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	402,271
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	274,589
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	279,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our working capital
	position at September 30, 2016 was $11,476,011, including cash and cash equivalents of $7,416,904 and short-term investments of
	$3,988,794. Management currently estimates that our operations, including research and development, capital expenditures and general
	and administrative expenses, will require approximately $6.0 million for the fiscal year ending September 30, 2017. Management
	has flexibility to adjust these expenditures based on a number of factors including the size and timing of capital expenditures,
	staffing levels, inventory levels, and the status of customer clinical trials. Management believes the current working capital
	is sufficient to meet our present requirements, including all contractual obligations and anticipated research and development
	expenditures for at least the next 12 months. In July 2016, we closed a registered direct offering of an aggregate of 1,687,500
	of our common shares, and a concurrent private placement of warrants to purchase up to an aggregate of 1,265,626 common shares
	with an exercise price of $4.50 per share, resulting in net proceeds of approximately $6 million. We may pursue opportunities to
	obtain additional financing in the future through equity financings. We have filed with the Securities and Exchange Commission,
	and the Securities and Exchange Commission declared effective, a universal shelf registration statement of up to $100 million worth
	of registered equity securities, of which we utilized approximately $6.75 million in our July 2016 offering. Under this effective
	registration statement, we may issue registered securities, from time to time, in one or more separate offerings or other transactions
	with the size, price and terms to be determined at the time of issuance. Pursuant to General Instruction I.B.6 of Form S-3, in
	no event will we sell securities in a public primary offering with a value of more than one-third of the aggregate market value
	of our common shares held by non-affiliates in any twelve-month period, so long as the aggregate market value of our common shares
	held by non-affiliates remains below $75 million. Registered securities issued using our existing shelf may be used to raise additional
	capital to fund our working capital, R&amp;D and other corporate needs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We expect to finance our
	future expenditures and obligations through revenues from product sales, contract services income, and sales of common shares.
	We expect to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue our business
	plan and continue as a going concern. We cannot provide any assurances that we will be able to raise additional capital. Our management
	believes that we have access to capital resources through possible public or private equity offerings, debt financings, corporate
	collaborations or other means, if needed; however, we have not secured any commitment for new financing at this time, nor can we
	provide any assurance that new financing will be available on commercially acceptable terms, if needed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Fiscal Year Ended September 30, 2016
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of September 30,
	2016, our working capital position was $11,476,011 compared to working capital of $7,485,971 as of September 30, 2015. Working
	capital was reduced by the noncash current portion of our warrant liability in the amount of $1,550,630 at September 30, 2015,
	however, there is no warrant liability at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our cash and cash equivalents
	totaled $7,416,904 at September 30, 2016, as compared to cash and cash equivalents of $3,955,503 at September 30, 2015, which represented
	an increase of $3,461,401. Our short-term investments totaled $3,988,794 at September 30, 2016, as compared to short-term investments
	of $5,015,171 at September 30, 2015, which represented a decrease of $1,026,377.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During fiscal 2016,
	operating activities used cash of $4,505,629. Items not affecting cash included: depreciation and amortization of $149,565; share-based
	compensation related to the issuance of share options of $259,379; unrealized foreign exchange gain of $76,800; and loss in fair
	value of warrant liability of $211,956 due to adjustment to fair value of warrants previously issued as a result of the increase
	in the price of our shares. Changes in working capital items include an decrease in accounts receivable of $71,827 due to timing
	of sales and cash receipts; decrease in inventory of $307,850 due to increased sales; increase in prepaid expenses of $197,150
	primarily due to prepaid R&amp;D supplies; decrease in accounts payable and accrued liabilities of $33,403; and decrease in deferred
	revenue of $173,333 recognized as sales when products were billed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Investing activities provided
	cash of $557,411. The acquisition of property, plant and equipment used cash of $402,271. Purchase of short-term investments used
	cash of $11,995,450. Proceeds on maturities of short-term investments provided cash of $13,021,827. Contribution to joint venture
	used cash of $66,695. The effect of exchange rate changes on cash and cash equivalents was an increase of $96,623.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Financing activities provided
	cash of $7,312,996. The proceeds from issuance of common shares and warrants provided cash of $6,277,500 and share issuance costs
	used cash of $332,764. The proceeds from exercise of warrants and options provided cash of $1,368,260.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	During fiscal 2016, a
	total of 2,151,500 common shares were issued:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,687,500
	common shares were issued in a registered direct offering for gross proceeds of $6,750,000.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	464,000 common shares were issued pursuant to the exercise of warrants for gross proceeds of $1,368,260.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Fiscal Year Ended September 30, 2015
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As of September 30, 2015,
	our working capital position was $7,485,971 compared to working capital of $12,650,004 as of August 31, 2014. Working capital is
	reduced by the noncash current portion of our warrant liability in the amount of $1,550,630 and $879,040 at September 30, 2015
	and August 31, 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our cash and cash equivalents
	totaled $3,955,503 at September 30, 2015, as compared to cash and cash equivalents of $8,423,089 at August 31, 2014, which represented
	a decrease of $4,467,586. Our short-term investments totaled $5,015,171 at September 30, 2015, as compared to short-term investments
	of $5,462,413 at August 31, 2014, which represented a decrease of $447,242.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During fiscal 2015, operating activities used cash of $4,412,395. Items not affecting cash included: depreciation
	and amortization of $159,521; share-based compensation related to the issuance of share options of $267,222; unrealized foreign
	exchange loss of $653,333; and gain in fair value of warrant liability of $2,131,062 due to adjustment to fair value of warrants
	previously issued as a result in the decrease in the price of our shares. Changes in working capital items include an increase
	in accounts receivable of $113,917 related mostly to increased revenues; increase in inventory of $522,389 caused by recording
	inventory beginning in fiscal 2015; increase in prepaid expenses of $45,758; increase in accounts payable and accrued liabilities
	of $77,018; and increase in deferred revenue of $86,666 related to deposits on custom manufactured products billed in advance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Investing activities provided
	cash of $122,470. The acquisition of property, plant and equipment used cash of $274,589. Purchase of short-term investments used
	cash of $13,677. Proceeds on maturities of short-term investments provided cash of $410,736. The effect of exchange rate changes
	on cash and cash equivalents was a reduction of $629,808.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Financing activities provided
	cash of $106,777 from the proceeds from exercise of warrants and options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	During fiscal 2015,
	a total of 42,773 common shares were issued upon the exercise of warrants and options, of which:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	4,020 common shares were issued pursuant to the exercise of warrants for gross proceeds of $12,609.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	38,753 common shares were issued pursuant to the exercise of options for proceeds of $94,168.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications.
	Our internal research has included, among other activities, continual improvement of methods for the culture and growth of Giant
	Keyhole Limpet, innovations in aquaculture systems and infrastructure, biophysical and biochemical characterization of the KLH
	molecule, analytical processes to enhance performance of our products, KLH manufacturing process improvements, new KLH formulations,
	and early development of potential new KLH-based immunotherapies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Research and development
	costs, including materials and salaries of employees directly involved in research and development efforts, are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table includes our research and
	development costs for each of the most recent three fiscal years:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 40%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fiscal Year
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Research and
<BR>
	Development Expense
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: CENTER">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	1,729,445
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,029,489
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,458,934
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Off Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: -10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We do not have any off balance sheet arrangements
	that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial
	condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Disclosure of Contractual Obligations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We lease three buildings
	and facilities used in operations under sublease agreements with the Oxnard Harbor District. In June 2015, we exercised our option
	to extend these sublease agreements, each for an additional five-year term beginning in October and November 2015. We also negotiated
	an option to extend the leases for two additional five-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We lease facilities used
	for executive offices and laboratories, and we must pay a portion of the common area maintenance. In July 2016, we exercised our
	option to extend this lease for a two-year term, with options to renew for three successive two-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In June 2015, we leased
	undeveloped land in Baja California, Mexico to assess its suitability for the long-term development and potential expansion of
	our production capability. The first two years rent was prepaid in June 2015. The initial term is three years and we may terminate
	early with 30 days&rsquo; notice. If we decide to proceed with development of the site, we have options to extend the lease for
	30 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have purchase commitments
	for contract research organizations, consultants and construction contractors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The approximate amounts
	of our contractual obligations are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Contractual Obligations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	As of September 30, 2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Less than 1
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	1-3
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	3-5
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	More than
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	year
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	5 years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: JUSTIFY">
	Operating lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	591,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	185,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	294,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	112,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Purchase obligations
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	314,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	314,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	905,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	499,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	294,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	112,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0IN; BACKGROUND-COLOR: WHITE">
<B>
	Significant Accounting
	Policies and Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0IN; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	consolidated financial statements, which are
</FONT>
	indexed under Item&nbsp;15 of this Annual Report on Form 10-K
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	,
	have been prepared in accordance with accounting principles generally accepted in the United States, which require that the management
	make certain assumptions and estimates and, in connection therewith, adopt certain accounting policies. Our significant accounting
	policies are set forth in Note 3 in the Notes to Consolidated Financial Statements. Of those policies, we believe that the policies
	discussed below may involve a higher degree of judgment or may otherwise be more relevant to our financial condition and results
	of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Investments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Investments at September
	30, 2016 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity
	and are reported at amortized cost, which approximates fair value. We regularly review these investments to determine whether any
	decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair value has
	occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value. Investments
	at September 30, 2015 consisted of a mutual fund of short-term fixed, floating and variable rate debt securities with normal weighted
	average effective maturity of approximately 1 year or less. This mutual fund investment is reported at fair value using level 1
	inputs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Inventory
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We record inventory at
	the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in
	first-out) cost. Work in process and finished goods are measured using average cost. Raw materials include inventory of manufacturing
	supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and
	allocated manufacturing overhead for inventory in process at the end of the year. Finished goods include products that are complete
	and available for sale. The Company recorded work in process and finished goods inventory only for those products with recent sales
	levels to evaluate net realizable value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Fair Value of Financial Instruments
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We use the fair value measurement
	framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements
	either permit or require fair value measurements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Fair value of a financial
	instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
	market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts
	payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term
	investments in U.S. Treasury Bills are reported at amortized cost, which approximates fair value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We follow the fair value
	hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
	fair value. There are three levels of inputs that may be used to measure fair value:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; MARGIN-LEFT: 0.5IN">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: JUSTIFY">
	Level&nbsp;&nbsp;1:
</TD>
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: JUSTIFY">
	Quoted prices in active markets for identical or similar assets and liabilities.&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level&nbsp;&nbsp;2:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level&nbsp;&nbsp;3:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 37.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We recorded our short-term
	investments in mutual fund debt securities at fair value using Level 1 inputs in the fair value hierarchy. We recorded our warrant
	liability at fair value using Level 2 input using the Black-Scholes option valuation model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Warrant Liability
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our equity offerings in
	prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. As a result of having exercise
	prices denominated in a currency other than our functional currency, our warrants with Canadian dollar exercise prices met the
	definition of derivatives and were therefore classified as derivative liabilities measured at fair value with noncash adjustments
	to fair value recognized through the consolidated statements of operations. Upon exercise of these warrants, the fair value of
	warrants included in derivative liabilities was reclassified to common shares. If these warrants expired, the related decrease
	in warrant liability was recognized as gain in fair value of warrant liability. There was no cash flow impact as a result of this
	accounting treatment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The fair value of the warrants
	was determined using the Black-Scholes option valuation model at the end of each reporting period. The losses and gains in each
	year were a reflection of our share price fluctuations whereby increases in share prices caused greater warrant liability and a
	resulting loss in fair value of warrant liability, while decreases in share prices caused a resulting gain in fair value of warrant
	liability. Changes in fair value of warrant liability had no impact on cash flow.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	All warrants with exercise
	prices denominated in Canadian dollars were exercised or expired. Therefore, there is no outstanding warrant liability at September
	30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Revenue Recognition
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: JUSTIFY">
<I>
	Product Sales
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	We recognize product sales when KLH
	product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive
	evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. We document arrangements
	with customers with purchase orders and sales agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	Product sales include sales made
	under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those
	produced from a customer&rsquo;s designated limpet colonies. The supply agreements are typically on a non-exclusive basis except
	within that customer&rsquo;s field of use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Contract Services Revenue
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	We recognize contract services
	revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An
	appropriate amount will be recognized as revenue in the period that we are assured of fulfilling the contract requirements. Amounts
	received in advance of performance of contract services are recorded as deferred revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Contract services include services
	performed under collaboration agreements effective December 2013 through 2015 and monthly maintenance of limpet colonies designated
	to meet the needs of the customer through December 2014. We also had the right to use raw material produced from designated limpet
	colonies at no cost to us with prior written consent from the customer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
<I>
	Share-Based Compensation
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We grant options to
	buy common shares of the Company to our directors, officers, employees and consultants, and grant other equity-based instruments
	to non-employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The fair value of share-based
	compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting
	period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model
	requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend
	yield, and expected life of the option.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
<I>
	Foreign Exchange
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Items included in the
	financial statements of our subsidiary are measured using the currency of the primary economic environment in which the entity
	operates (the &ldquo;functional currency&rdquo;). Our functional currency and the functional currency of our subsidiary is the
	U.S. dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Transactions in currencies
	other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
<I>
	Recent Accounting
	Pronouncements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Recent accounting pronouncements
	are contained in Note 3p to the financial statements, which are indexed under Item&nbsp;15 of this this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<B>
	CERTAIN INCOME TAX CONSIDERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	United States Federal Income Taxation
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As used below, a &ldquo;U.S.
	holder&rdquo; is a beneficial owner of a common share that is, for U.S. federal income tax purposes, (i) a citizen or resident
	alien individual of the United States, (ii) a corporation (or an entity treated as a corporation) created or organized under the
	law of the United States, any State thereof or the District of Columbia, (iii) an estate the income of which is subject to U.S.
	federal income tax without regard to its source or (iv) a trust if (1) a court within the United States is able to exercise primary
	supervision over the administration of the trust, and one or more United States persons have the authority to control all substantial
	decisions of the trust, or (2) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated
	as a United States person. For purposes of this discussion, a &ldquo;non-U.S. holder&rdquo; is a beneficial owner of a common share
	that is (i) a nonresident alien individual, (ii) a corporation (or an entity treated as a corporation) created or organized in
	or under the law of a country other than the United States or a political subdivision thereof or (iii) an estate or trust that
	is not a U.S. Holder. If a partnership (including for this purpose any entity treated as a partnership for U.S. federal tax purposes)
	is a beneficial owner of a common share, the U.S. federal tax treatment of a partner in the partnership generally will depend on
	the status of the partner and the activities of the partnership. A holder of a common share that is a partnership and partners
	in that partnership should consult their own tax advisers regarding the U.S. federal income tax consequences of holding and disposing
	of common shares. We have not sought a ruling from the Internal Revenue Service (&ldquo;IRS&rdquo;) or an opinion of counsel as
	to any U.S. federal income tax consequence described herein. The IRS may disagree with the description herein, and its determination
	may be upheld by a court. This discussion does not address U.S. federal tax laws other than those pertaining to U.S. federal income
	taxation (such as estate or gift tax laws), nor does it address any aspects of U.S. state or local or non-U.S. taxation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-UNDERLINE-STYLE: DOUBLE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	GIVEN THE COMPLEXITY OF THE TAX LAWS AND
	BECAUSE THE TAX CONSEQUENCES TO ANY PARTICULAR SHAREHOLDER MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN, SHAREHOLDERS ARE URGED
	TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE SPECIFIC TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF
	COMMON SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF STATE, LOCAL AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL TAX LAWS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Taxation of Dividends
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<U>
	U.S. Holders
</U>
	.
</B>
	In general, subject to the passive foreign investment company rules discussed below, a distribution on a common share will
	constitute a dividend for U.S. federal income tax purposes to the extent that it is made from a corporation&rsquo;s current or
	accumulated earnings and profits as determined under U.S. federal income tax principles. If a distribution exceeds the current
	and accumulated earnings and profits of the distributing corporation, it will generally be treated as a non-taxable reduction of
	basis to the extent of the U.S. holder&rsquo;s tax basis in the common share on which it is paid, and to the extent it exceeds
	that basis it will be treated as capital gain. The Company has not and does not plan to maintain calculations of earnings and profits
	under U.S. federal income tax principles. Accordingly, it is unlikely that U.S. holders will be able to establish that a distribution
	by the Company is in excess of its current and accumulated earnings and profits (as computed under U.S. federal income tax principles).
	Therefore, a U.S. holder should expect that a distribution by the Company will generally be taxable in its entirety as a dividend
	to U.S. holders for U.S. federal income tax purposes even though the distribution may be treated in whole or in part as a non-taxable
	distribution for Canadian tax purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The gross amount of
	any dividend on a common share (which will include the amount of any Canadian taxes withheld with respect to such dividend) generally
	will be subject to U.S. federal income tax as foreign source dividend income, and will not be eligible for the corporate dividends
	received deduction. The amount of a dividend paid in Canadian dollars will be its value in U.S. dollars based on the prevailing
	spot market exchange rate in effect on the day the U.S. holder receives the dividend. A U.S. holder will have a tax basis in any
	distributed Canadian dollars equal to their U.S. dollar value on the date of receipt, and any gain or loss realized on a subsequent
	conversion or other disposition of such Canadian dollars generally will be treated as U.S. source ordinary income or loss. If dividends
	paid in Canadian dollars are converted into U.S. dollars on the date they are received by a U.S. holder, the U.S. holder generally
	should not be required to recognize foreign currency gain or loss in respect of the dividend income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Subject to
	certain exceptions for short-term and hedged positions, as well as the passive foreign investment rules, a dividend that a
	non-corporate holder receives on a common share will generally be subject to a maximum federal income tax rate of 20% if the
	dividend is a &ldquo;qualified dividend.&rdquo; A dividend on a common share will be a qualified dividend if (i) either (a)
	the common shares are readily tradable on an established market in the United States or (b) we are eligible for the benefits
	of a comprehensive income tax treaty with the United States that the Secretary of the Treasury determines is satisfactory for
	purposes of these rules and that includes an exchange of information program, and (ii) we were not, in the year prior to the
	year the dividend was paid, and are not, in the year the dividend is paid, a passive foreign investment company
	(&ldquo;PFIC&rdquo;). The common shares are listed on The Nasdaq Capital Market which should be treated as an established
	securities market in the United States. In any event, the U.S. Canada Income Convention (the &ldquo;Treaty&rdquo;) satisfies
	the requirements of clause (i)(b), the Company is incorporated in and tax resident of Canada and should be entitled to the
	benefits of the Treaty. Based on our audited financial statements, income tax returns and relevant market and shareholder
	data, we believe that we likely will not be classified as a PFIC in the September 30, 2016 taxable year. There can be no
	assurance, however, that the Company will not be considered to be a PFIC for any particular year in the future because PFIC
	status is factual in nature, depends upon factors not wholly within the Company&rsquo;s control, generally cannot be
	determined until the close of the taxable year in question, and is determined annually. Accordingly, no assurance can be made
	that a dividend paid, if any, would be a &ldquo;qualified dividend.&rdquo; In addition, as described in the section below
	entitled &ldquo;Passive Foreign Investment Company Rules,&rdquo; if we were a PFIC in a year while a U.S. holder held a
	common share, and if the U.S. holder has not made a qualified electing fund election effective for the first year the U.S.
	holder held the common share, the common share remains an interest in a PFIC for all future years or until such an election
	is made. The IRS takes the position that such rule will apply for purposes of determining whether a common share is an
	interest in a PFIC in the year a dividend is paid or in the prior year, even if we do not satisfy the tests to be a PFIC in
	either of those years. Even if dividends on the common shares would otherwise be eligible for qualified dividend treatment,
	in order to qualify for the reduced qualified dividend tax rates, a non-corporate holder must hold the common share on which
	a dividend is paid for more than 60 days during the 120-day period beginning 60 days before the ex-dividend date,
	disregarding for this purpose any period during which the non-corporate holder has an option to sell, is under a contractual
	obligation to sell or has made (and not closed) a short sale of substantially identical stock or securities, is the grantor
	of an option to buy substantially identical stock or securities or, pursuant to U.S. Treasury regulations, has diminished
	such holder&rsquo;s risk of loss by holding one or more other positions with respect to substantially similar or related
	property. In addition, to qualify for the reduced qualified dividend tax rates, the non-corporate holder must not be
	obligated to make related payments with respect to positions in substantially similar or related property. Payments in lieu
	of dividends from short sales or other similar transactions will not qualify for the reduced qualified dividend tax
	rates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A non-corporate holder
	that receives an extraordinary dividend (generally, any dividend that is in excess of 10% of the holder's adjusted basis in the
	common share on which the dividend is paid) that is eligible for the reduced qualified dividend rates must treat any loss on the
	sale of the common share as a long-term capital loss to the extent of the dividend. For purposes of determining the amount of a
	non-corporate holder&rsquo;s deductible investment interest expense, a dividend is treated as investment income only if the non-corporate
	holder elects to treat the dividend as not eligible for the reduced qualified dividend tax rates. Special limitations on foreign
	tax credits with respect to dividends subject to the reduced qualified dividend tax rates apply to reflect the reduced rates of
	tax.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The U.S. Treasury has
	announced its intention to promulgate rules pursuant to which non-corporate holders of stock of non-U.S. corporations, and intermediaries
	through which the stock is held, will be permitted to rely on certifications from issuers to establish that dividends are treated
	as qualified dividends. Because those procedures have not yet been issued, it is not clear whether we will be able to comply with
	them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Non-corporate holders
	of common shares are urged to consult their own tax advisers regarding the availability of the reduced qualified dividend tax rates
	with respect to dividends, if any, received on the common shares in the light of their own particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any Canadian withholding
	tax imposed on dividends received with respect to the common shares will be treated as a foreign income tax eligible for credit
	against a U.S. holder&rsquo;s U.S. federal income tax liability, subject to generally applicable limitations under U.S. federal
	income tax law. For purposes of computing those limitations separately under current law for specific categories of income, a dividend
	generally will constitute foreign source &ldquo;passive category income&rdquo; or, in the case of certain holders, &ldquo;general
	category income.&rdquo; A U.S. holder will be denied a foreign tax credit with respect to Canadian income tax withheld from dividends
	received with respect to the common shares to the extent the U.S. holder has not held the common shares for at least 16 days of
	the 30-day period beginning on the date which is 15 days before the ex-dividend date or to the extent the U.S. holder is under
	an obligation to make related payments with respect to substantially similar or related property. Any days during which a U.S.
	holder has substantially diminished its risk of loss on the common shares are not counted toward meeting the 16-day holding period
	required by the statute. The rules relating to the determination of the foreign tax credit are complex, and U.S. holders are urged
	to consult with their own tax advisers to determine whether and to what extent they will be entitled to foreign tax credits as
	well as with respect to the determination of the foreign tax credit limitation. Alternatively, any Canadian withholding tax may
	be taken as a deduction against taxable income, provided the U.S. holder takes a deduction and not a credit for all foreign income
	taxes paid or accrued in the same taxable year. In general, special rules will apply to the calculation of foreign tax credits
	in respect of dividend income that is subject to preferential rates of U.S. federal income tax.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<U>
	Non-U.S. Holders
</U>
	.
</B>
	A dividend paid to a non-U.S. holder of a common share will generally not be subject to U.S. federal income tax unless the
	dividend is effectively connected with the conduct of trade or business by the non-U.S. holder within the United States (and is
	attributable to a permanent establishment or fixed base the non-U.S. holder maintains in the United States if an applicable income
	tax treaty so requires as a condition for the non-U.S. holder to be subject to U.S. taxation on a net income basis on income from
	the common share). A non-U.S. holder generally will be subject to tax on an effectively connected dividend in the same manner as
	a U.S. holder. A corporate non-U.S. holder under certain circumstances may also be subject to an additional &ldquo;branch profits
	tax,&rdquo; the rate of which may be reduced pursuant to an applicable income tax treaty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Taxation of Capital Gains
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<U>
	U.S. Holders
</U>
	.
</B>
	Subject to the passive foreign investment company rules discussed below, on a sale or other taxable disposition of a common
	share, a U.S. holder will recognize capital gain or loss in an amount equal to the difference between the U.S. holder&rsquo;s adjusted
	basis in the common share and the amount realized on the sale or other disposition, each determined in U.S. dollars. Such capital
	gain or loss will be long-term capital gain or loss if at the time of the sale or other taxable disposition the common share has
	been held for more than one year. In general, any adjusted net capital gain of an individual is subject to a maximum federal income
	tax rate of 20%. Capital gains recognized by corporate U.S. holders generally are subject to U.S. federal income tax at the same
	rate as ordinary income. The deductibility of capital losses is subject to limitations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Any gain a U.S. holder
	recognizes generally will be U.S. source income for U.S. foreign tax credit purposes, and, subject to certain exceptions, any loss
	will generally be a U.S. source loss. If a Canadian tax is paid on a sale or other disposition of a common share, the amount realized
	will include the gross amount of the proceeds of that sale or disposition before deduction of the Canadian tax. The generally applicable
	limitations under U.S. federal income tax law on crediting foreign income taxes may preclude a U.S. holder from obtaining a foreign
	tax credit for any Canadian tax paid on a sale or other disposition of a common share. The rules relating to the determination
	of the foreign tax credit are complex, and U.S. holders are urged to consult with their own tax advisers regarding the application
	of such rules. Alternatively, any Canadian tax paid on the sale or other disposition of a common share may be taken as a deduction
	against taxable income, provided the U.S. holder takes a deduction and not a credit for all foreign income taxes paid or accrued
	in the same taxable year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<U>
	Non-U.S. Holders
</U>
	.
</B>
	A non-U.S. holder will not be subject to U.S. federal income tax on gain recognized on a sale or other disposition of a common
	share unless (i) the gain is effectively connected with the conduct of trade or business by the non-U.S. holder within the United
	States (and is attributable to a permanent establishment or fixed base the non-U.S. holder maintains in the United States if an
	applicable income tax treaty so requires as a condition for the non-U.S. holder to be subject to U.S. taxation on a net income
	basis on income from the common share), or (ii) in the case of a non-U.S. holder who is an individual, the holder is present in
	the United States for 183 or more days in the taxable year of the sale or other disposition and certain other conditions apply.
	Any effectively connected gain of a corporate non-U.S. holder may also be subject under certain circumstances to an additional
	&ldquo;branch profits tax,&rdquo; the rate of which may be reduced pursuant to an applicable income tax treaty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Passive Foreign Investment Company Rules
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A special set of U.S.
	federal income tax rules applies to a foreign corporation that is a PFIC for U.S. federal income tax purposes. As noted above,
	based on our audited financial statements, income tax returns, and relevant market and shareholder data, we believe that we likely
	will not be classified as a PFIC in the September 30, 2016 taxable year. There can be no assurance, however, that the Company will
	not be considered to be a PFIC for any particular year in the future because PFIC status is factual in nature, depends upon factors
	not wholly within the Company&rsquo;s control, generally cannot be determined until the close of the taxable year in question,
	and is determined annually.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In general, a non-US
	corporation is a PFIC if in any taxable year either (i) at least 75% of its gross income is &ldquo;passive income&rdquo; or (ii)
	at least 50% of the quarterly average value of its assets is attributable to assets that produce or are held to produce &ldquo;passive
	income.&rdquo; In applying these tests, the Company generally is treated as holding its proportionate share of the assets and receiving
	its proportionate share of the income of any other corporation in which the Company owns at least 25% by value of the shares. Passive
	income for this purpose generally includes dividends, interest, royalties, rent and capital gains, but generally does not include
	certain royalties derived in an active business. Passive assets are those assets that are held for production of passive income
	or do not produce income at all. Thus cash will be a passive asset. Interest, including interest on working capital, is treated
	as passive income for purposes of the income test. Without taking into account the value of its goodwill, more than 50% of the
	Company&rsquo;s assets by value would be passive so that the Company would be a PFIC under the asset test. Based upon its current
	operations, its goodwill (the value of which should be based upon the Company&rsquo;s market capitalization) will likely be attributable
	to its activities that will generate active income and to such extent, should be treated as an active asset. The determination
	of whether a foreign corporation is a PFIC is a factual determination made annually and is therefore subject to change. Subject
	to exceptions pursuant to certain elections that generally require the payment of tax, once stock in a foreign corporation is stock
	in a PFIC in the hands of a particular shareholder that is a United States person, it remains stock in a PFIC in the hands of that
	shareholder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we are treated as
	a PFIC, contrary to the tax consequences described in &ldquo;Taxation of Dividends&rdquo; and &ldquo;Taxation of Capital Gains&rdquo;
	above, a U.S. holder that does not make an election described in the succeeding two paragraphs would be subject to special rules
	with respect to (i) any gain realized on a sale or other disposition of a common share (for purposes of these rules, a disposition
	of a common share includes many transactions on which gain or loss is not realized under general U.S. federal income tax rules)
	and (ii) any &ldquo;excess distribution&rdquo; by the Company to the U.S. holder (generally, any distribution during a taxable
	year in which distributions to the U.S. holder on the common share exceed 125% of the average annual taxable distributions (whether
	actual or constructive and whether or not out of earnings and profits) the U.S. holder received on the common share during the
	preceding three taxable years or, if shorter, the U.S. holder&rsquo;s holding period for the common share). Under those rules,
	(i) the gain or excess distribution would be allocated ratably over the U.S. holder&rsquo;s holding period for the common share,
	(ii) the amount allocated to the taxable year in which the gain or excess distribution is realized would be taxable as ordinary
	income in its entirety and not as capital gain, would be ineligible for the reduced qualified dividend rates, and could not be
	offset by any deductions or losses, and (iii) the amount allocated to each prior year, with certain exceptions, would be subject
	to tax at the highest tax rate in effect for that year, and the interest charge generally applicable to underpayments of tax would
	be imposed in respect of the tax attributable to each of those years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The special PFIC rules
	described above will not apply to a U.S. holder if the U.S. holder makes a timely election, which remains in effect, to treat the
	Company as a &ldquo;qualified electing fund&rdquo; (&ldquo;QEF&rdquo;) in the first taxable year in which the U.S. holder owns
	a common share and the Company is a PFIC and if the Company complies with certain requirements. Instead, a shareholder of a QEF
	generally is currently taxable on a pro rata share of the Company&rsquo;s ordinary earnings and net capital gain as ordinary income
	and long-term capital gain, respectively. Neither that ordinary income nor any actual dividend from the Company would qualify for
	the 20% maximum federal income tax rate on dividends described above if the Company is a PFIC in the taxable year the ordinary
	income is realized or the dividend is paid or in the preceding taxable year. A QEF election cannot be made unless the Company provides
	U.S. Holders the information and computations needed to report income and gains pursuant to a QEF election. The Company expects
	that will not provide this information. It is, therefore, likely that U.S. holders would not be able to make a QEF election in
	any year we are a PFIC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In lieu of a QEF election,
	a U.S. holder of stock in a PFIC that is considered marketable stock could elect to mark the stock to market annually, recognizing
	as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair market
	value of the stock and the U.S. holder&rsquo;s adjusted basis in the stock. Losses would be allowed only to the extent of net mark-to-market
	gain previously included in income by the U.S. holder under the election for prior taxable years. A U.S. holder&rsquo;s adjusted
	basis in the common shares will be adjusted to reflect the amounts included or deducted with respect to the mark-to-market election.
	If the mark-to-market election were made, the rules set forth in the second preceding paragraph would not apply for periods covered
	by the election. A mark-to-market election will not apply during any later taxable year in which the Company does not satisfy the
	tests to be a PFIC. In general, the common shares will be marketable stock if the common shares are traded, other than in
<I>
	de
	minimis
</I>
	quantities, on at least 15 days during each calendar quarter on a national securities exchange that is registered with
	the SEC or on a designated national market system or on any exchange or market that the Treasury Department determines to have
	rules sufficient to ensure that the market price accurately represents the fair market value of the stock
<B>
	.
</B>
	Under current
	law, the mark-to-market election may be available to U.S. holders of common shares because the common shares are listed on The
	Nasdaq Capital Market and the TSX Venture Exchange (at least one of which should constitute a qualified exchange for this purpose),
	although there can be no assurance that the common shares will be &ldquo;regularly traded&rdquo; for purposes of the mark-to-market
	election.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	If we are treated as
	a PFIC, each U.S. holder generally will be required to file a separate annual information return with the United States Internal
	Revenue Service (IRS) with respect to the Company (and any lower-tier PFICs). A failure to file this return will suspend the statute
	of limitations with respect to any tax return, event, or period to which such report relates (potentially including with respect
	to items that do not relate to a U.S. holder&rsquo;s investment in the common shares). Given the complexities of the PFIC rules
	and their potentially adverse tax consequences, U.S. holders of common shares are urged to consult their tax advisers about the
	PFIC rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Medicare Surtax on Net Investment Income
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Non-corporate U.S.
	Holders whose income exceeds certain thresholds generally will be subject to 3.8% surtax on their &ldquo;net investment income&rdquo;
	(which generally includes, among other things, dividends on, and capital gain from the sale or other taxable disposition of, the
	common shares). Absent an election to the contrary, if a QEF election is available and made, QEF inclusions will not be included
	in net investment income at the time a U.S. Holder includes such amounts in income, but rather will be included at the time distributions
	are received or gains are recognized. Non-corporate U.S. Holders should consult their own tax advisors regarding the possible effect
	of such tax on their ownership and disposition of the common shares, in particular the applicability of this surtax with respect
	to a non-corporate U.S. Holder that makes a QEF or mark-to-market election in respect of their common shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Information Reporting and Backup Withholding
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dividends paid on,
	and proceeds from the sale or other disposition of, a common share to a U.S. holder generally may be subject to information reporting
	requirements and may be subject to backup withholding unless the U.S. holder provides an accurate taxpayer identification number
	or otherwise establishes an exemption. The amount of any backup withholding collected from a payment to a U.S. holder will be allowed
	as a credit against the U.S. holder&rsquo;s U.S. federal income tax liability and may entitle the U.S. holder to a refund, provided
	certain required information is furnished to the Internal Revenue Service. A non-U.S. holder generally will be exempt from these
	information reporting requirements and backup withholding tax but may be required to comply with certain certification and identification
	procedures in order to establish its eligibility for exemption.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under U.S. federal
	income tax law and U.S. Treasury Regulations, certain categories of U.S. holders must file information returns with respect to
	their investment in, or involvement in, a foreign corporation. U.S. holders are urged to consult with their own tax advisors concerning
	such reporting requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Reporting Obligations of Individual
	Owners of Foreign Financial Assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Section 6038D of the
	Code generally requires U.S. individuals (and possibly certain entities that have U.S. individual owners) to file IRS Form 8938
	if they hold certain &ldquo;specified foreign financial assets,&rdquo; the aggregate value of which exceeds $50,000. The definition
	of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also,
	unless held in accounts maintained by a financial institution, any stock or security issued by a non-US. person, any financial
	instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign
	entity. Persons who are required to report foreign financial assets and fail to do so may be subject to substantial penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<U>
	Canadian Federal Income Tax Consequences
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following summary
	of the material Canadian federal income tax consequences is stated in general terms and is not intended to be legal or tax advice
	to any particular shareholder. Each shareholder or prospective shareholder is urged to consult his or her own tax advisor regarding
	the tax consequences of his or her purchase, ownership and disposition of common shares. The tax consequences to any particular
	holder of common shares will vary according to the status of that holder as an individual, trust, corporation or member of a partnership,
	the jurisdiction in which that holder is subject to taxation, the place where that holder is resident and, generally, according
	to that holder&rsquo;s particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This summary is applicable
	only to holders who are resident in the United States for income tax purposes, have never been resident in Canada for income tax
	purposes, deal at arm&rsquo;s length with the Company, hold their common shares as capital property and who will not use or hold
	the common shares in carrying on business in Canada. Special rules, which are not discussed in this summary, may apply to a United
	States holder that is an issuer that carries on business in Canada and elsewhere.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This summary is based
	upon the provisions of the Income Tax Act (Canada) and the regulations thereunder (collectively, the &ldquo;Tax Act&rdquo; or &ldquo;ITA&rdquo;)
	and the Canada-United States Tax Convention (the &ldquo;Tax Convention&rdquo;) at the date of this Annual Report and the current
	administrative practices of the Canada Revenue Agency. This summary does not take into account provincial income tax consequences.
	The comments in this summary that are based on the Tax Convention are applicable to U.S. holders only if they qualify for benefits
	under the Tax Convention. Management urges each holder to consult his own tax advisor with respect to the income tax consequences
	applicable to him in his own particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Non-Resident Holders
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The summary below is
	restricted to the case of a holder (a &ldquo;Holder&rdquo;) of one or more common shares who for the purposes of the Tax Act is
	a non-resident of Canada, holds his common shares as capital property and deals at arm&rsquo;s length with the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Dividends
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A Holder will be subject
	to Canadian withholding tax (&ldquo;Part XIII Tax&rdquo;) equal to 25%, or such lower rates as may be available under an applicable
	tax treaty, of the gross amount of any dividend paid or deemed to be paid on his common shares. The Company will be required to
	withhold the applicable amount of Part XIII Tax from each dividend so paid and remit the withheld amount directly to the Receiver
	General for Canada for the account of the Holder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Disposition of Common Shares
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A Holder who disposes
	of common shares, including by deemed disposition on death, will not be subject to Canadian tax on any capital gain thereby realized
	unless the common share constituted &ldquo;taxable Canadian property&rdquo; as defined by the Tax Act. Generally, a common share
	of a public corporation will not constitute taxable Canadian property of a Holder unless he held the common share as capital property
	used by him carrying on a business in Canada, or he, persons with whom he did not deal at arm&rsquo;s length or (under currently
	proposed rules) partnerships in which he or persons with whom he did not deal at arm&rsquo;s length held an interest, alone or
	together held or held options to acquire, at any time within the 60 months preceding the disposition, 25% or more of the issued
	shares of any class of the capital stock of the Company and at any time during the 60 months preceding the disposition more than
	50% of the value of the common shares is derived from, or from an interest in, Canadian real estate, including Canadian resource
	or timber resource properties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Holders Resident in the United States
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A Holder who is a resident
	of the United States and realizes a capital gain on disposition of common shares that was taxable Canadian property will, if qualified
	for benefits under the Tax Convention, generally be exempt from Canadian tax thereon unless (a) more than 50% of the value of the
	common shares is derived from, or from an interest in, Canadian real estate, including Canadian mineral resources properties, (b)
	the common shares formed part of the business property of a permanent establishment that the Holder has or had in Canada within
	the 12 months preceding disposition, or (c) the Holder (i) was a resident of Canada at any time within the ten years immediately
	preceding the disposition, and for a total of 120 months during any period of 20 consecutive years, preceding the disposition,
	(ii) owned the common shares when he ceased to be resident in Canada, and (iii) the common shares were not subject to a deemed
	disposition on the Holder&rsquo;s departure from Canada.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Inclusion in Taxable Income
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	A Holder who is subject
	to Canadian tax in respect of a capital gain realized on disposition of common shares must include one half of the capital gain
	(&ldquo;taxable capital gain&rdquo;) in computing his taxable income earned in Canada. The Holder may, subject to certain limitations,
	deduct one half of any capital loss (&ldquo;allowable capital loss&rdquo;) arising on disposition of taxable Canadian property
	from taxable capital gains realized in the year of disposition in respect to taxable Canadian property and, to the extent not so
	deductible, from such taxable capital gains of any of the three preceding years or any subsequent year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Subject to certain exceptions,
	a non-resident person who disposes of taxable Canadian property must notify the Canada Revenue Agency either before or after the
	disposition (within ten days of the disposition).
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_012">
</A>
<B>
	Item
</B>
<B>
	7A.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
	MARKET RISK
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are exposed to financial
	market risks associated with foreign exchange rates, concentration of credit, and liquidity. In accordance with our policies, we
	manage our exposure to various market-based risks and where material, these risks are reviewed and monitored by our Board of Directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Foreign Exchange Risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our exposure to
	foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. We incur
	operating expenses and capital expenditures mostly in U.S. dollars, with some operating expenses incurred in Canadian dollars
	which are subject to foreign currency fluctuations. The fluctuation of the U.S. dollar in relation to the Canadian dollar
	will have an impact upon our profitability and may also affect the value of our assets and the amount of shareholders&rsquo;
	equity. We have not entered into any agreements or purchased any instruments to hedge possible currency risks. At September
	30, 2016, we held approximately CDN$4,270,000 in cash and cash equivalents in Canadian dollars and the U.S. dollar was equal
	to 1.314 Canadian dollars. Based on the exposure at September 30, 2016, a 10% annual change in the Canadian/U.S. exchange
	rate over the prior year would impact our net loss by approximately $325,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Concentration of Credit Risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We are potentially
	subject to financial instrument concentration of credit risk through our cash equivalents, US Treasury bills, mutual fund debt
	securities and accounts receivables. We place our cash and cash equivalents in 4 week US Treasury bills or financial institutions
	believed to be credit worthy and perform periodic evaluations of their relative credit standing. We place short-term investments
	in 13 to 52 week US Treasury bills or a mutual fund that invests in high-quality, U.S. dollar-denominated short-term fixed-, floating-
	and variable-rate debt securities that have received either a minimum short-term rating of at least A-1 (or its equivalent) or
	a minimum long-term rating of A minus (or its equivalent), by one or more Nationally Recognized Statistical Ratings Organizations,
	or, if unrated, that are deemed by the fund to be of comparable quality at the time of purchase. Accounts receivables can be potentially
	exposed to a concentration of credit risk with our major customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company had concentrations
	of revenues in fiscal 2016, 2015 and 2014 as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 55%">
<FONT STYLE="FONT-SIZE: 10PT">
	Product sales and
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	76% from
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	82% from
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	73% from
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	contract services revenue
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3 customers
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3 customers
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2 customers
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	100% from
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Grant revenue
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1 grantor
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Company had concentrations
	of accounts receivable at fiscal year-end 2016 and 2015 as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.5IN">
<TR>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 66%; TEXT-ALIGN: LEFT">
	Accounts receivable
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	100 % from
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	91% from
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1 customer
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2 customers
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We assess the collectability
	of our accounts receivable through a review of our current aging, as well as an analysis of our historical collection rate, general
	economic conditions and credit status of our customers.&nbsp; As of September 30, 2016 and 2015, all outstanding accounts receivable
	were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. We determine terms and conditions
	for our customers primarily based on the volume purchased by the customer, customer creditworthiness and past transaction history.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Management works to
	mitigate our concentration of credit risk with respect to accounts receivable through our credit evaluation policies, reasonably
	short payment terms and geographical dispersion of sales. Revenue includes export sales to foreign companies located principally
	in Europe and Asia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Liquidity Risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Liquidity risk is
	the risk that we will not be able to meet our financial obligations as they fall due. We attempt to manage liquidity risk by
	maintaining sufficient cash and cash equivalent and short-term investment balances. Liquidity requirements are managed based
	on expected cash flows to ensure that there is sufficient capital in order to meet our short-term obligations. At September
	30, 2016 and 2015, we had cash and cash equivalents and short-term investment balances totaling $11,405,698 and $8,970,674,
	respectively, to settle current liabilities of $623,644 and $2,380,648, respectively. Current liabilities included the
	current portion of our warrant liability in the amount of $1,550,630 at September 30, 2015, which will not be settled in
	cash.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_013">
</A>
<B>
	Item
</B>
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.1PT; TEXT-INDENT: -56.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The financial statements
	and related financial information required to be filed hereunder are indexed under Item&nbsp;15 of this Annual Report on Form 10-K
	and are incorporated herein by reference.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 55.05PT; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_014">
</A>
<B>
	Item
</B>
<B>
	9.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
	ON ACCOUNTING AND FINANCIAL DISCLOSURE
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There were no reportable
	events under this item during the past two fiscal years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTING_CHANGES>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_015">
</A>
<B>
	Item
</B>
<B>
	9A.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	CONTROLS AND PROCEDURES
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management is responsible
	for establishing and maintaining disclosure controls and procedures to provide reasonable assurance that material information related
	to our Company, including our consolidated subsidiaries, is made known to senior management, including our Chief Executive Officer
	and the Chief Financial Officer, by others within those entities on a timely basis so that appropriate decisions can be made regarding
	public disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We carried out an evaluation,
	under the supervision and with the participation of our management, including our Principal Executive Officer and our Principal
	Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules
	13a-15(e) and 15d-15(e)) under the Securities and Exchange Act of 1934, as amended) as of September 30, 2016. Our Chief Executive
	Officer and Chief Financial Officer concluded that the disclosure controls and procedures as of September 30, 2016, were effective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Management&rsquo;s Annual Report on Internal Control over
	Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management is responsible
	for designing, establishing and maintaining a system of internal controls over financial reporting (as defined in Exchange Act
	Rule 13a-15(f)) to provide reasonable assurance that the financial information prepared by us for external purposes is reliable
	and has been recorded, processed and reported in an accurate and timely manner in accordance with accounting principles generally
	accepted in the United States. The Board of Directors is responsible for ensuring that management fulfills its responsibilities.
	The Audit Committee fulfills its role of ensuring the integrity of the reported information through its review of the interim and
	annual financial statements. Management reviewed the results of their assessment with our Audit Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Because of its inherent
	limitations, our internal control over financial reporting may not prevent or detect all possible misstatements or frauds. Also,
	projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
	of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Management has used
	the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;) in &ldquo;Internal
	Control &mdash; Integrated Framework (2013)&rdquo; to evaluate the effectiveness of our internal control over financial reporting.
	Management has assessed the effectiveness of our internal control over financial reporting and concluded that such internal control
	over financial reporting was effective as of September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Attestation Report of Our Registered
	Public Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	This Annual Report
	does not include an attestation report from our independent registered public accounting firm. We are an &ldquo;emerging growth
	company,&rdquo; as defined under the JOBS Act, and are subject to reduced public company reporting requirements. The JOBS Act
	provides that an emerging growth company is not required to have the effectiveness of such company&rsquo;s internal control over
	financial reporting audited by its external auditors for as long as such company is deemed to be an emerging growth company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Limitations on the Effectiveness of Controls
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our management, including
	the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal controls
	will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable,
	not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect
	the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because
	of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues
	and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments
	in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can
	be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.
	The design of any system of controls is also based, in part, upon certain assumptions about the likelihood of future events, and
	there can be no assurance that any design will succeed achieving its stated goals under all potential future conditions; over time,
	control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may
	deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur
	and not be detected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Changes in Internal Control over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There were no changes
	in our internal control over financial reporting that occurred during the fourth quarter ended September 30, 2016 that have materially
	affected, or are reasonably likely to materially affect, our internal control over financial reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_016">
</A>
<B>
	Item
</B>
<B>
	9B.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	OTHER INFORMATION.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_017">
</A>
<B>
	PART III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 55.05PT; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_018">
</A>
<B>
	Item
</B>
<B>
	10.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
	GOVERNANCE.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Directors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our directors and their
	ages as of December 9, 2016 are set forth below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 21%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 46%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Position(s) Held
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Director Since
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tessie M. Che, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	66
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 25, 2013
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Paul Chun (1)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	35
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David L. Hill, Ph.D. (1)(2)(3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	65
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	May 17, 2011
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Daniel E. Morse, Ph.D.
<SUP>
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	75
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	April 9, 2010
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Frank R. Oakes
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	66
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and Chairman of our Board of Directors
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	April 9, 2010
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Charles V. Olson, D.Sc.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	59
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 8, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Mayank D. Sampat (1)(2)(3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	61
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 15, 2012
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(1) Member of Audit Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(2) Member of Compensation Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(3) Member of the Nominating and Corporate Governance Committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	There are no family
	relationships between any of our directors or executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	Biographies
	and Qualifications.
</B>
	&nbsp;&nbsp;The biographies of our directors and certain information regarding each director&rsquo;s experience,
	attributes, skills and/or qualifications that led to the conclusion that the director should be serving as a director of our Company
	are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Tessie M. Che, Ph.D.
</B>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	has been a director of Stellar since September 2013. Dr. Che is currently General Manager
	and Chair of the Board of Directors of Amaran Biotechnology Inc., a privately-held biopharmaceuticals manufacturer based in Taiwan,
	a position she has held since 2012. She is also a director of OBI Pharma USA, a wholly-owned subsidiary of OBI Pharma, Inc., a
	publicly traded biotechnology corporation in Taiwan. From 1998 to 2011 she served as COO and Sr. V.P., Corporate Affairs of Optimer
	Pharmaceuticals Inc., a company she co-founded. At Optimer, Dr. Che guided the company&rsquo;s CMC team to the successful registration
	and commercialization of Dificid
<SUP>
	TM
</SUP>
	in the U.S., Canada and Europe. Prior to Optimer, Dr. Che&rsquo;s experience includes
	20 years in research, operations and management at global companies, including Exxon Mobil Corp., Aventis Pharmaceuticals Inc.,
	and EniChem SpA. Dr. Che holds bachelor degrees in chemistry from Illinois State University and Fu-Jen Catholic University (Taiwan)
	and a PhD in physical-inorganic chemistry from Brandeis University. She has authored numerous scientific publications and holds
	over 20 U.S. patents. Dr. Che has extensive scientific, operational, manufacturing, quality assurance, product development and
	senior management experience in the pharmaceutical and biotechnology industries, as well as experience serving on a board of directors
	within our industry.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Paul Chun&nbsp;
</B>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	has
	been a director of Stellar since December 2016.&nbsp; He is a Managing Partner of Eldred Advisors LLC, a life sciences advisory
	firm he founded in May 2016.&nbsp; From November 2015 to April 2016, he served as Director of Strategy and Corporate Development
	at Kiromic, LLC. From May 2011 to October 2015, Mr. Chun served as a life sciences principal with Westwicke Partners, LLC, a capital
	markets advisory firm. During his tenure at Westwicke,&nbsp;he supported the capital markets and investor engagement objectives
	of private and public biopharma companies, including the support of multiple initial public offerings and other strategic transactions.
	Prior to Westwicke,&nbsp;he&nbsp;held various roles in investment research and corporate finance, including at Amgen, Inc., Tavistock
	Life Sciences and Goldman, Sachs &amp; Co. He received his bachelors in biological sciences from Columbia University. Mr. Chun
	has broad experience in therapeutics development and commercialization, valuation, corporate development and finance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	David L. Hill, Ph.D.
</B>
	has been a director of Stellar since May 2011, and serves as the chair of the Compensation Committee. He currently serves as
	Scientific Director for the ART Reproductive Center, Beverly Hills, California, a position he has held since December 1999. He
	is also an Assistant Clinical Professor in the Dept. of Obstetrics and Gynecology at the David Geffen School of Medicine, University
	of California, Los Angeles, and a Research Assistant IV at Cedars-Sinai Medical Center, Los Angeles, California. Dr. Hill received
	his Ph.D. in Biological Sciences from the Department of Pathology, School of Life Sciences, University of Connecticut and completed
	a Postdoctoral Fellowship at the Dana Farber Cancer Institute through an appointment by the Department of Physiology and Biophysics,
	Harvard Medical School, Boston, Massachusetts. Dr. Hill has extensive scientific and clinical research experience in our industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Daniel E. Morse,
	Ph.D.
</B>
	has been a director of Stellar since April 2010. Dr. Morse is the Wilcox Professor Emeritus of Molecular Genetics and
	Biochemistry Biotechnology, Biomolecular Science and Engineering, a position he has held since 2008, and Director of the Marine
	Biotechnology Center, at the University of California, Santa Barbara, a position he has held since 1986. Previously, he served
	as Director of the UCSB-MIT-Caltech Institute of Collaborative Biotechnologies from 2003 to 2010, and also served as Stellar&rsquo;s
	Executive Vice-President, Science &amp; Technology from 2010 until December 2011. Dr. Morse is an expert in the structure and function
	of the KLH molecule and internationally recognized expert in protein chemistry, molecular biology, molluscan reproductive biology,
	and aquaculture, and has an intimate understanding of our technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Frank R. Oakes
</B>
	was appointed our President and Chief Executive Officer and Chairman of our Board of Directors in April 2010. Prior to that time,
	he served as founder and Chief Executive Officer of Stellar&rsquo;s California subsidiary since 1999. He has more than 40 years
	of management experience in aquaculture including a decade as Chief Executive Officer of The Abalone Farm, Inc., during which he
	led the company through the R&amp;D, capitalization, and commercialization phases of development to become the largest abalone
	producer in the United States. Mr. Oakes is the inventor of our patented method for non-lethal extraction of hemolymph from a live
	gastropod mollusk. He was the principal investigator on our Small Business Innovation Research (SBIR) grant from the National Science
	Foundation and was principal investigator on our Phase I and II SBIR grants from the NIH&rsquo;s Center for Research Resources,
	and a California Technology Investment Partnership (CalTIP) grant from the Department of Commerce. Mr. Oakes has consulted and
	lectured for the aquaculture industry around the world. He received his Bachelor of Science degree from California State Polytechnic
	University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance University&rsquo;s management-training
	program. Mr. Oakes is a valuable member of our Board due to his depth of operating, strategic, and senior management experience
	in our industry, specifically as related to aquaculture. Additionally, Mr. Oakes holds an intimate knowledge of Stellar due to
	his longevity in the industry and with us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Charles V. Olson,
	D.Sc.&nbsp;
</B>
	has been a director of Stellar since December 2016 and a member of our scientific advisory board since June 2014.&nbsp;
	Since April 2010, he has served at Anthera Pharmaceuticals Inc, where he is currently the Chief Technology Officer. He has also
	been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previously held senior and executive
	management positions at NGM Bioharmaceuticals Inc, Coherus BioSciences Inc, Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals,
	Inc, and Onyx Pharmaceuticals, Inc. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, followed by
	Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from Westmont
	College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry. Dr. Olson has extensive
	scientific, manufacturing operations, process development, and senior management experience in the biopharmaceutical industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Mayank (Mike) D.
	Sampat
</B>
	has been a director of Stellar since August 2012, and serves as the chair of the Audit Committee. Mr. Sampat is an
	independent consultant providing business services to companies seeking expertise in financial planning and analysis, accounting
	and financial reporting, M&amp;A transactions support and financial system implementation. He previously held the positions of
	controller at Precision Toxicology, LLC, a healthcare focused clinical laboratory specializing in providing quantitative drug
	testing, from February 2015 to May 2016, Zpower, LLC, an emerging manufacturer in the microbattery industry, from June 2012 to
	September 2014, and Imaging Advantage LLC from September 2010 to June 2012, and the position of Chief Financial Officer for Gamma
	Medica-Ideas, a supplier of imaging equipment to the medical industry, from September 2007 to June 2010. Mr. Sampat received a
	BBA in accounting from Bombay University and his MBA in Finance at Mercer University. Mr. Sampat is a seasoned finance and accounting
	executive, having worked with multiple companies ranging from startups to large Fortune 100 companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Executive Officers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Set forth below is
	certain information with respect to the names, ages, and positions of our executive officers as of December 9, 2016. Biographical
	information pertaining to Mr.&nbsp;Oakes, who is a director and an executive officer, may be found in the above section entitled
	&ldquo;Directors.&rdquo; The executive officers serve at the pleasure of our Board of Directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Name
</B>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Age
</B>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Position(s) Held
</B>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Date of Appointment
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Frank R. Oakes
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	66
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	President, Chief Executive Officer and Chairman of our Board of Directors
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	April 9, 2010
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Kathi Niffenegger, CPA
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	59
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Chief Financial Officer and Corporate Secretary
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	November 1, 2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Gregory T. Baxter, Ph.D.
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	57
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Executive Vice President of Corporate Development
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	December 1, 2016
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Kathi Niffenegger,
	CPA
</B>
	was appointed Chief Financial Officer in November 2013 and Corporate Secretary in June 2013. She initially joined Stellar
	in May 2012 as Controller, after previously serving as the company&rsquo;s outside Certified Public Accountant for more than 12
	years. Ms. Niffenegger has more than 30 years of experience in accounting and finance in a range of industries. She held positions
	of increasing responsibility in the audit division of Glenn Burdette CPAs from 1988 to 2012 and served most recently as technical
	partner. She obtained CFO experience at Martin Aviation, and began her career at Peat, Marwick, Mitchell &amp; Co. (now KPMG LLP).&nbsp;Ms.
	Niffenegger has held leadership roles for audits of manufacturing, aquaculture, pharmaceutical and governmental grant clients,
	and developed specific expertise in cost accounting systems and internal controls. Ms. Niffenegger holds a B.S. degree in Business
	Administration, Accounting from California State University, Long Beach and is a member of the American Institute of Certified
	Public Accountants (AICPA).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	Gregory T. Baxter,
	Ph.D.
</B>
	joined Stellar&rsquo;s executive management team in December 2016 following his service on the company&rsquo;s Board
	of Directors, which he joined in August 2012. Dr. Baxter has served as an executive and scientist for several biotechnology corporations
	and foundations. Since 2001, Dr. Baxter has been a Senior Scientist in the Department of Clinical Drug Development for CCS Associates
	Inc., a scientific research consulting firm specializing in technical and support services for clinical research, design strategies
	for preclinical studies, chemical information sciences and research and development support for translational science. His prior
	experience includes serving as Program Director for the National Science Foundation (NSF) Division of Industrial Innovation and
	Partnerships, Founder and CSO of Hurel Corporation, Founder and CEO of Aegen Biosciences and Research Scientist for Molecular Device
	Corporation. He also serves as Adjunct Associate Professor at Cornell University in the College of Chemical Engineering and on
	the Founders Board of Stanford University's StartX Med Program. Dr. Baxter received his B.A. and Ph.D. in Biochemistry/Molecular
	Biology from University of California, Santa Barbara.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Section 16(a) Beneficial Ownership Reporting Compliance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Section 16(a) of the Exchange Act, requires that our directors, executive officers, and greater-than-10% shareholders
	file reports with the SEC on their initial beneficial ownership of our common shares and any subsequent changes. To our knowledge,
	based solely on a review of copies of such reports furnished to us by our officers and directors, we believe that, during the fiscal
	year ended September 30, 2016, no person required to file reports under Section 16(a) of the Exchange Act failed to file such reports
	on a timely basis during such fiscal year.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Code of Ethics
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have adopted a Code
	of Ethics and Business Conduct that applies to all of our directors, officers, and employees. A copy of our Code of Ethics and
	Business Conduct is available on the Investor Relations section of our website at http://ir.stellarbiotechnologies.com. We intend
	to satisfy the SEC&rsquo;s disclosure requirements regarding amendments to, or waivers of, our Code of Ethics and Business Conduct
	by posting such information on our website. Copies of our Code of Ethics and Business Conduct may be obtained, free of charge,
	by writing to our Corporate Secretary, Stellar Biotechnologies, Inc., 332 East Scott Street, Port Hueneme, California 93041.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Nominations for Board of Directors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Board of Directors
	has approved an advance notice policy, which was subsequently approved by our shareholders, that requires advance notice be given
	to us in certain circumstances where nominations of persons for election to the Board are made by our shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the case of an annual
	meeting of shareholders, notice to the Company must be made not less than 30 days nor more than 65 days prior to the date of the
	annual meeting. However, in the event that the annual meeting is to be held on a date that is less than 40 days after the date
	on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close
	of business on the tenth (10th) day following such public announcement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In the case of a special
	meeting of shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of
	business on the fifteenth (15th) day following the day on which the first public announcement of the date
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	of
	the special meeting was made.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	Information
	about our Board Committees
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our
	Board of Directors has appointed an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee.
	The Board of Directors has determined that each director who serves on these committees is &ldquo;independent,&rdquo; as that term
	is defined by the listing rules of Nasdaq and rules of the Securities and Exchange Commission. The Board of Directors has adopted
	written charters for its Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Copies of
	these charters are available on our website at
<U>
	http://ir.stellarbiotechnologies.com
</U>
	. In addition, our board of directors
	appointed a temporary Listing Committee to approve actions related to our listing application for The Nasdaq Capital Market and
	a Pricing Committee to approve actions related to our capital raising transactions. There was no requirement for directors who
	served on these committees to be &ldquo;independent&rdquo;.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Audit Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our
	Audit Committee is composed of Paul Chun, David Hill, and Mayank Sampat (chair). The purpose of the Audit Committee is to oversee
	our accounting and financial reporting processes and the audits of our financial statements. In that regard, the Audit Committee
	assists the Board in monitoring: (a) the integrity of our financial statements; (b) our independent auditor&rsquo;s qualifications,
	independence, and performance; (c) the performance of our internal audit function, including our system of internal controls, financial
	reporting, and disclosure controls; and (d) our compliance with legal and regulatory requirements. To fulfill this obligation and
	perform its duties, the Audit Committee maintains effective working relationships with the Board, management, our internal auditor,
	and our independent auditor.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Mayank
	Sampat is the Chair of our Audit Committee and has extensive financial experience. He received an MBA in Finance from Mercer University,
	and has served in several financial positions with other companies, including several years as Chief Financial Officer for a medical
	equipment manufacturer. Mr. Sampat is considered to be &ldquo;independent&rdquo; as defined pursuant to the listing rules of the
	Nasdaq. The Board has determined that Mr.&nbsp;Sampat is an &ldquo;audit committee financial expert&rdquo; as defined in Item&nbsp;407(d)(5)(ii)
	of Regulation S-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	Compensation
	Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Our
	Compensation Committee is composed of David Hill (chair) and Mayank Sampat. The purpose of the Compensation Committee is to oversee
	the Board&rsquo;s responsibilities relating to compensation of our Company&rsquo;s Chief Executive Officer and our other executi
</FONT>
	ve
	officers. It has overall responsibility for approving and evaluating all of our compensation plans, policies and programs as such
	plans, policies and programs affect executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Nominating and Corporate Governance
	Committee
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Our Nominating and
	Corporate Governanc
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	e Committee is composed of David Hill and
	Mayank Sampat. The purpose of the Nominating and Corporate Governance Committee is to identify individuals qualified to become
	Board members; recommend to the Board individuals to serve as directors; advise the Board with respect to Board composition, procedures
	and committees; develop, recommend to the Board and annually review a set of corporate governance principles applicable to the
	Company; and oversee any related matters required by the federal sec
</FONT>
	urities laws.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_019">
</A>
<B>
	Item
</B>
<B>
	11.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	EXECUTIVE COMPENSATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Executive Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Our named executive officers for 2016 were Frank
	R. Oakes, Chief Executive Officer, President and Executive Chairman of our Board of Directors; Kathi Niffenegger, CPA, Chief Financial
	Officer and Corporate Secretary; Catherine Brisson, Ph.D., our former Chief Operating Officer until October 2016; and Mark McPartland,
	our former Vice President of Corporate Development and Communications until September 2016.
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Summary Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table sets forth information
	regarding the compensation awarded to, earned by or paid to the named executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name and Principal
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Salary ($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Bonus ($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Awards
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	($) (1)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	All Other
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Compensation ($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Total ($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 14%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Frank R. Oakes,
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	250,100
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	120,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59,737
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	429,837
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	President, Chief Executive
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	240,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	90,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	25,643
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	355,643
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Officer and Chairman of our
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Board of Directors
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Kathi Niffenegger, CPA,
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	196,560
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47,250
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	61,147
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	19,003
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;(3)&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	323,960
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Financial Officer and
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	189,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	27,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	106,287
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	17,320
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	339,607
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Corporate Secretary
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mark McPartland
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	214,978
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46,350
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	122,294
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13,014
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	396,636
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Vice President of Corporate
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	185,400
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5,400
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7,150
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	197,950
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Development and
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Communications (4)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Catherine Brisson, Ph.D.,
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	173,628
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	61,147
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12,863
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;(7)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	295,338
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Operating Officer (6)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	190,800
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13,989
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	222,789
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	&nbsp;
</SUP>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Represents the aggregate grant date fair value of the stock option award granted in the covered
	fiscal year as computed in accordance with FASB ASC Topic 718, Compensation &mdash; Stock Compensation. The fair value of each
	stock option award is estimated for the covered fiscal year on the date of grant using the Black-Scholes option valuation model.
	A discussion of the assumptions used in calculating the amounts in this column may be found in Note 9 to our audited consolidated
	financial statements for the year ended September 30, 2016 included in this Annual Report.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Represents (i) $35,516 in patent royalties paid by the Company, (ii) $16,271 in health insurance and (iii) $7,950 in 401(k)
	Company contributions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Represents (i) $11,789 in health insurance and (ii) $7,214 in 401(k) Company contributions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD>
	Mr. McPartland&rsquo;s employment with the Company ended in September 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Represents
	(i) $5,725 in health insurance and (ii) $7,289 in 401(k) Company contributions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(6)
</TD>
<TD>
	Dr. Brisson&rsquo;s employment with the Company ended in October 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(7)
</TD>
<TD>
	Represents (i) $6,991 in health insurance and (ii) $5,862 in 401(k) Company contributions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employment Agreements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We do not have employment
	agreements currently in effect with any of our named executive officers. Like our other employees, our executives are eligible
	for annual salary increases and discretionary equity grants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Performance Share Plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Under the merger agreement
	between our Company and our California subsidiary, we allotted 1,000,000 common shares (the &ldquo;Performance Shares&rdquo;) under
	a performance share plan (the &ldquo;Plan&rdquo;). The purpose of the Plan was to encourage the development of our products and
	business by distributing shares to key management, employees, and consultants upon the meeting of certain milestones. These milestones
	were set as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Completion of method development for commercial-scale manufacture of IMG KLH with applicable good
	GMP as a pharmaceutical intermediate, evidenced by completion of three GMP lots meeting all quality and product release specifications
	required for stability studies and process validation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Compilation and regulatory submittal of all required CMC data compiled in CTD format and evidenced
	by filing as a DMF with the USFDA; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Completion of preclinical toxicity and immunogenicity testing of IMG KLH and Subunit KLH in rodent
	and non-rodent species as evidenced by acceptance by study protocols and completion reports available to support customer United
	States FDA and EMEA filings.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	As each milestone
	was met as determined by our Board of Directors, one-third of the Performance Shares were available to be released to the Plan
	members. In January 2011, it was determined that Milestone No. 3 was successfully completed and the Board authorized the issuance
	of an aggregate of 333,334 Performance Shares to all participants in the Plan. In August 2012, the Board of Directors determined
	that Milestones No. 1 and 2 had been met and authorized the issuance of an aggregate of 131,313 Performance Shares to the non-director
	participants in the Plan. The Board did not take any action at that time on the issuance of shares to the participants of the Plan
	who were also directors of the Company. No action was taken regarding the Plan in fiscal 2013. In December 2013, we issued 151,515
	common shares to a former director of the Company named as an eligible participant in the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Mr. Oakes, our President,
	Chief Executive Officer and Chairman of the Board, and Dr. Morse, a director of our company, are eligible participants in the
	Plan. 235,690 and 134,680 shares, respectively, are reserved for future issuance to Mr. Oakes and Dr. Morse under the Plan. No
	other named executive officer or director is eligible to participate in the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_OPTIONS_AGGREGATE>
<A NAME="FIS_OPTIONS_AGGREGATE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Outstanding Equity Awards at 2016 Fiscal
	Year-End
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table summarizes
	the equity awards made to our named executive officers that were outstanding at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; BORDER-COLLAPSE: COLLAPSE; MARGIN-LEFT: 0.5IN">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="12" STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option Awards
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Number of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	securities
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	underlying
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	unexercised
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	options (#)
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	exercisable
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Number of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	securities
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	underlying
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	unexercised
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	options (#)
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	unexercisable
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(1)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	exercise prices
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	expiration
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 32%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Frank R. Oakes
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	103,500
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.80
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4/9/17
</FONT>
</TD>
</TR>
</EFX_OPTIONS_AGGREGATE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	42,560
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/8/18
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	37,560
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.20
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4/13/19
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Kathi Niffenegger, CPA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.90
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6/18/19
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/19/19
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.80
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/14/20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18.30
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/1/20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.20
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/12/21
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,333
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,667
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.24
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/22/22
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Catherine Brisson, Ph.D. (2)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.40
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10/25/17
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.00
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/22/18
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.70
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/9/19
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5,750
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.50
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/19/19
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CDN
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.80
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/14/20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18.30
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/1/20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,333
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,667
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.24
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/22/22
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mark McPartland (3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18.40
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/15/20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,667
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.24
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/22/22
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options granted to the named executive officers are subject to the following vesting schedule:
	(a) one-third of the option shall vest on the date of grant; (b) one-third of the option shall vest 12 months from the date of
	grant; and (c) the remaining one-third of the option shall vest 18 months from the date of grant.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN: 0">
	Dr. Brisson&rsquo;s employment with the Company ended in October 2016.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN: 0">
	Mr. McPartland&rsquo;s employment with the Company ended in September 2016.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Outstanding Equity Awards Narrative Disclosure
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Fixed Share Option Plan
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="COLOR: WINDOWTEXT">
	Our
	2013 Fixed Share Option Plan is comprised of 1,000,000 options to purchase our common shares. The purpose of the 2013 Fixed Share
	Option Plan is to advance the interests of the Company by encouraging equity participation in the Company through the acquisition
	of common shares of the Company. Our Board is
</FONT>
<FONT STYLE="COLOR: WINDOWTEXT">
	responsible for the general administration
	of the Fixed Share Option Plan and the proper execution of its provisions, its interpretation and the determination of all questions
	arising thereunder. Specifically, the Board has the power to, among other things:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 31.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	allot common shares for issuance in connection with the exercise of options;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 67.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	grant options;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	amend, suspend, terminate or discontinue the plan; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT; COLOR: WINDOWTEXT">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: WINDOWTEXT">
	delegate all or a portion of its administrative
	powers as it may determine to one or more committees.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Options may be awarded to our directors, officers,
	employees and consultants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Options to purchase 539,103 common shares at
	prices ranging from CDN$2.50 to CDN$18.70 and $2.22 to $18.40 are outstanding at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Options issued during fiscal 2016 to employees
	and consultants under the Fixed Share Option Plan totaled 56,300 options to purchase common shares, at exercise prices ranging
	from $2.22 to $7.24.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_OPTIONS>
<A NAME="FIS_OPTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Grants of Plan-Based Awards
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The following table provides information regarding grants of plan-based
	awards to our named executive officers during fiscal year 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant Date
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All Other
<BR>
	Option
<BR>
	Awards:
<BR>
	Number of
<BR>
	Securities
<BR>
	Underlying
<BR>
	Options (#)
<BR>
	(1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise or
<BR>
	Base Price of
<BR>
	Option
<BR>
	Awards
<BR>
	($/Sh)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant Date
<BR>
	Fair Value of
<BR>
	Option
<BR>
	Awards ($)(2)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT">
	Kathi Niffenegger, CPA
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: CENTER">
	12/22/15
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7.24
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	61,147
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Catherine Brisson, Ph.D. (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	12/22/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,147
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Mark McPartland (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	12/22/15
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	122,294
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_OPTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The option awards were issued under our 2013 Fixed Share Option Plan, and vest in thirds beginning December 2015.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Represents
	the aggregate grant date fair value of the stock option award granted in the covered fiscal year as computed in accordance with
	FASB ASC Topic 718, Compensation &mdash; Stock Compensation. The fair value of each stock option award is estimated for the covered
	fiscal year on the date of grant using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating
	the amounts in this column may be found in Note 9 to our audited consolidated financial statements for the year ended September
	30, 2016 included in this Annual Report.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Dr. Brisson&rsquo;s employment with the Company ended in October 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD>
	Mr. McPartland&rsquo;s employment with the Company ended in September 2016.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Retirement Benefits
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have established a 401(k)
	plan to provide retirement benefits to eligible executive officers and employees. Employees may enter the plan after they have
	been employed by us for at least three consecutive months. Under the plan, we contribute a flat non-elective contribution of 3%
	of eligible compensation for each plan participant at the end of the fiscal year. Any Company contributions we made to the plan
	for our named executive officers are reflected in the &ldquo;All Other Compensation&rdquo; column of the Summary Compensation Table
	above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Other than the funds contributed
	under our 401(k) plan, no other funds were set aside or accrued by us during fiscal 2016 to provide pension, retirement or similar
	benefits for our named executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Director Compensation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The following table sets forth information regarding
	the compensation of our non-employee directors for the fiscal year ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Fees Earned&nbsp;
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	or Paid in
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;Cash ($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Total&nbsp;&nbsp;($)
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 68%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Gregory T. Baxter, Ph.D. (1)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,850
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,850
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Tessie M. Che, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,400
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,400
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	David L. Hill, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Daniel E. Morse, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mayank D. Sampat
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,850
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,850
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Baxter resigned from the Board of Directors effective December 1, 2016 when he began employment as an executive officer.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Narrative to Director Compensation Table
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Non-Employee Director Compensation Policy
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Pursuant to our non-employee director compensation policy, non-employee directors receive $1,000 for each
	Board meeting attended in person and $350 for each Board meeting attended by telephone. Members of Board committees also receive
	$350 for each committee meeting attended. Non-executive directors may also receive stock option awards at the discretion of the
	Board of Directors. No options were awarded to the Company&rsquo;s non-executive directors in fiscal year 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Non-Employee Directors on our Scientific
	Advisory Board
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Dr. Morse and Dr. Olson
	are members of our Scientific Advisory Board. As compensation for their services, the members of our Scientific Advisory Board
	receive certain advisory fees and expense reimbursements. Dr. Baxter was a member of our Scientific Advisory Board until December
	1, 2016, when he resigned from the Scientific Advisory Board simultaneously with the effective date of his employment as an executive
	officer of the Company. During fiscal 2016, we paid an aggregate of $4,950 to Dr. Baxter, $6,200 to Dr. Morse and $12,250 to Dr.
	Olson for their services as members of our Scientific Advisory Board and such amounts are not reflected in the Director Compensation
	table above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Compensation Committee Interlocks and Insider
	Participation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The members of our Compensation
	Committee during the fiscal year ended September 30, 2016 were Gregory Baxter, David Hill (chairman), and Mayank Sampat.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	None of the individuals
	who served as a member of the Compensation Committee during fiscal 2016 was at any time during fiscal 2016 an officer or employee
	of our Company.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_020">
</A>
<B>
	Item 12.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
	AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
<I>
	.
</I>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Equity Compensation Plan Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The following table provides certain information
	as of September 30, 2016 about our common shares that may be issued under our equity compensation plans:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan category
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of securities to
<BR>
	be issued upon exercise
<BR>
	of outstanding options,
<BR>
	warrants and rights
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average
<BR>
	exercise price of
<BR>
	outstanding options,
<BR>
	warrants and rights
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of securities
<BR>
	remaining available for
<BR>
	future issuance under equity
<BR>
	compensation plans
<BR>
	(excluding securities
<BR>
	reflected in column (a))
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	(a)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	(b)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	(c)
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by security holders
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,804,729
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4.74
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	357,897
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Equity compensation plans not approved by security holders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0; PADDING-LEFT: 0.25IN">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,804,729
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.74
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	357,897
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Security Ownership of Certain Beneficial Owners and Management
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following tables sets forth certain information as of December 9, 2016, with respect to the beneficial ownership of our common
	shares by: (1) all of our directors; (2) our named executive officers listed in the Summary Compensation Table; (3) all of directors
	and executive officers as a group; and (4) each person known by us to beneficially own more than 5% of our outstanding common
	shares.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	We have determined beneficial
	ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information
	furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	common
</FONT>
	shares that they beneficially own, subject to applicable
	community property laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Common shares subject to
	options or warrants currently exercisable or exercisable within 60&nbsp;days of December 9, 2016 are deemed outstanding for computing
	the share ownership and percentage of the person holding such options and warrants, but are not deemed outstanding for computing
	the percentage of any other person. The percentage ownership of our common shares of each person or entity named in the following
	table is based on 10,136,258
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	common
</FONT>
	shares outstanding as of December
	9, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Directors and Officers
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name and Address of Beneficial Owner (1)
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Amount and
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Nature of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Beneficial
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Ownership
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Percent of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Shares
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Beneficially
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Owned
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 72%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Frank R. Oakes
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	372,585
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 3%; TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3.6
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Kathi Niffenegger, CPA
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	48,667
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Catherine Brisson, Ph.D. (4)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	63,051
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Mark A. McPartland (6)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16,667
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Gregory T. Baxter, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,250
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Tessie M. Che, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,000
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	David L. Hill, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12,000
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Daniel E. Morse, Ph.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	151,109
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Charles V. Olson, D.Sc.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,250
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Mayank D. Sampat
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,000
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	All directors and executive officers as a group (11 persons)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	686,329
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	(14)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	6.5
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	%
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	* Percentage of shares beneficially owned does
	not exceed one percent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unless otherwise indicated, the address of each beneficial owner is c/o Stellar Biotechnologies,
	Inc., 332 E. Scott Street, Port Hueneme, California 93041.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	(2)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	This amount includes (i) 183,620 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016; and excludes (ii) 20,867 common shares and 5,400 common shares issuable upon the exercise of outstanding options currently exercisa
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	ble or exercisable within 60&nbsp;days of December 9, 2016 which are held by Mr. Oakes&rsquo; spouse who has sole voting and dispositive power over the securities, and as to which Mr. Oakes disclaims beneficial ownership. Mr. Oakes does not have the power to vote or dispose of, or to direct the voting or disposition of, the shares held by his spouse, or with respect to any shares acquired under her outstanding options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 48,667 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Brisson&rsquo;s employment with the Company ended in October 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 47,583 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(6)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Mr. McPartland&rsquo;s employment with the Company ended in September 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 16,667 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 8,250 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 7,000 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 10,000 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 54,600 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 1,250 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(13)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Represents 7,000 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(14)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 384,637 shares issuable upon the exercise of options currently exercisable or exercisable within 60&nbsp;days of December 9, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Shareholders Known by Us to Own 5% or More
	of Our Common Shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Name and Address of Beneficial Owner
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Amount and
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Nature of Beneficial
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Ownership
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Percent of Shares
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Beneficially
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Owned
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 72%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Ernesto Echavarria
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Blvd. Anaya
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	1225 Culiacan Sinaloa, Mexico 80040
</P>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,411,310
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 3%; TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13.9
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Anson Investments Master Fund LP (1)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	5950 Berkshire Lane, Suite 210
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Dallas, Texas 75225
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,416,513
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Empery Asset Management, LP (3)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	1 Rockefeller Plaza, Suite 1205
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	New York, New York 10020
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,321,242
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Voting and investment power over the shares held by Anson Investments Master Fund LP is exercised by the co-investment advisors to Anson Investments Master Fund LP. The co-investment advisors of Anson Investments Master Fund LP consist of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership, and M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada Corporation. As the general partner of Frigate Ventures LP, Admiralty Advisors LLC, a Texas limited liability company, may direct the vote and disposition of the common shares held by Anson Investments Master Fund LP. As the principal of Frigate Ventures LP and Admiralty Advisors, LLC, Bruce R. Wilson may direct the vote and disposition of the common shares held by Anson Investments Master Fund LP. As directors of M5V Advisors Inc., Adam Spears and Moez Kassam may each direct the vote and disposition of the common shares held by Anson Investments Master Fund LP..
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 632,813 common shares issuable upon the exercise of warrants, which are exercisable beginning January 6, 2017 and expire in January 2022. Under the terms of these warrants, the holders may not exercise such warrants to the extent such exercise would cause such holder, together with its affiliates and attribution parties, to beneficially own a number of common shares which would exceed 4.99% of our then outstanding common shares following such exercise, excluding for purposes of such determination common shares issuable upon exercise of such warrants which have not been exercised.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	These shares are held by Empery Asset Master, LTD, Empery Tax Efficient, LP and Empery Tax Efficient II, LP (together, the &ldquo;Empery Entities&rdquo;). Empery Asset Management, LP is the investment manager for the Empery Entities and has discretionary authority to vote and dispose of the shares held by the Empery Entities and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by the Empery Entities. The Empery Entities, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This amount includes 632,813 common shares issuable upon the exercise of warrants, which are exercisable beginning January 6, 2017 and expire in January 2022. Under the terms of these warrants, the holder may not exercise such warrants to the extent such exercise would cause such holder, together with its affiliates and attribution parties, to beneficially own a number of common shares which would exceed 4.99% of our then outstanding common shares following such exercise, excluding for purposes of such determination common shares issuable upon exercise of such warrants which have not been exercised.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_021">
</A>
<B>
	Item 13.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
	DIRECTOR INDEPENDENCE.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Related Party Transactions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Patent Royalty Agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	On August 14, 2002, through
	our California subsidiary, we entered into an agreement with Frank Oakes, our Chief Executive Officer, where he would receive royalty
	payments in exchange for the assignment of his rights to U.S. Patent No. 6,852,338 to us. The royalty is 5% of gross receipts from
	products using this invention in excess of $500,000 annually. Our current operations utilize this invention. Patent royalties of
	$35,516 and $1,495 were paid to Mr. Oakes for the years ended September 30, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<I>
	Collaboration Agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In December 2013, we entered
	into a collaboration agreement (the &ldquo;Amaran Agreement&rdquo;) with Amaran Biotechnology, Inc. to develop and evaluate methods
	for Amaran&rsquo;s potential manufacture of the OBI-822 active immunotherapy using our GMP grade Stellar KLH&trade;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Revenues received from
	Amaran under the Amaran Agreement totaled $32,000 and $180,000 during the fiscal years ended September 30, 2016 and 2015. The
	Amaran Agreement also provides for Amaran to pay us fees for certain expenses and costs associated with the collaboration. Subject
	to certain conditions and timing, the terms of the collaboration with Amaran also provide for the possible negotiation of a commercial
	supply agreement for Stellar KLH&trade; in the future. The Amaran Agreement expired by its terms on December 7, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Tessie Che, a member of
	our Board of Directors, currently serves as general manager and chair of the board of directors of Amaran.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Policies and Procedures for Review of Related Party Transactions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Audit Committee reviews,
	approves and oversees any transaction between us and any &ldquo;related person&rdquo; (as defined in Item 404 of Regulation S-K)
	and any other potential conflict of interest situations, on an ongoing basis. Under these policies and procedures, the Audit Committee
	is to be informed of transactions subject to review before their implementation. The procedures establish our practices for obtaining
	and reporting information to the Audit Committee regarding such transactions on a periodic and an as-needed basis. The policy provides
	that such transactions are to be submitted for approval before they are initiated but also provides for ratification of such transactions.
	No director who is interested in a transaction may participate in the Audit Committee&rsquo;s determinations as to the appropriateness
	of such transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	Director Independence
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In evaluating the independence
	of our Board members and the composition of the committees of our Board of Directors, the Board of Directors utilizes the definition
	of &ldquo;independence&rdquo; as that term is defined by the Securities Exchange Act of 1934, and the Nasdaq Listing Rules. Using
	this standard, the Board of Directors has determined that Paul Chun, David Hill, Daniel Morse, Charles Olson and Mayank Sampat
	are &ldquo;independent directors.&rdquo; This means that our Board of Directors is composed of a majority of independent directors
	as required by the rules of Nasdaq.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<A NAME="V453489_10K_HTM_SBI_022">
</A>
<B>
	Item&nbsp;14.&#9;&nbsp;&nbsp;&nbsp;&nbsp;PRINCIPAL ACCOUNTING FEES AND SERVICES
<I>
	.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The following table shows
	the aggregate fees paid or accrued for audit and other services provided for the years ended September 30, 2016 and 2015 rendered
	by Moss Adams LLP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Principal Accountant Fees and Services
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Type of Service
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fiscal Year 2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fiscal Year 2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT">
	Audit Fees
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	238,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	194,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Audit-Related Fees
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax Fees
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	All Other Fees
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	238,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	194,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
<I>
	Audit Fees
</I>
</B>
	consisted
	of fees incurred for professional services rendered for audits of the years ended September 30, 2016 and 2015 and include procedures
	related to registrations and offerings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Pre-Approval Policies and Procedures
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	The Audit Committee is
	directly responsible for the appointment, compensation and oversight of our auditors. It has established procedures for the receipt,
	retention, and treatment of complaints received by us regarding accounting, internal accounting controls, or auditing matters,
	and the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters.
	The Audit Committee also has the authority and the funding to engage independent counsel and other outside advisors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	In accordance with the
	requirements of the Sarbanes-Oxley Act of 2002 and rules issued by the Securities and Exchange Commission, our Audit Committee
	Charter includes a procedure for the review and pre-approval of all audit and permitted non-audit and tax services, subject to
	the de minimis exception for non-audit services described in Section 10A(i)(1)(B) of the Exchange Act and the Commission rules
	promulgated thereunder that may be provided by our independent auditor or other registered public accounting firms. The procedure
	requires that all proposed engagements of the auditor for audit and permitted non-audit services are submitted to the Audit Committee
	for approval prior to the beginning of any such services. The Audit Committee pre-approved 100% of the audit services performed
	by our independent registered public accounting firm for the fiscal year ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_023">
</A>
<B>
	PART IV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<A NAME="V453489_10K_HTM_SBI_024">
</A>
<B>
	Item 15.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 55.05PT; TEXT-INDENT: -55.1PT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The following documents are filed as a part of this Annual
	Report:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	(1) Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	The list of consolidated financial statements
	and notes required by this Item 15 (a) (1) is set forth in the &ldquo;Index to Financial Statements&rdquo; on page F-1 of this
	Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	(2) Financial Statement Schedules
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	All schedules have been omitted because the
	required information is included in the financial statements or notes thereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Exhibits
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	The exhibits listed on the Exhibit Index below
	are filed as part of this Annual Report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBIT INDEX
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Exhibit No.
</U>
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&#9;
<U>
	Description
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
	3.1
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certificate of Incorporation of the Company, dated June 12, 2007 (included as Exhibit 1(a) to the
	Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.2
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certificate of Amendment, dated April 15, 2008 (included as Exhibit 1(b) to the Company&rsquo;s
	Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.3
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certificate of Continuation of the Company, dated November 25, 2009 (included as Exhibit 1(c) to
	the Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.4
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certificate of Name Change of the Company, dated April 7, 2010 (included as Exhibit 1(f) to the
	Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.5
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notice of Articles of the Company, dated April 7, 2010 (included as Exhibit 1(g) to the Company&rsquo;s
	Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.6
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Articles of the Company, effective November 20, 2009 (included as Exhibit 1(h) to the Company&rsquo;s
	Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	3.7
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amended and Restated Articles of Stellar Biotechnologies, Inc., dated October 29, 2015 (included
	as Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on October 30, 2015, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Warrant dated June
	30, 2016 (included as Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed on June 30, 2016, and incorporated herein
	by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	10.1
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Patent Assignment Agreement between the Company and Frank Oakes, dated August 14, 2002 (included
	as Exhibit 4(a) to the Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by
	reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	10.2
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Sublease Agreement (Units 3, 4 and 5) between the Company and the Port Hueneme Surplus Property
	Authority, dated October 2, 2000 (included as Exhibit 4(j) to the Company&rsquo;s Registration Statement on Form 20-F filed on
	February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	10.3
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Sublease Agreement (Unit 7) between the Company and the Port Hueneme Surplus Property Authority,
	dated March 21, 2005 (included as Exhibit 4(k) to the Company&rsquo;s Registration Statement on Form 20-F filed on February 3,
	2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	10.4
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Lease Agreement between the Company and Beachport Center, dated March 29, 2011 (included as Exhibit
	4(l) to the Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.5
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Research Collaboration Agreement between the Company and Bayer Innovation GmbH, dated August 27, 2009 (included as Exhibit 4(16) to the Company&rsquo;s Amendment No. 2 to its Registration Statement on Form 20-F filed on July 5, 2012, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.6 #
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Joint Venture Agreement, dated May 11, 2016, by and among the Company and Neovacs, S.A. (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on May 17, 2016, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.7
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN: 0PT 0">
	License Agreement between the Company and University of Guelph, dated July 24, 2013 (included as Exhibit
	99.1 to the Company&rsquo;s Report on Form 6-K filed on August 30, 2013, and incorporated herein by reference).
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.8 @
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Share Option Plan, as Amended, dated December 13, 2011 (included as Exhibit 10(b) to the Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.9 @
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Fixed Share Option Plan dated December 18, 2013 (included as Exhibit 10.11 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.10
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Shareholder&rsquo;s Rights Plan, as amended, dated January 9, 2014 (included as Exhibit 10.12 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.11 @
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Performance Share Plan dated April 9, 2010 (included as Exhibit 10(d) to the Company&rsquo;s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.12
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Advance Notice Policy, adopted October 31, 2013 (included as Exhibit 10.14 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.13
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment One to Lease Agreement between the Company and Beachport Center, dated June 24, 2014 (included as Exhibit 10.15 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease Amendment No. 2 (Units 4 and 5) to Sublease Agreement between the Company and the Port Hueneme Surplus Property Authority, dated October 2, 2010 (included as Exhibit 10.16 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.15
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease Amendment No. 1 (Unit 7) to Sublease Agreement between the Company and the Port Hueneme Surplus Property Authority, dated March 21, 2010 (included as Exhibit 10.17 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.16
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Collaboration Agreement by and between Stellar Biotechnologies, Inc. and Amaran Biotechnology dated December 7, 2013 (included as Exhibit 10.18 to Amendment No. 2 of the Company&rsquo;s Annual Report on Form 10-K filed on September 9, 2015, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.17
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Collaboration Agreement, dated July 27, 2015, by and between Stellar Biotechnologies, Inc. and Ostiones Guerrero SA de CV (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 30, 2015, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease Amendment No. 1 (Units 4 and 5) to Sublease Agreement between the Company and the Port Hueneme Surplus Property Authority, and establishment of new commencement date for Sublease Agreement (Unit 7) between the Company and the Port Hueneme Surplus Property Authority, dated October 31, 2005 (included as Exhibit 10.20 to the Company&rsquo;s Annual Report on Form 10-K filed on December 14, 2015, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease Amendment No.
	3 (Unit 4 and 5) to Sublease Agreement between the Company and the Port Hueneme Surplus Property Authority, dated June 4, 2015
	(included as Exhibit 10.21 to the Company&rsquo;s Annual Report on Form 10-K filed on December 14, 2015, and incorporated herein
	by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sublease Amendment No.
	2 (Unit 7) to Sublease Agreement between the Company and the Port Hueneme Surplus Property Authority, dated June 4, 2015 (included
	as Exhibit 10.22 to the Company&rsquo;s Annual Report on Form 10-K filed on December 14, 2015, and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Securities Purchase
	Agreement, dated June 30, 2016 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on June 30, 2016,
	and incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	14.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Code of Ethics and Business
	Conduct (included as Exhibit 99.4 to the Company&rsquo;s Report on Form 6-K filed on August 14, 2014, and incorporated herein
	by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	21
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Subsidiaries of Stellar
	Biotechnologies, Inc. (included as Exhibit 21 to the Company&rsquo;s Annual Report on Form 10-K filed on November 14, 2014, and
	incorporated herein by reference).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	23.1
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Consent of Moss Adams LLP (filed herewith).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	31.1
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and
	Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	31.2
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities and
	Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	32.1 ^
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	32.2 ^
</TD>
<TD>
	Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002 (filed herewith).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.INS
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL
</FONT>
	Instance
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Document
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	101.SCH
</TD>
<TD>
	XBRL Taxonomy Extension Schema Document
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	101.CAL
</TD>
<TD>
	XBRL Taxonomy Calculation Linkbase Document
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	101.DEF
</TD>
<TD>
	XBRL Taxonomy Extension Definition Linkbase Document
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	101.LAB
</TD>
<TD>
	XBRL Taxonomy Label Linkbase Document
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.75IN">
	101.PRE
</TD>
<TD>
	XBRL Taxonomy Presentation Linkbase Document
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	@
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Management
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	contract or compensatory plan
	or arrangement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	#
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Confidential treatment has been granted for certain portions of this exhibit. Original copies have
	been filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934,
	as amended.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	^
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	A signed original of this written statement required by Section 906 has been provided and will
	be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_INDEX>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_025">
</A>
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Pursuant to the requirements of Section&nbsp;13
	or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
	thereunto duly authorized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%">
	Date: December 14, 2016
</TD>
<TD STYLE="WIDTH: 50%">
<B>
	STELLAR BIOTECHNOLOGIES, INC.
</B>
</TD>
</TR>
<TR>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 0.1IN">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Frank R. Oakes
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 0.1IN">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Frank R. Oakes
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	President and Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	(Principal Executive Officer)
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
	Pursuant to the requirements of the Securities
	Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
	and on the dates indicated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Signature
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 55%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Title
</B>
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Date
</B>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Frank R. Oakes
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer, and
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Frank R. Oakes
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board of Directors (Principal Executive Officer)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Kathi Niffenegger
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Kathi Niffenegger
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	(Principal Financial and Accounting Officer)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Tessie M. Che
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Tessie M. Che
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	PAUL CHUN
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Paul Chun
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	DAVID L. HILL
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	David L. Hill
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	DANIEL E. MORSE
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Daniel E. Morse
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	CHARLES V. OLSON
</FONT>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Charles V. Olson
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Mayank D. Sampat
</FONT>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 14, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Mayank D. Sampat
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	Page
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	STELLAR BIOTECHNOLOGIES, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	INDEX TO FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; TEXT-DECORATION: NONE">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE">
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: LEFT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-DECORATION: NONE; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-DECORATION: NONE">
<B>
	Page
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-DECORATION: NONE; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE">
<A HREF="#V453489_10K_HTM_SBI_026">
<FONT STYLE="FONT-SIZE: 10PT">
	Report of Independent Registered Public Accounting Firm, dated December 14, 2016
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE">
<A HREF="#V453489_10K_HTM_SBI_027">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Balance Sheets at September 30, 2016 and September 30, 2015
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-DECORATION: NONE; TEXT-INDENT: -0.15IN">
<A HREF="#V453489_10K_HTM_SBI_028">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Operations for the years ended September 30, 2016 and September 30, 2015, one month ended September 30, 2014, and year ended August 31, 2014
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-DECORATION: NONE; TEXT-INDENT: -0.15IN">
<A HREF="#V453489_10K_HTM_SBI_029">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows for the years ended September 30, 2016 and September 30, 2015, one month ended September 30, 2014, and year ended August 31, 2014
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 0.15IN; TEXT-DECORATION: NONE; TEXT-INDENT: -0.15IN">
<A HREF="#V453489_10K_HTM_SBI_030">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Changes in Equity for the years ended September 30, 2016 and September 30, 2015, one month ended September 30, 2014, and year ended August 31, 2014
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-7
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-DECORATION: NONE; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE">
<A HREF="#V453489_10K_HTM_SBI_031">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
	F-8
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/14/0001144204-16-139528_TPG1IMG1_10K.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	Consolidated
	Financial Statements
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	For the Years
	Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
	(In U.S.
	Dollars)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<A NAME="V453489_10K_HTM_SBI_026">
</A>
<B>
	REPORT
	OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Board of Directors
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Stellar Biotechnologies, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated balance sheets
	of Stellar Biotechnologies, Inc. (the &ldquo;Company&rdquo;) as of September 30, 2016 and 2015, and the related consolidated statements
	of operations, changes in equity and cash flows for the fiscal years ended September 30, 2016 and 2015, the one month period ended
	September 30, 2014, and the fiscal year ended August 31, 2014. These consolidated financial statements are the responsibility of
	the Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial statements based on
	our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance with the standards of
	the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
	reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not
	required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included
	consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
	circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over
	financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
	the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant
	estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that
	our audits provide reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the consolidated financial statements referred
	to above present fairly, in all material respects, the consolidated financial position of Stellar Biotechnologies, Inc. as of September
	30, 2016 and 2015, and the consolidated results of its operations and its cash flows for fiscal years ended September 30, 2016
	and 2015, the one month period ended September 30, 2014, and the fiscal year ended August 31, 2014, in conformity with accounting
	principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	/s/ Moss Adams LLP
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Los Angeles, California
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	December 14, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A NAME="V453489_10K_HTM_SBI_027">
</A>
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Balance Sheets
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars )
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,416,904
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,955,503
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Accounts receivable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,813
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	157,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Short-term investments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,988,794
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,015,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Inventory
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	249,430
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	557,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Prepaid expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	358,714
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	181,068
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Total current assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,099,655
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,866,619
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Noncurrent assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Equity investment in joint venture
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	66,695
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Property, plant and equipment, net
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	756,114
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	503,408
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Deposits
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	15,340
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	15,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Total noncurrent assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	838,149
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	519,308
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 9.35PT">
	Total Assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,937,804
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,385,927
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Liabilities and Shareholders' Equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	623,644
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	656,685
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Deferred revenue
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	173,333
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Warrant liability, current portion
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,550,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Total Current Liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	623,644
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,380,648
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Commitments
<I>
	(Note 8)
</I>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shareholders' equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.25IN">
	Common shares, unlimited common shares authorized, no
	par value, 10,136,258 and 7,984,758 issued and outstanding at September 30, 2016 and 2015, respectively
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,280,792
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,114,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Accumulated share-based compensation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,394,763
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,226,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(40,361,395
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(35,335,315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT; PADDING-BOTTOM: 1PT">
	Total Shareholders' Equity
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12,314,160
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8,005,279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 9.35PT">
	Total Liabilities and Shareholders' Equity
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,937,804
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,385,927
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A NAME="V453489_10K_HTM_SBI_028">
</A>
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Operations
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars )
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	One Month Ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Revenues:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Product sales
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,239,689
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	563,689
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	32,786
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	143,553
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Contract services revenue
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	195,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	192,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Grant revenue
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	36,579
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,271,689
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	758,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52,786
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	372,132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Costs of sales and contract services
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	818,566
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	580,824
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,636
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	469,149
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Costs of aquaculture
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	309,262
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	259,423
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,063
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	254,531
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Grant costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,579
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Research and development
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,729,445
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,029,489
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	178,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,458,934
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	General and administrative
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,322,772
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,227,545
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	293,130
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,871,455
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,180,045
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,097,281
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	505,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,090,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Income (Loss) from Operations
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,908,356
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,338,592
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(452,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,718,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Other Income (Loss)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Foreign exchange gain (loss)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	76,800
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(653,333
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(97,866
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(222,437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Gain (loss) in fair value of warrant liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(211,956
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,131,062
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,680,040
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,533,305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Investment income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	24,632
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	54,634
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,853
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	61,935
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(110,524
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,532,363
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,584,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,693,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Income (Loss) Before Income Tax
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,018,880
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,806,229
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,131,704
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,412,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Income tax expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	36,800
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,800
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net Income (Loss)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,026,080
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,843,029
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,127,904
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(8,439,523
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Earnings (loss) per common share:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Basic
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.57
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(0.36
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.14
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1.11
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Diluted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.57
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(0.36
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.13
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1.11
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Weighted average number of common shares outstanding:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Basic
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,826,312
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,956,962
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,867,575
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,582,664
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Diluted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,826,312
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,956,962
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,714,045
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,582,664
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%">
<A NAME="V453489_10K_HTM_SBI_029">
</A>
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars )
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	One Month Ended
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash Flows Used In Operating Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Net income (loss)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,026,080
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(2,843,029
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,127,904
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(8,439,523
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustments to reconcile net income (loss) to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	149,565
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	159,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,529
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	158,313
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Share-based compensation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	259,379
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	267,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	956,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Foreign exchange (gain) loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(76,800
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	653,333
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97,866
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	222,437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	(Gain) loss in fair value of warrant liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	211,956
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,131,062
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,680,040
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,533,305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Loss on disposal of property, plant and equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,670
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Impairment loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90,476
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Changes in working capital items:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Accounts receivable
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	71,827
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(113,917
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,352
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	121,075
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Deferred share issuance costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,656
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Inventory
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	307,850
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(522,389
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(34,891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Prepaid expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(197,150
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(45,758
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	490
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(94,974
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Deposits
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	560
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 9.35PT">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(33,403
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77,018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58,922
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Deferred revenue
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(173,333
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	86,666
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	71,667
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,505,629
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,412,395
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(296,692
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,266,707
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash Flows From Investing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Acquisition of property, plant and equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(402,271
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(274,589
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,477
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(279,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Proceeds on sale of property, plant and equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Purchase of short-term investments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,995,450
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,491
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,468,815
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Proceeds on sales and maturities of short-term investments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,021,827
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	410,736
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Contribution to joint venture
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(66,695
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	557,411
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	122,470
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,147
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,745,730
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash Flows From Financing Activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Proceeds from issuance of common shares, net
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,277,500
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,613,675
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Payments for share issuance costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(332,764
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(134,578
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Proceeds from exercise of warrants and options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,368,260
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	106,777
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	739,292
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,308,878
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,312,996
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,777
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	739,292
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,787,975
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Effect of exchange rate changes on cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	96,623
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(629,808
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(84,083
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(212,338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net change in cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,461,401
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,812,956
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	345,370
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	563,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents - beginning of year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,955,503
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,768,459
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,423,089
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,859,889
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents - end of year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,416,904
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,955,503
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,768,459
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,423,089
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash (demand deposits)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	972,412
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,955,503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,895,229
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,474,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,444,492
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,873,230
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,948,934
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,416,904
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,955,503
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,768,459
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	8,423,089
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Supplemental disclosure of non-cash transactions
<I>
	(Note 11)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%">
<A NAME="V453489_10K_HTM_SBI_030">
</A>
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Changes in Equity
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in US Dollars )
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Total
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Common
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Shares
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Share-Based
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Shareholders'
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Subscribed
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Compensation
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Deficit
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equity
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: BOLD">
	Balance - August 31, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	5,794,616
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	13,180,677
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	5,155,674
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	4,648,317
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	(25,180,667
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	(2,195,999
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Issuance of common shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,142,857
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Share issuance costs including fair value of&nbsp;broker units
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(907,801
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	386,898
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(520,903
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Issuance of performance shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	151,515
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	422,728
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(422,728
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	593,730
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,920,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(155,674
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,764,460
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,591,546
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,591,546
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	144,167
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	544,418
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	544,418
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	489,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(489,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	956,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	956,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,439,523
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,439,523
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - August 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,826,885
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,240,838
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,079,985
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(33,620,190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,700,633
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	110,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	727,804
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	727,804
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	890,214
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(29,817
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	860,397
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,488
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,488
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Net income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,127,904
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,127,904
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - September 30, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,941,985
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,883,877
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,073,144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(32,492,286
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,464,735
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,609
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,609
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(426
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,574
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,753
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113,561
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(113,561
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	267,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	267,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,843,029
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,843,029
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,984,758
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,114,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,226,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(35,335,315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,005,279
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Issuance of common shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,687,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Share issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(805,264
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(805,264
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9.35PT">
	Proceeds from exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	464,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,368,260
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,368,260
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,853,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(90,995
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,762,586
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9.35PT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	259,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	259,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 9.35PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,026,080
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,026,080
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance - September 30, 2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,136,258
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,280,792
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,394,763
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(40,361,395
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,314,160
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<A NAME="V453489_10K_HTM_SBI_031">
</A>
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	1.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Nature of Operations
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Stellar Biotechnologies, Inc.
	(the &ldquo;Company&rdquo;) is organized under the laws of British Columbia, Canada. The Company&rsquo;s common shares are listed
	on The Nasdaq Capital Market under the trading symbol &ldquo;SBOT.&rdquo; The Company&rsquo;s common shares trade on The Nasdaq
	Capital Market in the United States under the symbol &ldquo;SBOT&rdquo; since November 5, 2015. From January 15, 2013 through November
	4, 2015, the Company&rsquo;s common shares were traded in the United States on the U.S. OTCQB Marketplace Exchange under the symbol
	&ldquo;SBOTF.&rdquo; From April 19, 2010 to April 8, 2016 the Company&rsquo;s common shares were listed in Canada on the TSX Venture
	Exchange as a Tier 2 issue under the trading symbol &ldquo;KLH.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In April 2010, the Company changed
	its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies,
	Inc., a California corporation, which was founded in September 1999, and remains the Company&rsquo;s wholly-owned subsidiary and
	principal operating entity. The Company&rsquo;s executive offices are located at 332 E. Scott Street, Port Hueneme, California,
	93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7,
	Canada.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Nature of Operations
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s business
	is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (&ldquo;KLH&rdquo;).
	The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and
	clinical research organizations in Europe, the United States, and Asia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Management Plans
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	For the fiscal years 2016, 2015,
	and 2014, the Company reported net losses of approximately $5.0 million, $2.8 million, and $8.4 million, respectively. The most
	significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability,
	which was a loss of $212,000, gain of $2.1 million, and loss of 2.5 million for the fiscal years 2016, 2015, and 2014, respectively.
	As of September 30, 2016, the Company had an accumulated deficit of approximately $40.4 million and working capital of approximately
	$11.5 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In the past, operations of the
	Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue
	and product sales. In July 2016, the Company closed a $6.75 million registered direct offering. Management believes the Company&rsquo;s
	working capital is sufficient to support the Company&rsquo;s current initiatives at the current level for at least 12 months. Management
	is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek
	additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, as
	well as additional equity financing and debt financing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated
	financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for
	the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of
	business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Functional Currency
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	The consolidated financial statements
	of the Company are presented in U.S. dollars, which is the Company&rsquo;s functional currency, unless otherwise stated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Reverse Share Split
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	On September 2, 2015, the Company
	effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10. As a result of the reverse
	split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding
	common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share
	was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split
	reduced the number of common shares outstanding from 79,847,550 to 7,984,758 after fractional share rounding. The number of warrants,
	broker units, and options were proportionately adjusted by the split ratio and the exercise prices correspondingly increased by
	the same split ratio. All historical shares and exercise prices are presented on a post-split basis in these condensed interim
	consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	2.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Basis of Presentation
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.75IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The accompanying consolidated
	financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&ldquo;U.S.
	GAAP&rdquo;) and include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant
	intercompany balances and transactions have been eliminated in consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Change in Fiscal Year End
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	On June 3, 2014, the Board
	of Directors of the Company approved a change in the Company&rsquo;s fiscal year end from August 31 to September 30 of each year.
	This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month
	transition period from September 1, 2014 to September 30, 2014. Included in this report are the Company&rsquo;s consolidated balance
	sheets as of September 30, 2016 and 2015; and the consolidated statements of operations, cash flows and changes in equity for
	the 12 months ended September 30, 2016 (&ldquo;fiscal 2016&rdquo;), September 30, 2015 (&ldquo;fiscal 2015&rdquo;), August 31,
	2014 (&ldquo;fiscal 2014&rdquo;), and the one month ended September 30, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Significant Accounting Policies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Use of Estimates
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The preparation of financial
	statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the
	reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated
	financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant
	liability, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes.
	Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature
	are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting
	adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical
	experience, current and future economic conditions and other factors, including expectations of future events that are believed
	to be reasonable under the circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash and Cash Equivalents
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents consist
	of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities
	of three months or less when purchased.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Investments
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Investments at September 30,
	2016 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity
	and are reported at amortized cost, which approximates fair value. The Company regularly reviews these investments to determine
	whether any decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair
	value has occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value.
	Investments at September 30, 2015 consisted of a mutual fund of short-term fixed, floating and variable rate debt securities with
	normal weighted average effective maturity of approximately 1 year or less. This mutual fund investment is reported at fair value
	using level 1 inputs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	d)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Allowance for Doubtful Accounts Receivable
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company assesses the collectability
	of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general
	economic conditions and credit status of its customers.&nbsp; As of September 30, 2016 and 2015, all outstanding accounts receivable
	were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	e)
</TD>
<TD>
	Inventory
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The Company records inventory at the lower of cost
	or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost.
	Work in process and finished goods are measured using average cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	f)
</TD>
<TD>
	Property, Plant and Equipment
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Property, plant and equipment
	are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line
	method over useful lives ranging from 1.5 to 15 years. Leasehold improvements are depreciated over the shorter of the useful life
	of the improvement or remaining term of lease. Maintenance and repairs are charged to operations as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	g)
</TD>
<TD>
	Impairment of Long-Lived Assets
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	If indicators of impairment exist, the Company assesses
	the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered
	through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing
	the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying
	value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived
	assets requires judgment, and assumptions could differ materially from actual results. See Note 7 for impairment of licensing rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	h)
</TD>
<TD>
	Fair Value of Financial Instruments
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 37.4PT; TEXT-ALIGN: JUSTIFY">
	The Company uses the fair value
	measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting
	pronouncements either permit or require fair value measurements. See Note 12 for fair value measurements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 37.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	i)
</TD>
<TD>
	Revenue Recognition
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<I>
	Product Sales
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company recognizes product
	sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there
	is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company
	documents arrangements with customers with purchase orders and sales agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Product sales include sales made under supply agreements
	with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from a customer&rsquo;s
	designated limpet colonies. Supply agreements are typically on a non-exclusive basis except within that customer&rsquo;s field
	of use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
<I>
	Contract services revenue
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company recognizes contract
	services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability.
	An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements.
	Amounts received in advance of performance of contract services are recorded as deferred revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Contract services include services performed under
	collaboration agreements effective December 2013 through 2015 and monthly maintenance of limpet colonies designated to meet the
	needs of the customer through December 2014. The Company also had the right to use raw material produced from designated limpet
	colonies at no cost to the Company with prior written consent from the customer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
<I>
	Grants
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The Company has taken the income
	approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company
	will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate
	amount of earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	j)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and Development
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Research
	and development expenses principally consist of personnel costs related to the Company&rsquo;s research and development staff as
	well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory
	supplies, reimbursable costs associated with government grants and collaborative agreements, third-party contract payments, consultants,
	facility and related overhead costs.
</FONT>
	Research and development costs are expensed as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	k)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share-Based Compensation
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 37.4PT; TEXT-ALIGN: JUSTIFY">
	The Company grants options to
	buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments
	to non-employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 37.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The fair value of share-based compensation
	is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net
	of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires
	the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield,
	and expected life of the option.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	l)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Foreign Exchange
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Items included in the financial
	statements of the Company&rsquo;s subsidiary are measured using the currency of the primary economic environment in which the entity
	operates (the &ldquo;functional currency&rdquo;). The functional currency of the parent and its subsidiary is the U.S. dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Transactions in currencies other than the U.S. dollar
	are recorded at exchange rates prevailing on the dates of the transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	m)
</TD>
<TD>
	Income Taxes
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Income tax expense comprises
	current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly
	in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively
	enacted at year-end, adjusted for amendments to tax payable with regards to previous years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	Deferred tax is recorded using
	the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial
	reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill
	not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement
	of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	A deferred tax asset is recognized
	only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be
	utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered,
	it provides a valuation allowance against that excess.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The Company periodically evaluates
	its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the
	appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2016 with respect to
	uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature
	that will increase or decrease within 12 months of the reporting date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The Company files income tax
	returns in the U.S. federal and state jurisdictions and in Canada. Management believes that there are no material uncertain tax
	positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and
	penalties related to unrecognized tax benefits in income tax expense. The Company may be subject to examination by the Internal
	Revenue Service for tax years 2012 through 2015 and by the Canada Revenue Agency for tax years 2012 through 2016. The Company may
	also be subject to examination on certain state and local jurisdictions for the&nbsp;tax years 2011 through 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	n)
</TD>
<TD>
	Earnings (Loss) Per Share
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Basic earnings (loss) per share
	is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during
	the period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The computation of diluted earnings (loss)
	per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance
	would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities is reflected in diluted
	earnings per share by application of the &ldquo;if converted&rdquo; method. The dilutive effect of outstanding options and warrants
	and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding
	warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2016 and
	2015 and August 31, 2014 and are therefore excluded from the computation of diluted loss per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT">
	o)
</TD>
<TD>
	Segments
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The Company operates in one
	reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other
	fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements
	under evaluation in Baja California, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 17.45PT; TEXT-ALIGN: LEFT">
	p)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Recent Accounting Pronouncements
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	In
	May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update
	(&ldquo;ASU&rdquo;) 2014-09,
<I>
	Revenue from Contracts with Customers (Topic 606)
</I>
	, as
<I>
</I>
	amended by ASU 2015-14 to
	defer the effective date (&ldquo;ASU 2014-09&rdquo;). ASU 2014-09 creates a new topic in the Accounting Standards
	Codification (&ldquo;ASC&rdquo;) Topic 606 and establishes a new control-based revenue recognition model, changes the basis
	for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific
	topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification,
	ASC 340-40,
<I>
	Other Assets and Deferred Costs: Contracts with Customers
</I>
	, to provide guidance on costs related to
	obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of
	another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after
	December 15, 2017, including interim periods
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	within those years
</FONT>
	. Early
	application is only permitted as of annual reporting periods beginning after December 15, 2016, including interim reporting
	periods within that reporting period. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU
	No. 2016-08,
<I>
	Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations
</I>
	(&ldquo;ASU
	2016-08&rdquo;); ASU No. 2016-10,
<I>
	Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations
	and Licensing
</I>
	(&ldquo;ASU 2016-10&rdquo;); and ASU No. 2016-12,
<I>
	Revenue from Contracts with Customers (Topic 606):
	Narrow-Scope Improvements and Practical Expedients
</I>
	(&ldquo;ASU 2016-12&rdquo;). The Company must adopt ASU 2016-08, ASU
	2016-10 and ASU 2016-12 with ASU 2014-09 (collectively, the &ldquo;new revenue standards&rdquo;). Management is in the
	process of assessing the impact of ASU 2014-09 and the new revenue standards on the Company&rsquo;s consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	August 2014, the FASB issued ASU 2014-15,
</FONT>
<I>
	Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure
	of Uncertainties about an Entity's Ability to Continue as a Going Concern
</I>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	. ASU 2014-15
	defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue
	as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods
	beginning after
</FONT>
	December 15, 2016
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	, with early application permitted. Management is
	in the process of assessing the impact of ASU 2014-15 on the Company&rsquo;s
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial
	statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	In July 2015, FASB issued ASU 2015-11,
<I>
	Simplifying the Measurement of Inventory (Topic 330)
</I>
	. ASU 2015-11 indicates that an entity should measure inventory at the
	lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business,
	less reasonably predictable costs of completion, disposal, and transportation. The ASU does not apply to inventory measured using
	LIFO or the retail inventory method. It does apply to all other inventory, including inventory measured using FIFO or average cost.
	The guidance in ASU 2015-11 is effective for public entities for annual reporting periods beginning after December 15, 2016, including
	interim periods therein. The provisions should be applied prospectively with early application permitted. Management is in the
	process of assessing the impact of ASU 2015-11 on the Company&rsquo;s consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.3PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	January 2016, the FASB issued ASU 2016-01,
<I>
	Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial
	Assets and Financial Liabilities
</I>
	(&ldquo;ASU 2016-01&rdquo;), which
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	primarily
	affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure
	requirements for financial instruments. In addition,
</FONT>
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU 2016-01
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	clarified
	guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on
	available-for-sale debt securities
</FONT>
	.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The guidance is effective for public entities
	for fiscal years beginning after December 15, 2017, including interim periods within those years, with early adoption permitted.
</FONT>
	The Company has not yet determined the impact of
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU 2016-01 on its
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	February 2016, the FASB issued ASU 2016-02,
<I>
	Leases (Topic 842)
</I>
	(&ldquo;ASU 2016-02&rdquo;), which establishes a new lease
	accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities on the balance sheet
	arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The
	amended guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods
	within those years, with early adoption permitted.
</FONT>
	The Company has not yet determined the impact of
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU
	2016-02 on its
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	March 2016, the FASB issued ASU 2016-09,
<I>
	Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based
	Payment Accounting
</I>
	(&ldquo;ASU 2016-09&rdquo;), which is part of the FASB's Simplification Initiative. The updated guidance
	simplifies the accounting for share-based payment transactions,
</FONT>
	including the income tax consequences, classification of
	awards as either equity or liabilities, and classification on the statement of cash flows
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	.
	The amended guidance is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods
	within those years, with early adoption permitted.
</FONT>
	The Company has not yet determined the impact of
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU
	2016-09 on its
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	May 2016, the FASB issued ASU 2016-11,
<I>
	Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of
	SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 (&ldquo;ASU 2016-11&rdquo;)
</I>
	, which rescinds certain
	SEC paragraphs from the FASB Accounting Standards Codification in response to SEC staff announcements at the March 3, 2016 Emerging
	Issues Task Force meeting, and which supersedes certain SEC observer comments on the topics of revenue and expense recognition
	for freight service in process, accounting for shipping and handling fees and costs, accounting for consideration given by a vendor
	to a customer and accounting for gas-balancing arrangements upon the adoption of ASU 2014-09. The effective date for ASU 2016-11
	is the same as the effective date of ASU 2014-09
</FONT>
	as
<I>
</I>
	amended by ASU 2015-14
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	,
</FONT>
	for annual reporting periods beginning after December 15, 2017, including interim periods
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	within
	those years.
</FONT>
	The Company has not yet determined the impact of
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU 2016-11 on its
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	June 2016, the FASB issued ASU 2016-13,
<I>
	Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial
	Instruments
</I>
	(&ldquo;ASU 2016-13&rdquo;), which includes provisions that require financial assets measured at amortized cost
	basis to be presented at the net amount expected to be collected and credit losses relating to available-for-sale debt securities
	to be recorded through an allowance for credit losses, which requires recognition of an estimate of all current expected credit
	losses. The guidance is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods
	within those years, with early adoption permitted for fiscal years beginning after December 15, 2018.
</FONT>
	The Company has not
	yet determined the impact of
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	ASU 2016-13 on its
</FONT>
	consolidated
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	financial
	statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar Biotechnologies, Inc.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	For the Years Ended September 30, 2016 and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	(Expressed in U.S. Dollars)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Investments
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Short-term investments consisted of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: JUSTIFY">
	U.S. Treasury Bills
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,988,794
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Mutual fund debt securities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5,015,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,988,794
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,015,171
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	U.S. Treasury Bills are carried at amortized cost
	which approximates fair value and classified as held-to-maturity investments. Mutual fund debt securities are carried at fair value
	using level 1 inputs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Inventory
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Raw materials include inventory
	of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing
	and testing, and allocated manufacturing overhead for inventory in process at the end of the year. Finished goods include products
	that are complete and available for sale. At September 30, 2016 and 2015, the Company recorded work in process and finished goods
	inventory only for those products with recent sales levels to evaluate net realizable value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
	Inventory
	consisted of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: JUSTIFY">
	Raw materials
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	38,764
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	42,549
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Work in process
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	137,021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Finished goods
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	167,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	377,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	249,430
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	557,280
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.55PT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	6.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Property, Plant and Equipment, net
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Property, plant and equipment, net consisted of the
	following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Aquaculture system
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	126,257
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	124,529
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Laboratory facilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Computer and office equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,030
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	78,936
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tools and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	894,319
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	714,764
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Vehicles
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,347
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Leasehold improvements
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	282,305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	123,562
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,516,291
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,114,821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Less: accumulated depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(793,057
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(643,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Depreciable assets, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	723,234
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	471,329
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Construction in progress
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	32,880
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	32,079
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	756,114
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	503,408
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Depreciation expense amounted to $149,565, $159,521,
	$12,529 and $132,122 for the years ended September 30, 2016 and 2015, one month ended September 30, 2014, and year ended August
	31, 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Intangible Assets - Licensing Rights
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In August 2011, the Company
	acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed under collaboration with
	a customer. The Company paid a $200,000 license fee for the licensing rights, which are jointly owned by the Company and the customer.
	The licensing rights do not have a fixed term or termination provisions. The licensing rights were amortized over the estimated
	useful life of seven years and shown net of accumulated amortization and impairment losses. During the year ended August 31, 2014,
	the Company discontinued its use of these licensing rights and recorded impairment loss for the remaining value of licensing rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Amortization expense amounted
	to $26,191 for the year ended August 31, 2014. Impairment loss for the year ended August 31, 2014 totaled $90,476 and is included
	in general and administrative expenses in the accompanying consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Commitments
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Operating leases
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company leases buildings
	and facilities used in its operations under three sublease agreements with the Oxnard Harbor District. In June 2015, the Company
	exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015.
	The Company negotiated an option to extend the leases for two additional five-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company leases facilities
	used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2016, the Company
	extended this lease for a two-year term, with options to renew for three successive two-year terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company leases undeveloped
	land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production.
	The lease term is three years from June 2015 with options to extend the lease for 30 years. The Company may terminate early with
	30 days&rsquo; notice. The first two years of rent under the lease totaling $74,606 were prepaid in June 2015, and are not included
	in the future minimum lease payments below. The Company has a related agreement with the lessor to collaborate on the design, expansion
	and development of marine aquaculture resources and KLH production facilities on the leased property. Under that agreement, the
	Company is responsible for certain leasehold improvements including construction of structures and a power-generating facility,
	which will be owned by the Company. The Company will reimburse the lessor for local operational support. The collaboration agreement
	expires in June 2018, unless terminated earlier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Aggregate future minimum lease
	payments at September 30, 2016 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<U>
	For The Year Ending September 30,
</U>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.875IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
	2017
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
	185,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.875IN">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.875IN">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.875IN">
	2020
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.875IN">
	2021
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	591,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Rent expense on these lease
	agreements amounted to approximately $235,000, $192,000, $15,000 and $181,000 for the years ended September 30, 2016 and 2015,
	one month ended September 30, 2014, and year ended August 31, 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	Purchase obligations
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company has commitments
	totaling approximately $314,000 at September 30, 2016, for signed agreements with contract research organizations, consultants
	and construction contractors. All purchase obligations are expected to be fulfilled within the next 12 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Supply agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company has two commitments
	under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer&rsquo;s
	field of use. One amended and restated supply agreement replaced two prior agreements that automatically renewed each year. The
	new agreement is effective March 2015 through March 2020 and is renewable for one-year terms upon written request of the customer.
	The other customer supply agreement is effective October 2014 through October 2019 and is renewable for one-year terms upon written
	request of the customer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Joint venture agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In May 2016, the Company entered
	into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated
	therapeutic vaccines. The joint venture is organized as a French simplified corporation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company holds a 30% equity
	interest in the joint venture in exchange for an initial capital contribution of &euro;120,000. One-half of the initial contribution,
	approximately $67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined
	future events. The Company will also provide the joint venture additional financing as may be required, on a pro rata basis in
	line with our equity interest. If the joint venture does not achieve certain milestones by December 2017, the joint venture will
	be dissolved, unless (i) the parties mutually agree to pursue the joint venture arrangement, or (ii) either party decides to purchase
	the equity interests of the other party. Each of the parties is entitled, upon the occurrence of certain defined events, to acquire
	the interest of the other party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In connection with the formation
	of the joint venture and the execution of its strategy, the parties intend over time to enter into an exclusive supply agreement
	within a limited field of use for Stellar to supply KLH to the joint venture, a supply agreement designating the joint venture
	as the exclusive manufacturer and supplier of the other party&rsquo;s vaccines, and services agreements for the provision of various
	knowledge and expertise by each of the parties. The other party will also license certain of its intellectual property to the joint
	venture.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The joint venture has an initial
	ten-year term, renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration
	date of an applicable term that it does not wish to continue its participation in the joint venture, the other party will have
	a right to acquire all of such terminating party&rsquo;s equity interests in the joint venture.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The joint venture agreement
	contains customary restrictions on transfer of the equity interests, tag-along and drag-along rights, non-competition, non-solicitation,
	confidentiality and termination provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Licensing fees
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In July 2013, the Company acquired
	the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against
<I>
	Clostridium
	difficile
</I>
	infection (&ldquo;C. diff&rdquo;). The license agreement required an initial, non-refundable license fee of $25,000,
	which was paid in fiscal August 2013, and payment of an aggregate of $200,000 in delayed license fees, which were paid in fiscal
	August 2014. Beginning September 2014, the terms also require a license fee of $20,000 to be paid annually, creditable against
	royalties due, if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a
	percentage of related non-royalty sublicensing revenue, if any. No royalties have been incurred to date. The Company also reimbursed
	patent filing costs of approximately $11,000, $52,000 and $34,000 for the years ended September 30, 2016, September 30, 2015 and
	August 31, 2014, respectively, and will reimburse certain future patent filing, prosecution, and maintenance costs. There were
	no patent cost reimbursements during the one month ended September 30, 2014. License fees and patent cost reimbursements have been
	accounted for as research and development expense in the accompanying consolidated statements of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The license agreement expires
	when the last valid patent claim licensed under the license agreement expires, which is currently 2030. Prior to that time, the
	license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 days after written notice
	from the licensor to cure the problem prior to termination of the license agreement. The Company can terminate the agreement with
	three months&rsquo; prior written notice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Upon execution of the license
	agreement, the Company issued 37,120 common shares and warrants to purchase up to 27,840 of the Company&rsquo;s common shares to
	the licensor, as further described in Note 9. The warrants expired on January 23, 2015 and were not exercised.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The license agreement provides
	for the Company to pay up to an aggregate of $6,020,000 in milestone payments to the licensor upon achievement of various financing
	and development targets up to the first regulatory approval. Remaining contingent milestone payments to the licensor totaling $57,025,000
	are related to achievement of sales targets. A financing milestone was met during the year ended August 31, 2014, and accordingly,
	the Company made a milestone payment of $100,000. No milestones were met during any other annual period, and there can be no assurance
	that any of the remaining milestones will be met in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Retirement savings plan 401(k)
	contributions
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company sponsors a 401(k)
	retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages.
	All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees
	are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately
	$64,000, $58,000, $5,000 and $52,000, for the years ended September 30, 2016, and 2015 one month ended September 30, 2014, and
	year ended August 31, 2014 respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Related party commitments:
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Patent
</I>
	r
<I>
	oyalty agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	On August 14, 2002, through
	its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive
	royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products
	using this invention in excess of $500,000 annually. The Company&rsquo;s current operations utilize this invention. Royalty expense
	incurred during the year ended September 30, 2016 and 2015 was approximately $35,500 and $1,500. There was no royalty expense incurred
	during the one month ended September 30, 2014 and year ended August 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Collaboration agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	In December 2013, the Company
	entered into a collaboration agreement with a privately-held Taiwanese biopharmaceuticals manufacturer effective through December
	2015. Under the terms of the agreement, the Company was responsible for the production and delivery of GMP grade KLH for evaluation
	as a carrier molecule in the collaboration partner&rsquo;s potential manufacture of OBI-822 active immunotherapy. The Company was
	also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The
	collaboration partner was responsible for development objectives and product specifications. The agreement provided for the collaboration
	partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing,
	the collaboration also provided for the parties to negotiate a commercial supply agreement for Stellar KLH&trade; in the future.
	However, there can be no assurance that any such negotiations will lead to successful execution of a supply or other agreements
	related to this collaboration.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The privately-held Taiwanese
	biopharmaceuticals manufacturer is a beneficial owner of over 5% of the Company&rsquo;s common shares. In addition, a member of
	the Company&rsquo;s Board of Directors currently serves as the manufacturer&rsquo;s general manager and chair of its board of
	directors. There are no arrangements or agreements between the Company and the manufacturer relating to representation on the
	Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	9.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Share Capital
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 31.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
	The Company
	had the following transactions in share capital:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	One Month
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%">
	Number of common shares issued
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2,151,500
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	42,773
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	115,100
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2,032,269
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Issuance of common shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Share issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(805,264
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(907,801
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Proceeds from exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,368,260
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,609
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	727,804
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,764,460
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,853,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	890,214
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,591,546
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Proceeds from exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94,168
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,488
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	544,418
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer to common shares on exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113,561
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	489,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	259,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	267,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	956,634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 31.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
<I>
	Performance
	Shares
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	There were 1,000,000 common
	shares allotted as performance shares to be issued to certain officers, directors and employees of the Company based on meeting
	milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal
	of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of
	products under a performance share plan. Share-based compensation was recorded over the estimated vesting period ending in August
	2012.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	At September 30, 2016, there
	are 383,838 performance shares reserved for issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
<I>
	License Agreement
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	During the year ended August
	31, 2013, the Company entered into a license agreement and issued 37,120 common shares and warrants to purchase up to 27,840 of
	the Company&rsquo;s common shares to the licensor. Each warrant entitled the holder to purchase one common share of the Company
	at a price of CDN$12.50 per share on or before January 23, 2015. The common shares were subject to a hold period that ended on
	November 25, 2013. The warrants expired on January 23, 2015 and were not exercised. The value of the shares and warrants were recorded
	as research and development expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Black-Scholes option valuation
	model
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company uses the Black-Scholes
	option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require
	the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility
	to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value
	estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company&rsquo;s
	warrants, broker units and share options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Warrants
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 31.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -13.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	A summary of the Company&rsquo;s warrants activity
	is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Warrants
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: BOLD">
	Balance - September 30, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	1,054,531
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	9.05
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(27,870
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,022,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,265,626
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(424,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(598,761
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 9PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(40,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance - September 30, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,265,626
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	4.50
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	There are no outstanding warrants
	with exercise prices denominated in Canadian dollar at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The weighted average contractual
	life remaining on the outstanding warrants at September 30, 2016 is 63 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	The following table summarizes information about
	the warrants outstanding at September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise Price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Warrants
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiry Date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 20%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	$4.50
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,265,626
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 54%; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	January 6, 2022*
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,265,626
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	* Exercisable beginning January
	6, 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Warrant Liability
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	All warrants with exercise prices
	denominated in Canadian dollars were exercised or expired. Therefore, there is no outstanding warrant liability at September 30,
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Equity offerings conducted by
	the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company&rsquo;s
	functional currency is in U.S. dollars. As a result of having exercise prices denominated in other than the Company&rsquo;s functional
	currency, those warrants met the definition of derivatives and were therefore classified as derivative liabilities measured at
	fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants were
	exercised, the fair value of the recorded warrant liability on date of exercise was included in common shares along with the proceeds
	from the exercise. If those warrants expired, the related decrease in warrant liability was recognized in profit or loss, as part
	of the change in fair value of warrant liability. There was no cash flow impact as a result of this accounting treatment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The fair value of these warrants
	was determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants,
	the fair value of warrants included in derivative liabilities was reclassified to equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The fair value of warrants exercised
	was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	One Month
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; TEXT-ALIGN: LEFT">
	Risk free interest rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.48
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.44
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.12
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1.07
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected life (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.03
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Expected share price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	There were no warrants granted
	during the year ended September 30, 2015 or the one month ended September 30, 2014. The fair value of warrants granted was determined
	using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT">
	Risk free interest rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	0.52
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	1.48
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected life (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Expected share price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	112
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Broker units
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company granted broker units
	as finders&rsquo; fees in conjunction with equity offerings in prior years. Broker units were fully vested when granted and allowed
	the holders to purchase equity units. A unit consisted of one common share and either one whole warrant or one half warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	A summary of broker units activity is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Units
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 65%; FONT-WEIGHT: BOLD">
	Balance - September 30, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	46,720
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Exercised
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(120
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5.00
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.87
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(40,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(6,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2.50
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance - September 30, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	There were no broker units granted during the years
	ended September 30, 2016 and 2015, the one month ended September 30, 2014, or the year ended August 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<I>
	Options
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company has a fixed share
	option plan adopted in 2013 (&ldquo;the Plan&rdquo;) to be administered by the Board of Directors, which has the discretion to
	grant up to an aggregate of 1,000,000 options. The exercise price of an option is set at the closing price of the Company&rsquo;s
	common shares on the date of grant. Share options granted to directors, officers, employees and consultants are subject to the
	following vesting schedule:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 20PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	One-third shall vest immediately;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 20PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	One-third shall vest 12 months from the date of grant; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 20PT">
	(c)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	One-third shall vest
	18 months from the date of grant.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Share options granted to investor
	relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of
	grant, and a further 25% on each successive date that is three months from the date of the prior vesting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Options have been issued under
	the Plan allowing the holders to purchase common shares of the Company as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	Options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	Average
<BR>
	Exercise Price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT-WEIGHT: BOLD">
	Balance - September 30, 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	588,553
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	5.56
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(38,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.06
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,333
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(5,332
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	7.76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Balance - September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	557,638
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	56,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,334
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT; PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(53,501
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	CDN $
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Balance - September 30, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	539,103
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.29
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The weighted average contractual
	life remaining on the outstanding options is 2.57 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The following table summarizes
	information about the options under the Plan outstanding and exercisable at September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.75IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of Options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercisable at
<BR>
	September 30, 2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Range of exercise prices
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiry Dates
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: RIGHT">
	283,610
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 22%; TEXT-ALIGN: RIGHT">
	283,610
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24%; TEXT-ALIGN: RIGHT">
	&nbsp;CDN$0.01 - 5.00
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 24%; TEXT-ALIGN: RIGHT">
	Apr 2017-Dec 2019
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,867
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;$0.01 - 5.00
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	Sep 2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	142,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	141,193
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;CDN$5.01 - 10.00
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	Oct 2017-Jun 2022
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;$5.01 - 10.00
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	Dec 2022
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;CDN$15.01 - 20.00
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	Nov 2018-Nov 2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	49,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	49,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	&nbsp;$15.01 - 20.00
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	Nov 2020
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	539,103
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	514,570
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	There were no share options
	granted in the one month ended September 30, 2014. The estimated fair value of the share options granted was determined using a
	Black-Scholes option valuation model with the following weighted average assumptions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Risk free interest rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1.01
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1.65
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	2.01
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected life (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Expected share price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	120
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The weighted average fair value
	of share options granted during the years ended September 30, 2016 and 2015, and August 31, 2014 was $5.56, $9.48, and $15.14,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	As of September 30, 2016, the
	Company had approximately $86,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period
	of 1.5 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The intrinsic value of the options
	exercised during the year ended September 30, 2015, one month ended September 30, 2014, and year ended August 31, 2014, was $8.28,
	$15.99, and $12.78, respectively. There were no options exercised during the year ended September 30, 2016. The intrinsic value
	of the vested options at September 30, 2016 was $0.10.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	10.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The breakdown of loss before
	income tax by jurisdiction is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	One Month
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="6" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<B>
	Year Ended
</B>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	August 31,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 48%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	U.S.
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	$
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(4,001,206
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(3,258,355
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(334,841
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4,183,392
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Canadian
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(1,026,520&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	405,203
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,462,652
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4,096,931
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other foreign
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	8,846&nbsp;
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46,923
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,893
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(132,000
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Total Loss Before Income Tax
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	$
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(5,018,880
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2,806,229
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,131,704
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(8,412,323
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Deferred income tax assets and
	liabilities of the Company are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	September 30,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	2016
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30,
<BR>
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	August 31,
<BR>
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	Deferred income tax assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Non-capital loss carry-forwards
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,000,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	8,028,900
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6,561,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	6,418,300
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Research and development tax credits
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	808,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	716,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	626,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	616,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Deferred expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	70,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	82,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	84,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Property, plant and equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	400
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Share issuance costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	207,200
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	67,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	124,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	131,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred income tax liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	U.S. federal benefit net of state taxes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(764,500
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(628,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(517,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(509,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Property, plant and equipment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Valuation allowance
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,321,100
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,268,900
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,865,900
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,733,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net deferred income tax asset (liability)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Realization of the deferred tax assets is dependent
	upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets
	have been fully offset by a valuation allowance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	As of September 30, 2016, the
	Company had federal net operating loss (&ldquo;NOL&rdquo;) carryforwards of approximately $20,708,000 expiring 2030 through 2036,
	California NOL carryforwards of approximately $20,472,000 expiring 2018 through 2036, and Canadian federal and provincial NOL carryforwards
	of approximately CDN$5,855,000 expiring 2029 through 2036. Portions of these NOL carryforwards may be used to offset future taxable
	income, if any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	As of September 30, 2016, the
	Company also has federal and California research and development tax credit carryforwards of approximately $384,000 and $424,000,
	respectively, available to offset future taxes. The federal credits begin expiring in 2030 and continue expiring through 2036.
	The state tax credits do not expire.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Under the provisions of Section
	382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards
	and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been
	established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect
	the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The recovery of income taxes
	shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before
	provision for income taxes due to the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT>
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	One Month
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="6" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<B>
	Year Ended
</B>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	August 31,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Combined Canadian federal and provincial tax rates
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26.0
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	26.0
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	26.0
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	26.0
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected income tax (recovery)/expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,304,900
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(729,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	294,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,187,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Nondeductible share-based payments
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(67,400
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	248,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Nondeductible change in fair value of warrant liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(55,100
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(554,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(436,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	659,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Effect of higher income tax rate in U.S.
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(550,600
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(445,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(46,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(602,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Foreign currency differences
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	169,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(50,900
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Other
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,800
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(43,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(219,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in valuation allowance on deferred tax assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,968,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,570,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	161,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,179,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Income tax expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,200
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	36,800
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,800
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	27,200
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The components of income tax
	provision (benefits) are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	One Month
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="6" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<B>
	Year Ended
</B>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	August 31,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current tax provision
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	U.S. federal
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Canadian
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	Other foreign
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,400
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	36,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	26,400
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	State
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax provision
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 9PT">
	U.S. federal
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,265,700
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,032,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(107,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,431,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 9PT">
	Canadian
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(303,300
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(209,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(289,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 9PT">
	State
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(399,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(328,700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(32,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(458,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in valuation allowance on deferred tax assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,968,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,570,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	161,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,179,200
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,200
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	36,800
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,800
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	27,200
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	11.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Supplemental Disclosure of Cash Flow and Non-Cash Transactions
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Supplemental disclosure of cash
	flow information follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	One Month
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Years Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Cash paid during the period for taxes
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7,200
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	36,800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	30,200
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Supplemental disclosure of non-cash
	financing and investing activities follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	One Month
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Years Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Share issuance costs - broker units and warrants
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	386,898
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share issuance costs withheld from escrow proceeds
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	472,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	386,325
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer to common shares on exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,853,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	890,214
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,591,546
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer to common shares on exercise of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113,561
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	489,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer to common shares on issuance of performance shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	422,728
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shares subscribed transferred to common shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,155,674
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	12.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Fair Value of Financial Instruments
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company uses the fair value
	measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting
	pronouncements either permit or require fair value measurements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Fair value of a financial instrument
	is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
	at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued
	liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments
	in U.S. Treasury Bills are reported at amortized cost, which approximates fair value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company follows the fair
	value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
	measuring fair value. There are three levels of inputs that may be used to measure fair value:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Level 1:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Quoted prices in active markets for identical or similar assets and liabilities.
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Level 2:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Quoted prices for identical
	or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets
	for identical or similar assets and liabilities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
	Level 3:
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unobservable inputs that are supported by little or no
	market activity and that are significant to the fair value of the assets or liabilities.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 37.4PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company recorded its short-term
	investments in mutual fund debt securities at fair value using Level 1 inputs in the fair value hierarchy. The Company recorded
	its warrant liability at fair value using Level 2 inputs using the Black-Scholes option valuation model and assumptions disclosed
	in Note 9.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The following table summarizes
	fair values for those assets and liabilities with fair value measured on a recurring basis. There are no short-term investments
	in mutual fund debt securities or warrant liability at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair&nbsp;Value&nbsp;Measurements&nbsp;Using
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Quoted&nbsp;Prices&nbsp;
<BR>
	in Active&nbsp;
<BR>
	Markets
	for&nbsp;
<BR>
	Identical
<BR>
	Instruments
<BR>
	(Level&nbsp;1)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Significant&nbsp;
<BR>
	Other&nbsp;
<BR>
	Observable&nbsp;
<BR>
	Inputs&nbsp;
<BR>
	(Level&nbsp;2)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Significant
<BR>
	Unobservable
<BR>
	Inputs&nbsp;
<BR>
	(Level&nbsp;3)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Total&nbsp;Fair Value
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	September 30, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Short-term investments in U.S. Treasury Bills
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,988,794
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,988,794
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	September 30, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Short-term investments in mutual fund debt securities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,015,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,015,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Warrant liability, current portion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,550,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,550,630
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<B>
	13.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Concentrations of Credit Risk
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Credit risk is the risk of an
	unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments
	that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, US Treasury
	bills, mutual fund debt securities and accounts receivable. The Company estimates its maximum credit risk at the amount recorded
	on the balance sheet.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Management&rsquo;s assessment
	of the Company&rsquo;s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed
	to be credit worthy or US Treasury bills. The Company limits its exposure to credit loss for short-term investments by using US
	Treasury bills or a mutual fund that invests in high-quality, U.S. dollar-denominated short-term fixed-, floating- and variable-rate
	debt securities that have received either a minimum short-term rating of at least A-1 (or its equivalent) or a minimum long-term
	rating of A minus (or its equivalent), by one or more Nationally Recognized Statistical Ratings Organizations, or, if unrated,
	that are deemed by the fund to be of comparable quality at the time of purchase. Based on credit monitoring and history, the Company
	considers the risk of credit losses due to customer non-performance on accounts receivable to be low.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company had the following
	concentrations of revenues by customers and grantors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	One Month
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="5" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Ended
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	August 31,
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 10PT">
	Product sales and contract services revenue
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	76% from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	3 customers
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;82% from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	3 customers
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;86% from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	3 customers
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;73% from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	2 customers
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Grant revenue
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;100% from
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	1 grantor
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company had the following
	concentrations of revenues by geographic areas:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	One Month
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Year Ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	September 30,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	August 31,
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 20%">
	Europe
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Asia
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	U.S.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other countries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	The Company had the following
	concentrations of accounts receivable:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 74%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	September 30,
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;100 % from
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1 customer
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;91% from
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2 customers
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Stellar
	Biotechnologies, Inc.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notes to Consolidated Financial Statements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the Years Ended September 30, 2016
	and 2015, One Month Ended September 30, 2014, and Year Ended August 31, 2014
</P>
<P STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PX; MARGIN-BOTTOM: 0PX">
<I>
	(Expressed
	in U.S. Dollars)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 0.25IN">
<B>
	14.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Reclassifications
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY">
	Certain reclassifications have been made to the
	prior period to conform with the current period&rsquo;s presentation. These include the Company&rsquo;s reclassification of a
	mutual fund investing in short-term debt securities from cash equivalents to short-term investments and reclassification of costs
	related to aquaculture to present such costs separately from costs of sales and contract services. There was no impact on total
	assets, total shareholders&rsquo; equity, accumulated deficit, total expenses or net income (loss) resulting from these reclassifications.
	The statement of cash flows reflects the mutual fund activity as cash flows from investing activities rather than changes in cash.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage105"></A>
<A NAME="V453489_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We consent to the incorporation by reference
	in the Registration Statements on Form S-3 (No. 333-203595 and 333-213654) of Stellar Biotechnologies, Inc. of our report dated
	December 14, 2016, relating to the consolidated financial statements of Stellar Biotechnologies, Inc., which report appears in
	this Annual Report on Form 10-K for the year ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	/s/ Moss Adams LLP
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Los Angeles, California
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	December 14, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage106"></A>
<A NAME="V453489_EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 31.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
	PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SECTION 302(a) OF THE SARBANES-OXLEY ACT OF
	2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(18 U.S.C. SECTION 1350)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	I, Frank R. Oakes, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	I have reviewed this Annual Report on Form 10-K of Stellar Biotechnologies, Inc. for the year ended
	September 30, 2016;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or
	omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
	were made, not misleading with respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Based on my knowledge, the financial statements, and other financial information included in this
	report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
	as of, and for, the periods presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
	disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
	reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
	to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
	subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
	prepared;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Designed such internal control over financial reporting, or caused such internal control over financial
	reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
	and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
	in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
	by this report based on such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
	that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
	of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
	control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
	evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
	board of directors (or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All significant deficiencies and material weaknesses in the design or operation of internal control
	over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
	and report financial information; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Any fraud, whether or not material, that involves management or other employees who have a significant
	role in the registrant&rsquo;s internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Date: December 14, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ Frank R. Oakes
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Frank R. Oakes
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal Executive Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage107"></A>
<A NAME="V453489_EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 31.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF CHIEF FINANCIAL OFFICER
	PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SECTION 302(a) OF THE SARBANES-OXLEY ACT OF
	2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(18 U.S.C. SECTION 1350)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	I, Kathi Niffenegger, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	I have reviewed this Annual Report on Form 10-K of Stellar Biotechnologies, Inc. for the year ended
	September 30, 2016;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or
	omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
	were made, not misleading with respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Based on my knowledge, the financial statements, and other financial information included in this
	report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
	as of, and for, the periods presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
	disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
	reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
	to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
	subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
	prepared;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Designed such internal control over financial reporting, or caused such internal control over financial
	reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
	and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
	in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
	by this report based on such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
	that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
	of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
	control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
	evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
	board of directors (or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All significant deficiencies and material weaknesses in the design or operation of internal control
	over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
	and report financial information; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Any fraud, whether or not material, that involves management or other employees who have a significant
	role in the registrant&rsquo;s internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Date: December 14, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ Kathi Niffenegger
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Kathi Niffenegger
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal Financial Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage108"></A>
<A NAME="V453489_EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 32.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
	PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In connection with the Annual Report on Form
	10-K of Stellar Biotechnologies, Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended September 30, 2016 (the &ldquo;Report&rdquo;),
	as filed with the Securities and Exchange Commission on the date hereof, I, Frank R. Oakes, Chief Executive Officer of the Company,
	certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The information contained in the Report fairly presents, in all material respects, the financial
	condition and results of operations of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
	Date: December 14, 2016
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: JUSTIFY">
	By:
</TD>
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Frank R. Oakes
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Frank R. Oakes
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	President and Chief Executive Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	(Principal Executive Officer)
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage109"></A>
<A NAME="V453489_EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 32.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
	PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In connection with the Annual Report on Form
	10-K of Stellar Biotechnologies, Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended September 30, 2016 (the &ldquo;Report&rdquo;),
	as filed with the Securities and Exchange Commission on the date hereof, I, Kathi Niffenegger, Chief Financial Officer of the Company,
	certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The information contained in the Report fairly presents, in all material respects, the financial
	condition and results of operations of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Date: December 14, 2016
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	By:
</TD>
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Kathi Niffenegger
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Kathi Niffenegger
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Chief Financial Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	(Principal Financial Officer)
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="COLOR: #0070C0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
